You have free access to this content

Hematological Oncology

© John Wiley & Sons Ltd

Cover image for Vol. 35 Issue S2

Supplement: 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

June 2017

Volume 35, Issue Supplement S2

Pages 1–466

  1. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ISSUE INFORMATION

      You have free access to this content
      Issue Information (pages 1–3)

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2433

  2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ACKNOWLEDGEMENTS

      You have free access to this content
      14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland) 14 - 17 June, 2017 (pages 4–8)

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2434

    2. CONFERENCE SCHEDULE

      You have free access to this content
      14-ICML - 14th International Conference on Malignant Lymphoma (pages 9–21)

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2435

    3. SATELLITE SYMPOSIA SCHEDULE

      You have free access to this content
      Satellite symposia schedule (page 22)

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2436

  3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      HENRY KAPLAN MEMORIAL LECTURE: “IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS” (page 23)

      R. Levy

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437

    2. You have free access to this content
      GIANNI BONADONNA MEMORIAL LECTURE: “GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES” (pages 23–24)

      M.A. Shipp

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_1

    3. You have free access to this content
      JOHN ULTMANN MEMORIAL LECTURE: “GENOMES IN TRANSIT: WHAT MULTI-OMICS CAN TELL US ON LYMPHOMAS” (page 24)

      R. Siebert

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_2

    4. You have free access to this content
      INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS (pages 24–25)

      F. Morschhauser, G. Salles, P. McKay, H. Tilly, A. Schmitt, J. Gerecitano, P. Johnson, S. Le Gouill, M.J. Dickinson, C. Fruchart, T. Lamy, A. Chaidos, W. Jurczak, S. Opat, J. Radford, P.L. Zinzani, S. Assouline, G. Cartron, A. Clawson, N. Picazio, S. Ribich, S.J. Blakemore, J. Larus, H. Miao, P.T. Ho and V. Ribrag

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_3

    5. You have free access to this content
      CRISPR-CAS9 GENETIC SCREENS UNCOVER A B CELL RECEPTOR-MYD88 SUPERPATHWAY IN DIFFUSE LARGE B CELL LYMPHOMA (page 25)

      R.M. Young, J.D. Phelan, D.E. Webster, S. Roulland, G. Wright, D. Huang, R. Schmitz and L.M. Staudt

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_4

    6. You have free access to this content
      BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG) (pages 25–27)

      P. Cramer, J. von Tresckow, J. Bahlo, S. Robrecht, O. Al-Sawaf, P. Langerbeins, A. Engelke, A.M. Fink, K. Fischer, T. Seiler, L.Fischer von Weikersthal, H. Hebart, K.A. Kreuzer, M. Ritgen, M. Kneba, C.M. Wendtner, S. Stilgenbauer, B. Eichhorst and M. Hallek

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_5

    7. You have free access to this content
      GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS (page 27)

      S.J. Schuster, M.R. Bishop, C. Tam, E.K. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, S.R. Foley, P.J. Ho, S. Mielke, H. Holte, O. Anak, L. Pacaud, R. Awasthi, F. Tai, G. Salles and R. Maziarz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_6

    8. You have free access to this content
      AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1 (page 28)

      S.S. Neelapu, F.L. Locke, N.L. Bartlett, L.J. Lekakis, D. Miklos, C.A. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Y. Lin, J. Timmerman, P. Reagan, L. Navale, Y. Jiang, J. Aycock, M. Elias, J. Wiezorek and W.Y. Go

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_7

    9. You have free access to this content
      WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT MELANOMA (pages 28–29)

      A.M.M. Eggermont

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_8

    10. You have free access to this content
      WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER (page 29)

      R. Stahel

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_9

    11. You have free access to this content
      OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG (pages 29–31)

      J.L. Brady, M.S. Binkley, C. Hajj, M.R. Chelius, K.W. Chau, M. Levis, S. Choi, C. Suh, S.J. Hardy, L.S. Constine, A. Krog Vistisen, S.V. Bratman, G. Reinartz, H.T. Eich, M. Oguchi, Y.M. Kirova, A.K. Ng, V.S. Warbey, S.F. Barrington, T.C. El-Galaly, A.R. Filippi, U. Ricardi, J. Yahalom, R.T. Hoppe and N.G. Mikhaeel

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_10

    12. You have free access to this content
      CVP OR R-CVP GIVEN AFTER INVOLVED-FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I-II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL (page 31)

      M.P. Macmanus, R. Fisher, D. Roos, P. O'Brien, A. Macann, R. Tsang, S. Davis, D. Christie, B. McClure, D. Joseph and J.F. Seymour

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_11

    13. You have free access to this content
      RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO (page 32)

      E. Hoster, M. Unterhalt, M. Hänel, G. Prange-Krex, R. Forstpointner, A. Florschütz, U. Graeven, N. Frickhofen, G. Wulf, E. Lengfelder, C. Lerchenmüller, R. Schlag, J. Dierlamm, L. Fischer Von Weikersthal, A. Ahmed, H. Harich, A. Rosenwald, W. Klapper, M. Dreyling, W. Hiddemann and M. Herold

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_12

    14. You have free access to this content
      DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL (pages 32–33)

      R. Pettengell, R. Uddin, A. Boumendil, S.P. Robinson, G. Smith, T. Hawkins, B. Metzner, M.D. Caballero, H. Tilly, J. Romejko-Jarosinska, I. Bence-Bruckler, B. To, C. Niemann, E. Kimby, P. Dreger, N. Schmitz, A.H. Goldstone and S. Montoto

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_13

    15. You have free access to this content
      LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY (page 34)

      S. Luminari, V. Tarantino, A. Anastasia, C. Boccomini, A. Chiarenza, L. Rigacci, E. Angelucci, A. Ferrari, A. Pulsoni, S. Rattotti, F. Angrilli, G. Gaidano, C. Stelitano, G. Bertoldero, N. Cascavilla, F. Salvi, A.J. Ferreri, D. Vallisa, M. Balzarotti, M.C. Cox, R. Freilone, L. Marcheselli, A. Dondi, M. Manni and M. Federico

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_14

    16. You have free access to this content
      CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS (pages 34–35)

      C. Sarkozy, B. Link, H. Ghesquieres, M. Maurer, E. Nicolas-Virelizier, C. Thompson, A. Traverse-Glehen, A. Feldman, C. Allmer, S. Slager, S. Ansell, T. Habermann, E. Bachy, J. Cerhan and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_15

    17. You have free access to this content
      PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) FOR PATIENTS WITH EARLY STAGE HODGKIN LYMPHOMA ENROLLED IN THE STANDARD ARM OF THE H10 (EORTC/LYSA/FIL) TRIAL (pages 35–36)

      A. Cottereau, A. Versari, A. Loft, R. Casasnovas, M. Bellei, R. Ricci, S. Bardet, A. Castagnoli, P. Brice, J. Raemaekers, B. Deau, C. Fortpied, T. Raveloarivahy, T. Girinsky, E. Van Zele, T. Vander Borght, M. Federico, M. Hutchings, U. Ricardi, M. Andre and M. Meignan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_16

    18. You have free access to this content
      BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE (pages 36–37)

      A.J. Moskowitz, H. Schöder, S. Gavane, K.L. Thoren, M. Fleisher, J. Yahalom, S.J. McCall, S.Y. Fox, J. Gerecitano, R. Grewal, P.A. Hamlin, S. Horwitz, A. Kumar, M. Matasar, A. Ni, A. Noy, M.L. Palomba, M. Perales, C.S. Portlock, C. Sauter, D. Straus, A. Younes, A.D. Zelenetz and C.H. Moskowitz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_17

    19. You have free access to this content
      CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033) (pages 37–38)

      L.C. Pike, A.A. Kirkwood, P. Patrick, J. Radford, C. Burton, L. Stevens, L. Clifton-Hadley, P.W. Johnson and S.F. Barrington

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_18

    20. You have free access to this content
      CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL) (page 38)

      L. Rigacci, B. Puccini, P. Zinzani, S. Kovalchuk, A. Broccoli, A. Evangelista, D. Gioia, L. Mannelli, A. Castagnoli, A. Santoro, M. Bonfichi, G. Rossi, A. Anastasia, F. Zaja, U. Vitolo, V. Pavone, A. Pulsoni, G. Gaidano, C. Stelitano, F. Salvi, C. Rusconi, M. Tani, R. Freilone, E. Borsatti and A. Levis

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_19

    21. You have free access to this content
      PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY (pages 38–40)

      J. Trotman, S. Barrington, D. Belada, M. Meignan, R. MacEwan, C. Owen, V. Ptáčník, A. Rosta, G. Fingerle-Rowson, F. Mattiello, T. Nielsen, D. Sahin, W. Hiddemann, R. Marcus and A. Davies

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_20

    22. You have free access to this content
      FDG-PET as a Biomarker of Response in DLBCL: the HOVON 84 Study Experience (pages 40–41)

      C.N. Burggraaff, H.C. de Vet, O.S. Hoekstra, A.I. Arens, B. de Keizer, B. van der Holt, P.J. Lugtenburg and J.M. Zijlstra

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_21

    23. You have free access to this content
      NON-MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA (pages 41–42)

      C. Sarkozy, A. Mottok, H. Ghesquieres, C. Herbeaux, S. Ben-Neriah, C. Chassagne-Clément, C. Copie-Bergmann, J. Picquenot, J. Cornillon, R. Lemal, A. Bonnet, G. Manson, C. Golfier, A. Michallet, G. Salles, C. Steidl and A. Traverse-Glehen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_22

    24. You have free access to this content
      FOXP1 EXPRESSION IS INVERSELY CORRELATED WITH EZH2 MUTATION STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY (page 42)

      A. Mottok, V. Jurinovic, P. Farinha, A. Rosenwald, G. Ott, W. Klapper, M. Boesl, W. Hiddemann, C. Steidl, J.M. Connors, L.H. Sehn, R.D. Gascoyne, E. Hoster, O. Weigert and R. Kridel

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_23

    25. You have free access to this content
      ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R-CHOP (pages 42–43)

      C. Keane, C. Gould, G. Gifford, W. Stevenson, S. Birch, J. Tobin, D. Talaulikar, S. Jain, S. Francis, M. Matthew, S. Gabrielli, E. Abro, F. Vari and M. Gandhi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_24

    26. You have free access to this content
      CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY (pages 43–44)

      M. Klanova, L.H. Sehn, I. Bence-Bruckler, F. Cavallo, J. Jin, M. Martelli, D. Stewart, U. Vitolo, F. Zaja, Q. Zhang, F. Mattiello, M.Z. Oestergaard, G.R. Fingerle-Rowson, T. Nielsen and M. Trneny

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_25

    27. You have free access to this content
      NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY (pages 44–45)

      M. Cheminant, J. Bruneau, G. Malamut, D. Sibon, N. Guegan, A. Trinquand, L. Lhermitte, N. Brousse, F. Suarez, L. Frenzel, R. Delarue, A. Marçais, E. Macintyre, V. Asnafi, F. Lhospice, C. Bonnafous, T. Molina, B. Meresse, C. Cellier, N. Cerf-Bensussan and O. Hermine

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_26

    28. You have free access to this content
      ADULT PATIENTS WITH CAEBV-LIKE FEATURES: A DISTINCT SUBTYPE OF EPSTEIN-BARR VIRUS POSITIVE T/NK-CELL LYMPHOPROLIFERATIVE DISORDER (page 45)

      K. Kawamoto, H. Miyoshi, Y. Sasaki, D. Kurita, K. Yamada, J. Shimono, H. Sone, J. Takizawa, M. Seto, H. Kimura and K. Ohshima

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_27

    29. You have free access to this content
      PHARMACOLOGICAL ACTIVITY OF CB-103 IN HAEMATOLOGICAL MALIGNANCIES – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION (page 46)

      D. Weber, R. Lehal, V. Frismantas, J. Bourquin, M. Bauer, M. Murone and F. Radtke

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_28

    30. You have free access to this content
      ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B-CELL NON-HODGKIN LYMPHOMA (pages 46–47)

      P. Pérez-Galán, A. Vidal-Crespo, A. Matas-Céspedes, V. Rodriguez, C. Rossi, G. Roué, A. López-Guillermo, E. Giné, E. Campo, D. Colomer, A. Wiestner, C. Bezombes, S. Balasubramanian, C. Chiu and P. Doshi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_29

    31. You have free access to this content
      A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY (pages 47–48)

      S. Le Gouill, M. Wermke, F. Morschhauser, S.T. Lim, G. Salles, I. Kloos, V. de Burgat, M. Becquart, G. Paux, L. Kraus-Berthier, S. Pennaforte, S. Stilgenbauer, J. Walewski and V. Ribrag

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_30

    32. You have free access to this content
      Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results (pages 48–49)

      M. Bagot, P. Porcu, C. Ram-Wolff, M. Khodadoust, W. Basem, M. Battistella, A. Marie-Cardine, M. Vermeer, S. Mathieu, S. Whittaker, M. Duvic, A. Bensussan, C. Paturel, C. Bonnafous, N. Thonnart, A. Widemann, C. Bonin, H. Sicard, C. Paiva, K. Pilz and Y.H. Kim

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_31

    33. You have free access to this content
      A PHASE 1 STUDY OF THE ANTI-CD37 ANTIBODY-DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS (page 49)

      A. Sawas, K.J. Savage, R.P. Perez, R.H. Advani, J.M. Zaine, J.M. Lackey, F. Trave, B. Anand, R. Chu, L.M. Reyno and O.A. O'Connor

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_32

    34. You have free access to this content
      FIRST CLINICAL RESULTS OF ADCT-402, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B-CELL LINEAGE NHL (pages 49–51)

      B. Kahl, M. Hamadani, P.F. Caimi, E.G. Reid, K. Havenith, S. He, J.M. Feingold and O.A. O'Connor

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_33

    35. You have free access to this content
      FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (page 51)

      P. Martin, S. Jung, B. Pitcher, N.L. Bartlett, K.A. Blum, T. Shea, J. Ruan, S.E. Smith, J.P. Leonard and B.D. Cheson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_34

    36. You have free access to this content
      L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) – A SINGLE-ARM PHASE II STUDY (pages 51–52)

      G. Salles, E. González Barca, W. Jurczak, A.M. Liberati, J. Duell, Z. Nagy, T. Papajík, M. Andre, N. Kalakonda, M. Dreyling, P.L. Zinzani, S. Ambarkhane, J. Weirather and K. Maddocks

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_35

    37. You have free access to this content
      A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA (pages 52–53)

      F. Morschhauser, S. Le Gouill, P. Feugier, E. Van Den Neste, E. Nicolas-Virelizier, F. Bijou, G.A. Salles, H. Tilly, K. Van Eygen, A. Van Hoof, C. Bonnet, C. Haioun, R. Bouabdallah, B. Fabiani, L. Xerri, G. Cartron and R. Houot

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_36

  4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL) (page 53)

      J.M. Michot, R. Bouabdallah, J.K. Doorduijn, U. Vitolo, A. Chiappella, M.J. Kersten, P.L. Zinzani, R. Sarmiento, S. Mosulen, M. Petrarca, M. Pourdehnad, K. Hege, Z. Yang, Z. Nikolova and V. Ribrag

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_37

  5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA (page 54)

      C. Batlevi, P. Hamlin, M. Matasar, J. Gerecitano, P. Drullinsky, A. Hamilton, D. Straus, S. Horwitz, A. Kumar, C. Moskowitz, A. Moskowitz, A. Zelenetz, S. Ahsanuddin, D. Callan, B. Freidin, R. Porzio, J. Soiffer, A. Copeland, T. Dang, J. Rademaker, H. Schoder, A. Ni and A. Younes

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_38

    2. You have free access to this content
      UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR-1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL (pages 54–55)

      M.S. Davids, H.T. Kim, A. Nicotra, A. Savell, K. Francoeur, J.M. Hellman, H. Miskin, P. Sportelli, A. Bashey, L. Stampleman, J. Rueter, A. Boruchov, J.E. Arnason, C.A. Jacobson, E.J. Jacobsen, D.C. Fisher and J.R. Brown

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_39

    3. You have free access to this content
      GB VIRUS-C (GBV-C) INFECTION AND RISK OF LYMPHOMA: A CASE-CONTROL STUDY FROM NORTH AMERICA (pages 55–56)

      A. Fama, C. Allmer, B.K. Link, J. Xiang, D. Klinzman, A.J. Feldman, G.S. Nowakowski, M. Liebow, M.C. Larson, S.L. Slager, T.G. Call, T.M. Habermann, J.R. Cerhan and J.T. Stapleton

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_40

    4. You have free access to this content
      DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS (page 56)

      S. Dietrich, M. Oleś, L. Sellner, S. Anders, J. Lu, B. Velten, A. Mock, C. Oakes, L. Sutton, E. Young, R. Rosenquist, D. Rossi, K. Zirlik, M. Herling, F. Nguyen-Khac, C. Plass, C. von Kalle, J. Dürig, I. Ringshausen, W. Huber and T. Zenz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_41

    5. You have free access to this content
      ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL-LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (pages 56–57)

      V. Priebe, E.Y. Chung, L. Cascione, I. Kwee, A. Arribas, G. Sartori, S. Napoli, A. Rinaldi, A.A. Mensah, M. Ponzoni, E. Zucca, D. Rossi, G. Lenz, M. Thome and F. Bertoni

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_42

    6. You have free access to this content
      NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY a MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS (pages 57–58)

      F. Pozzo, T. Bittolo, E. Vendramini, R. Bomben, P. Bulian, F.M. Rossi, A. Zucchetto, E. Tissino, M. Degan, G. D'Arena, F. Di Raimondo, F. Zaja, G. Pozzato, D. Rossi, G. Gaidano, G. Del Poeta, V. Gattei and M. Dal Bo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_43

  6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      ACTIVATION OF RHOA-VAV1 SIGNALING IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (pages 57–59)

      M. Sakata-Yanagimoto, M. Fujisawa, S. Nishizawa, D. Komori, P. Gershon, M. Kiryu, T. Swarna, K. Fukumoto, T. Enami, M. Muratani, K. Yoshida, S. Ogawa, K. Matsue, N. Nakamura, K. Takeuchi, K. Izutsu, T. Teshima, K. Fujimoto, H. Miyoshi, P. Gaulard, K. Ohshima and S. Chiba

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_44

  7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA (page 59)

      R.L. Boddicker, G. Hu, S. Dasari, Y.W. Asmann, P.T. Greipp, R.A. Knudson, B.W. Eckloff, J. Jen, B.K. Link, N. Bennani, J.R. Cerhan and A.L. Feldman

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_45

    2. You have free access to this content
      MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT (pages 59–60)

      A. Mottok, G.W. Wright, A. Rosenwald, G. Ott, C. Ramsower, E. Campo, R.M. Braziel, J. Delabie, D.D. Weisenburger, J.Y. Song, J.W. Chan, J.R. Cook, K. Fu, T. Greiner, E. Smeland, H. Holte, B. Glinsmann-Gibson, R.D. Gascoyne, L.M. Staudt, E.S. Jaffe, J.M. Connors, D. Scott, C. Steidl and L.M. Rimsza

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_46

    3. You have free access to this content
      METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA. (pages 60–61)

      L. Ceriani, L. Milan, M. Martelli, A.J. Ferreri, A. Di Rocco, L. Giovanella, F. Cavalli, P.W. Johnson and E. Zucca

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_47

    4. You have free access to this content
      OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH DOSE-ADJUSTED EPOCH-R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS (pages 61–62)

      L.G. Roth, T. O'Donohue, Z. Chen, N. Bartlett, W. Martin-Doyle, M.J. Barth, K. Davies, B. Christian, C. Casulo, J. Godfrey, M.J. Oberley, S. Alexander, S. Weitzman, B. Appel, J. Svoboda, Z. Afify, M. Pauly, H. Dave, R. Gardner, D.M. Stephens, W.A. Zeitler, C. Forlenza, J. Levine, M.E. Williams, C.M. Bollard and J.P. Leonard

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_48

    5. You have free access to this content
      Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial (pages 62–63)

      P. Zinzani, C. Thieblemont, V. Melnichenko, D. Osmanov, K. Bouabdallah, J. Walewski, A. Majlis, L. Fogliatto, M.D. Caballero Barrigón, B. Christian, Z. Gulbas, M. Özcan, G.A. Salles, M.A. Shipp, A. Balakumaran, S. Chlosta, A. Chatterjee and P. Armand

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_49

    6. You have free access to this content
      RESTORE & TARGET: a CONCEPTUALLY NOVEL TREATMENT APPROACH TO CLASSICAL HODGKIN'S LYMPHOMA (pages 63–64)

      C. Schmitt, J. Du, A. Bittner, N. Neuendorff, Y. Yu, J. von Kries, S. Mathas, B. Dörken and S. Lee

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_50

  8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy (pages 64–65)

      A. Bruscaggin, V. Spina, M. Di Trani, M. Martini, S. Locatelli, E. Cupelli, G. Forestieri, A. Condoluci, A. Cuccaro, A. Moccia, A. Stathis, M. Manzoni, C. Deambrogi, F. Diop, G. Stüssi, F. Cavalli, F. Bertoni, E. Zucca, L.M. Larocca, G. Gaidano, S. Hohaus, C. Carlo-Stella and D. Rossi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_51

  9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM-PET-POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL (page 65)

      P. Borchmann, H. Goergen, C. Kobe, D. Eichenauer, R. Greil, A. Lohri, U. Novak, J. Markova, H. Beck, J. Meissner, J.M. Zijlstra, H. Ostermann, M. Feuring-Buske, J. Dierlamm, H. Eich, C. Baues, A. Rosenwald, M. Fuchs, V. Diehl, G. Kuhnert, M. Dietlein and A. Engert

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_52

    2. You have free access to this content
      RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033). (pages 65–67)

      J. Trotman, A. Fosså, M. Federico, L. Stevens, A. Kirkwood, L. Clifton-Hadley, P. Patrick, L. Berkahn, F. D'Amore, G. Enblad, S. Luminari, J. Radford, S.F. Barrington and P. Johnson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_53

    3. You have free access to this content
      BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI–PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL) (page 67)

      R. Chen, A.L. Gibb, G.P. Collins, R. Popat, D. El-Sharkawi, C. Burton, D. Lewis, F.M. Miall, A. Forgie, A. Compagnoni, G. Andreola, S. Brar, A. Thall, A. Woolfson and J. Radford

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_54

    4. You have free access to this content
      COMBINED RISK OF SECOND MALIGNANT NEOPLASMS AND CARDIOVASCULAR DISEASE IN LONG-TERM HODGKIN LYMPHOMA SURVIVORS (pages 67–68)

      B.M. Aleman, S. de Vries, F.A. van Nimwegen, M. Schaapveld, P.J. Lugtenburg, A.D. Krol, J. Roesink, J.M. Raemaekers and F.E. van Leeuwen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_55

    5. You have free access to this content
      CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (pages 68–69)

      G. Lenz, E. Hawkes, G. Verhoef, C. Haioun, S. Lim, D. Heo, K. Ardeshna, G. Chong, J.H. Christensen, V. Shi, S. Lippert, F. Hiemeyer, P. Piraino, G. Beckmann, C. Peña, V. Buvaylo, B.H. Childs, I. Gorbatchevsky and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_56

    6. You have free access to this content
      DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (pages 69–70)

      P. Zinzani, N. Wagner-Johnston, C. Miller, K. Ardeshna, S. Tertreault, S. Assouline, J. Mayer, F. Passamonti, S. Lunin, A. Pettitt, Z. Nagy, O. Tournilhac, K. Abou-Nassar, M. Crump, E. Jacobsen, S. De Vos, H. Youssoufian, J. Porter, S. Prado and I. Flinn

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_57

    7. You have free access to this content
      BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) (pages 70–71)

      J. Trotman, S. Opat, P. Marlton, D. Gottlieb, D. Simpson, G. Cull, D. Ritchie, E. Verner, S. Ratnasingam, M. Anderson, P. Wood, L. Wang, L. Xue, E. Hedrick, J. Huang, J. Hilger, J.F. Seymour, A.W. Roberts and C.S. Tam

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_58

    8. You have free access to this content
      IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK. (page 72)

      C. Soussain, S. Choquet, C. Houillier, F. Bijou, R. Houot, E. Boyle, R. Gressin, E. Nicolas-Virelizier, M. Barrie, C. Moluçon-Chabrot, M. Lelez, A. Clavert, S. Coisy, M. Ertault de la Bretonnière, A. El Yamani, V. Touitou, N. Cassoux, S. Boussetta, F. Broussais, B. Gelas-Dore, N. Barzic, H. Ghesquières and K. Hoang-Xuan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_59

    9. You have free access to this content
      TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY (pages 72–74)

      J. Kaplan, L. Gordon, J. Infante, R. Popat, A. Rambaldi, S. Madan, M.R. Patel, G. Gritti, D. El-Sharkawi, I. Chau, J. Radford, J. Perez De Oteyza, P. Zinzani, S. Iyer, S. Faucette, E. Sheldon-Waniga, K. Stumpo, Y. Shou, C. Carpio and F. Bosch

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_60

    10. You have free access to this content
      THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (page 74)

      P.A. Hamlin, C.M. Farber, T.S. Fenske, J.L. Khatcheressian, C.B. Miller, J. Munoz, M.R. Patel, M.T. Schreeder, S.M. Smith, D.A. Stevens, A. Pandey, M.R. Birrell, J.M. Leeds, Y.L. Wang, G.P. Coffey and J.T. Curnutte

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_61

    11. You have free access to this content
      GENE EXPRESSION PROFILING USING a RTMLPA ASSAY ALLOWS FOR AN ACCURATE CLASSIFICATION OF PERIPHERAL T-CELL LYMPHOMA AND HIGHLIGHTS NOVEL SUBGROUPS WITHIN PTCLS-NOS (pages 74–75)

      P. Ruminy, F. Drieux, A. Abdel Sater, V. Fataccioli, V. Marchand, M. Parrens, C. Bossard, P. Dobay, P. Viailly, L. Veresezan, A. Dupuy, A. Pujals, J. Picquenot, H. Tilly, L. De Leval, F. Jardin and P. Gaulard

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_62

    12. You have free access to this content
      CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO-T TRIAL (pages 75–76)

      M. Gleeson, C. Peckitt, Y.M. To, L. Edwards, I. Chau, P. Johnson, K.M. Ardeshna, A. Wotherspoon, A. Attygalle, R. Begum, S. Chua, I. Zerizer, E.A. Hawkes, M.P. Macheta, G.P. Collins, J.A. Radford, A. Forbes, A. Hart, S. Montoto, P. McKay, K. Benstead, N. Morley, N. Kalakonda, Y. Hasan, D. Turner and D. Cunningham

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_63

    13. You have free access to this content
      ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS (pages 76–77)

      G. Fossard, F. Broussais, I. Coelho, S. Bailly, E. Nicolas-Virelizier, E. Toussaint, C. Lancesseur, F. Lebras, E. Willems, E. Tchernonog, R. Delarue, R. Gressin, A. Chauchet, E. Gyan, G. Cartron, C. Bonnet, C. Haioun, G. Damaj, P. Gaulard, L. Fornecker, H. Ghesquieres, O. Tournilhac, M. Gomes Da Silva, R. Bouabdallah, G. Salles and E. Bachy

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_64

    14. You have free access to this content
      BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION (pages 77–78)

      Y.H. Kim, H.M. Prince, S. Whittaker, S.M. Horwitz, M. Duvic, J. Scarisbrick, P. Quaglino, P.L. Zinzani, P. Wolter, O. Bechter, Y. Wang, M.C. Palanca-Wessels, K.W. Wood, M. Li, Y. Liu, H. Lin, M. Little, H. Danaee, W. Trepicchio and R. Dummer

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_65

    15. You have free access to this content
      IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT (pages 78–79)

      C.P. Fox, M. Bellei, M. Manni, S.J. Kim, Y.H. Ko, A.R. Shustov, M.E. Cabrera, C.S. Chiattone, S.M. Horwitz, M. Spina, R.H. Advani, F. Angrilli, C.A. De Souza, I. Dlouhy, R. Fernandez-Alvarez, R. Gabús, F. Hitz, D. Laszlo, S. Montoto, A. Nagler, A. Pavlovsky, U. Vitolo, L. Zoppegno, M. Federico and W.S. Kim

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_66

    16. You have free access to this content
      GAD-M REGIMEN FOR NEWLY DIAGNOSED EXTRANODAL NK/T CELL LYMPHOMA: ANALYSIS OF EFFICACY AND SAFETY FROM PHASE II STUDY (NCT 01991158) (pages 79–80)

      Y. Wang, T. Gao, Z. Liu, Y. Xia, P. Liu, P. Sun, X. Bi, H. Yang, W. Jiang and Z. Li

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_67

    17. You have free access to this content
      RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY) (pages 80–81)

      A. Gibb, S. Pirrie, K. Linton, K. Paterson, A. Davies, G. Collins, T. Menne, P. McKay, P. Fields, F. Miall, E. Nagy, K. Wheatley, V. Warbey, S. Barrington and J. Radford

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_68

    18. You have free access to this content
      BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON-BULKY HODGKIN LYMPHOMA: AN UPDATE FROM a PHASE 2 CLINICAL TRIAL (pages 81–82)

      S.I. Park, O. Olajide, N.M. Reddy, L.E. Budde, N. Ghosh, K.L. Richards, A.M. Deal, J.F. Noe, T.C. Shea and S.M. Ansell

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_69

    19. You have free access to this content
      RESULTS OF a MULTICENTRE UK-WIDE STUDY EVALUATING THE EFFICACY OF BRENTUXIMAB VEDOTIN IN RELAPSED, REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE PRE-TRANSPLANT NAÏVE SETTING (pages 82–83)

      T.A. Eyre, E.H. Phillips, K.M. Linton, S. Kassam, A. Gibb, S. Allibone, K. Peggs, C. Burton, G. Stewart, R. Ledieu, C. Booth, W. Osborne, F. Miall, D.W. Eyre, K. Ardeshna and G.P. Collins

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_70

    20. You have free access to this content
      BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY (pages 83–84)

      A. Bazarbachi, A. Boumendil, H. Finel, M. Mohty, L. Castagna, D. Blaise, K. Peggs, B. Afanasyev, J. Diez-Martin, P. Corradini, G. Socié, S. Robinson, G. Gutiérrez-García, F. Bonifazi, I. Yakoub-Agha, Z. Gülbas, A. Bloor, J. Delage, A. Esquirol, R. Malladi, C. Scheid, H. Ghesquières, S. Montoto, P. Dreger and A. Sureda

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_71

    21. You have free access to this content
      SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412) (pages 84–85)

      C.S. Diefenbach, F. Hong, K. David, J. Cohen, M. Roberston, R. Advani, N. Palmisano, R. Ambinder, B. Kahl and S. Ansell

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_72

    22. You have free access to this content
      INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (pages 85–86)

      A.F. Herrera, A.J. Moskowitz, N.L. Bartlett, J.M. Vose, R. Ramchandren, T.A. Feldman, A.S. Lacasce, S.M. Ansell, C.H. Moskowitz, K. Fenton, C. Ogden, D. Taft, Q. Zhang, K. Kato, M. Campbell and R.H. Advani

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_73

    23. You have free access to this content
      CLARITHROMYCIN AS a “REPURPOSING DRUG” AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) (pages 86–87)

      A.J. Ferreri, C. Cecchetti, B. Kiesewetter, M. Sassone, T. Calimeri, S. Perrone, M. Ponzoni and M. Raderer

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_74

    24. You have free access to this content
      A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) (pages 87–88)

      J.E. Amengual, R. Lichtenstein, J.K. Lue, A. Sawas, C. Deng, E. Lichtenstein, K. Khan, H. Kim, L. Atkins, I. Turenne, C. Rojas, C. Chiuzan, S. Cremers and O.A. O'Connor

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_75

    25. You have free access to this content
      CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR-DLBCL) - OUTCOME OF IBRUTINIB + R-GDP (page 88)

      J. Kuruvilla, M. Crump, D. Villa, M. Aslam, A. Prica, D.W. Scott, N. Abdel-Samad, S. Couban, S. Doucet, J. Dudebout, I. Fleury, G. Fraser, J. Larouche, M. Shafey, P. Skrabek, T. Skamene, C. Winch, L. Shepherd, B.E. Chen and A.E. Hay

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_76

    26. You have free access to this content
      EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL. (pages 88–89)

      A.R. Pettitt, N. Kalakonda, F. Polydoros, M. Bickerstaff, G. Menon, S.E. Coupland, M. Oates, K. Lin, C. Pocock, S. Jenkins, A. Schuh, F. Wandroo, S. Rassam, A.S. Duncombe, M. Jenner, P. Cervi, S. Paneesha, M. Aldouri, C.P. Fox, C. Knechtli, M. Hamblin, D. Turner and P. Hillmen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_77

    27. You have free access to this content
      VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY (page 90)

      L.J. Swinnen, C.R. Flowers, D. Wang, E. Reid, N. Fowler, J. Cordero, M. Dunbar, S. Enschede, C. Nolan, A.M. Petrich, J. Ross, A.H. Salem, M. Verdugo, S. Wong, L. Zhou, M. Kozloff, L. Nastoupil and S. de Vos

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_78

    28. You have free access to this content
      POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (pages 90–91)

      H. Tilly, J. Sharman, N. Bartlett, F. Morschhauser, C. Haioun, J. Munoz, A. Chen, T. Lamy, L. Wang, E. Penuel, J. Hirata, C. Lee and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_79

    29. You have free access to this content
      APPLICATION OF a GENE EXPRESSION-BASED MODEL IN COMBINATION WITH FDG-PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033) (pages 91–92)

      C.H. Burton, D. Scott, A.A. Kirkwood, M. Gandhi, J. Radford, S. Barrington, M. Federico, S. Luminari, J. Trotman, L. Berkhan, F.A. D'Amore, P. Kamp, G. Enblad, D. Molin, R. Chalkley, P. Smith, L. Stevens, T. Roberts, P. Patrick, F. Chan, Y. Harvey, A. Mottok, R. Gascoyne and P. Johnson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_80

    30. You have free access to this content
      THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL (pages 92–93)

      D.W. Scott, H. Li, Y. Harvey, F. Chan, A. Mottok, M. Boyle, A.M. Evens, H. Schoder, D.J. Straus, N.L. Bartlett, J.W. Sweetenham, P.M. Barr, M.A. Fanale, E.D. Hsi, J.R. Cook, B.S. Kahl, J.P. Leonard, J.W. Friedberg, M. Leblanc, C. Steidl, R.D. Gascoyne, L.M. Rimsza and O.W. Press

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_81

  10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP (pages 93–94)

      I. Dlouhy, K. Karube, A. Enjuanes, I. Salaverría, P. Pérez-Galán, P. Jares, D. Martín-García, F. Nadeu, A. Rivas-Delgado, J. Rovira, B. Gonzalez, A. Mozos, G. Clot, J.M. Sancho, A. Salar, S. Mercadal, L. Escola, J. Briones, L. Colomo, M. Alcoceba, A. Valera, E. Campo and A. López-Guillermo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_82

  11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL (pages 94–95)

      S. Ferrero, D. Rossi, A. Bruscaggin, A. Evangelista, A. Di Rocco, V. Spina, V. Stefoni, P. Ghione, D. Barbero, L. Monitillo, M. Gomes Da Silva, A. Santoro, A. Molinari, A. Ferreri, A. Piccin, S. Cortelazzo, M. Ladetto and G. Gaidano

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_83

  12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      BASELINE CIRCULATING CELL-FREE DNA LOAD IS RELATED TO, BUT ADDS PROGNOSTIC VALUE TO METABOLIC TUMOR BURDEN MEASURED BY FDG PET/CT IN FOLLICULAR LYMPHOMA (page 95)

      M.H. Delfau-Larue, I. Benmaad, P. Robert, S. Hamdane, I. Nel, J. Dupuis, C. Haioun, A. Berriolo Riedinger, R.O. Casasnovas and E. Itti

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_84

  13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL (pages 96–97)

      S. Huet, E. Szafer-Glusman, L. Xerri, C. Bolen, E. Punnoose, L. Tonon, H. Tilly, P. Brice, P. Feugier, B. Tesson, A. Viari, J.M. Venstrom and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_85

  14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA (pages 97–98)

      S. Alig, V. Jurinovic, M. Dreyling, A. Pastore, R. Kridel, R. Gascoyne, W. Hiddemann, M. Unterhalt, E. Hoster and O. Weigert

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_86

  15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY (pages 98–99)

      M.H. Delfau-Larue, A. Beldi-Ferchiou, J. Jais, N. Godard, G.A. Salles, R. Casasnovas, H. Tilly, C. Fruchart, F. Morschhauser, C. Haioun, J. Lazarovici, A. Perrot, C. Sebban, R. Bouabdallah, H. Gonzalez, B. Corront, L. Oberic, J. Briere, P. Gaulard, B. Coiffier and C. Thieblemont

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_87

  16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP (pages 99–100)

      O. Al-Sawaf, J. Bahlo, K. Fischer, C. Herling, M. Bergmann, A.M. Fink, J. von Tresckow, P. Langerbeins, P. Cramer, S. Stilgenbauer, C.M. Wendtner, B. Eichhorst, M. Hallek and V. Goede

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_88

    2. You have free access to this content
      UNMET MEDICAL NEEDS IN HODGKIN LYMPHOMA WITH SPECIAL FOCUS ON THE ELDERLY – a POPULATION-BASED STUDY OF PATIENTS DIAGNOSED IN SWEDEN 1973-2014 (pages 100–101)

      M. Bjorkholm, C.E. Weibull, S. Eloranta, K. Ekström-Smedby, I. Glimelius and P.W. Dickman

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_89

    3. You have free access to this content
      TREATMENT STRATEGIES AND OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA OF THE ELDERLY: A DANISH POPULATION-BASED COHORT STUDY OF 1,011 PATIENTS (pages 100–102)

      M.B. Juul, P.H. Jensen, H. Engberg, S. Wehberg, A. Dessau-Arp, D. Haziri, H.B. Kristensen, J. Baech, L. Schurmann, M.R. Clausen, R.X. Valentin, L.M. Knudsen, L. Munksgaard, T.C. El-Galaly, H. Frederiksen and T.S. Larsen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_90

  17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP (pages 102–103)

      C. Thieblemont, R. Casasnovas, N. Mounier, A. Perrot, F. Morschhauser, H. Tilly, C. Fruchart, B. Corront, C. Haouin, K. Van Eygen, L. Obéric, R. Bouabdallah, C. Sebban, D. Bordessoule, O. Fitoussi, A. Van Hoof, J.C. Eisenmann, P. Lionne-Huyghe, D. Deeren, M. Gomes Da Silva, J. Trotman, S. Grosicki, R. Greil, D. Caballero and B. Coiffier

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_91

    2. You have free access to this content
      A SINGLE-CELL BASED MODEL EXPLAINS PATTERNS OF CLONAL EVOLUTION IN PRIMARY AND RELAPSED FOLLICULAR LYMPHOMA (pages 103–104)

      M. Loeffler, M. Horn, M. Kreuz, R. Siebert, C. Pott, H. Trautmann, W. Klapper and R. Küppers

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_92

    3. You have free access to this content
      FULL TRANSCRIPTOME SEQUENCING OF SORTED HODGKIN AND REED-STERNBERG CELLS REVEALS PLASMACYTIC DIFFERENTIATION: INSIGHTS INTO MECHANISMS OF ONCOGENESIS AND IMMUNE EVASION (pages 104–105)

      M. Roshal, J. Reichel, F. Wagner, S. Zairis, J. Sadek, J. Brody, O. Elemento, R. Rabadan, S. Dave and E. Cesarman

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_93

    4. You have free access to this content
      PROFILING OF DNA METHYLATION IN EPIDEMIOLOGICAL AND CLINICAL SUBGROUPS OF BURKITT LYMPHOMA IN THE FRAMEWORK OF THE MMML: ICGC AND BLUEPRINT CONSORTIA (pages 105–106)

      R. Wagener, H. Kretzmer, O. Ammerpohl, C. López, M. Rohde, E. Carillo-De-Santa-Pau, I. Salaverria, M. Szczepanowski, B. Burkhardt, M. Hummel, W. Klapper, R. Küppers, M. Löffler, P. Möller, J. Neequaye, W. Wößmann, P. Lichter, H. Stunnenberg, L. Trümper, S.M. Mbulaiteye, S. Hoffman and R. Siebert

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_94

    5. You have free access to this content
      MUTATIONAL SIGNATURES IN GERMINAL CENTER DERIVED B-CELL LYMPHOMAS FROM ADULT PATIENTS ANALYZED IN THE ICGC MMML-SEQ CONSORTIUM (pages 106–107)

      D. Huebschmann, K. Kleinheinz, R. Wagener, H. Kretzmer, U.H. Toprak, S.H. Bernhart, C. Lopez Gonzales, M. Kreuz, R. Eils, M. Hansmann, S. Hoffmann, M. Hummel, W. Klapper, C. Lawerenz, M. Loeffler, P. Möller, J. Richter, P. Rosenstiel, A. Rosenwald, S. Stilgenbauer, M. Weniger, L. Trümper, R. Küppers, M. Schlesner and R. Siebert

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_95

    6. You have free access to this content
      CROSS-PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP) BASED CELL OF ORIGIN (COO) CLASSIFICATION IN a CLINICAL LABORATORY SETTING (page 107)

      C. Burton, S. Barrans, S. Ahmed, M.A. Bentley, A. Clipson, M. Wang, J. Taylor, R. Detute, D.R. Westhead, M.A. Care, M.Q. Du, A. Davies and P.W. Johnson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_96

    7. You have free access to this content
      THE LANDSCAPE OF SOMATIC MUTATIONS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG-TYPE (pages 107–109)

      F. Jardin, S. Mareschal, A. Pham-Ledard, P. Viailly, M. Carlotti, S. Dubois, P. Bertrand, C. Maingonnat, E. Bohers, P. Ruminy, I. Tournier, P. Courville, A. Duval, E. Andrieu, L. Verneuil, M. Fontanillles, B. Vergier, H. Tilly, P. Joly, T. Frebourg, M. Beylot-Barry and J. Merlio

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_97

    8. You have free access to this content
      INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE (pages 109–110)

      E. Tissino, D. Benedetti, S.E. Herman, E. ten Hacken, I.E. Ahn, K.G. Chaffee, E. Bayer, A. Haerzschel, J.C. Gutjahr, M. Postorino, E. Santinelli, A. Ayed, F. Zaja, A. Chiarenza, A. Chigaev, L.A. Sklar, J.A. Burger, A. Ferrajoli, T.D. Shanafelt, A. Wiestner, G. Del Poeta, T.N. Hartmann, V. Gattei and A. Zucchetto

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_98

    9. You have free access to this content
      INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS (pages 109–111)

      T.J. Kipps, G. Fraser, S.E. Coutre, J.R. Brown, J.C. Barrientos, P.M. Barr, J.C. Byrd, S.M. O'Brien, M. Dilhuydy, P. Hillmen, U. Jaeger, C. Moreno, P. Cramer, S. Stilgenbauer, A.A. Chanan-Khan, M. Mahler, M. Salman, M. Cheng, A. Londhe, J. Ninomoto, A. Howes, D.F. James and M. Hallek

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_99

    10. You have free access to this content
      UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY (pages 111–112)

      J.P. Sharman, D.M. Brander, A. Mato, S. Kambhampati, J.M. Burke, F. Lansigan, M.T. Schreeder, S.D. Lunin, N. Ghosh, A. Zweibach, M.I. Shtivelband, P.M. Travis, J. Chandler, K.S. Kolibaba, P. Sporteli, H.P. Miskin, M.S. Weiss and I.W. Flinn

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_100

    11. You have free access to this content
      CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. (pages 112–113)

      L. Nastoupil, M.A. Lunning, J.M. Vose, M.T. Schreeder, T. Siddiqi, C.R. Flowers, J.B. Cohen, J.A. Burger, W.G. Wierda, S. O'Brien, P. Sportelli, H.P. Miskin, M.A. Purdom, M.S. Weiss and N.H. Fowler

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_101

    12. You have free access to this content
      SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (page 113)

      C.S. Tam, H. Quach, A. Nicol, X. Badoux, H. Rose, H. Prince, M.F. Leahy, R. Eek, N. Wickham, S. Patil, J. Huang, X. Zhang, L. Wang, E. Hedrick, W. Novotny and I. Flinn

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_102

    13. You have free access to this content
      GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA (pages 113–115)

      S. Huet, B. Tesson, J. Jais, A.L. Feldman, L. Magnano, E. Thomas, A. Traverse-Glehen, B. Albaud, L. Xerri, S. Ansell, K. Tarte, S. Boyault, C. Haioun, B. Link, P. Feugier, A. Lopez-Guillermo, P. Brice, S. Hayette, F. Jardin, F. Offner, D. Gentien, A. Viari, E. Campo, J.R. Cerhan and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_103

    14. You have free access to this content
      THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE (pages 115–116)

      M. Federico, D. Caballero, L. Marcheselli, V. Tarantino, C. Sarkozy, A. Lopez Guillermo, M. Wondergem, E. Kimby, C. Rusconi, E. Zucca, S. Montoto, M.G. da Silva, I. Aurer, E. Paszkiewicz-Kozik, G. Cartron, F. Morschhauser, M. Alcoceba, M. Chamuleau, S. Lockmer, C. Minoia, D. Issa, S. Alonso, L. Conte, G. Salles and B. Coiffier

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_104

    15. You have free access to this content
      PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS (pages 116–117)

      A. Cottereau, A. Versari, J. Dupuis, L. Chartier, M. Menga, R. Casasnovas, C. Haioun, H. Tilly, V. Tarantino, J. Dubreuil, M. Federico, G. Salles, S. Luminari, J. Trotman and M. Meignan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_105

    16. You have free access to this content
      IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN (pages 117–119)

      W. Hiddemann, A.M. Barbui, M.A. Canales Albendea, P.K. Cannell, G.P. Collins, J. Dürig, R. Forstpointner, M. Herold, M. Hertzberg, M. Klanova, J.A. Radford, K. Tobinai, A. Burciu, G.R. Fingerle-Rowson, T. Nielsen, M. Wolbers and R. Marcus

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_106

    17. You have free access to this content
      COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1) (pages 119–120)

      M. Dreyling, A. Santoro, L. Mollica, S. Leppä, G.A. Follows, G. Lenz, W. Kim, A. Nagler, P. Panayiotidis, J. Demeter, M. Özcan, M. Kosinova, K. Bouabdallah, F. Morschhauser, D.A. Stevens, D. Trevarthen, M. Giurescu, L. Liu, K. Koechert, C. Peña, L. Cupit, S. Yin, F. Hiemeyer, J. Garcia-Vargas, B.H. Childs and P. Zinzani

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_107

    18. You have free access to this content
      HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN-LABEL, PHASE II STUDY (pages 120–121)

      L.J. Nastoupil, J. Westin, N. Fowler, M. Fanale, F. Samaniego, Y. Oki, C. Obi, J. Cao, X. Cheng, M. Ma, Z. Wang, F. Chu, L. Feng, S. Zhou, R.E. Davis and S.S. Neelapu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_108

    19. You have free access to this content
      NON-CANONICAL ROLE OF EZH2 IN NATURAL KILLER / T-CELL LYMPHOMA (pages 121–122)

      W.J. Chng, J. Yan, B. Li, B. Lin and S.B. Ng

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_109

    20. You have free access to this content
      EBV-ASSOCIATED NODAL T AND NK-CELL LYMPHOMA SHOWS DISTINCT MOLECULAR SIGNATURE AND COPY NUMBER CHANGES (page 122)

      W.J. Chng, T.H. Chung, V. Selvarajan and S.B. Ng

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_110

    21. You have free access to this content
      NK/T-CELL LYMPHOMA: WHEN PATIENTS MEET OMICS (pages 122–123)

      W. Zhao

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_111

    22. You have free access to this content
      TREATMENT OF EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE (ENKTL) (page 123)

      W.S. Kim

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_112

    23. You have free access to this content
      FIRST-LINE L-ASPARAGINASE-BASED CHEMOTHERAPY PLUS RADIOTHERAPY IS ACTIVE IN STAGE I/II EXTRANODAL NK/T-CELL LYMPHOMA: RESULTS FROM PEKING UNIVERSITY CANCER HOSPITAL (page 124)

      Y. Song, J. Jia, M. Wu, X. Leng, N. Lin, Y. Xie, W. Zheng, X. Wang, L. Ping, M. Tu, Z. Ying, C. Zhang, W. Liu, L. Deng and J. Zhu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_113

  18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      CURRENT TREATMENT FOR NK/T CELL LYMPHOMA:SUN YAT-SEN UNIVERSITY CANCER CENTER EXPERIENCE, CHINA (pages 124–125)

      H. Huang, Y. Gao, B. Bai, X. Wang, Y. Zhang, Z. Li, Q. Cai and W. Jiang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_114

  19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      MOLECULAR CHARACTERIZATION OF EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMAS, NASAL TYPE FROM LATIN AMERICA (pages 125–126)

      L. Quintanilla-Fend, I. Montes-Mojarro, J. Steinhilber, C. Lome-Maldonado, A.F. Ramirez-Ibarguen, B. Acosta, C. Barrionuevo, D. Duenas, M. Narbaitz, I. Bonzheim and F. Fend

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_115

    2. You have free access to this content
      NK/T-CELL LYMPHOMA, THE FRENCH EXPERIENCE. (pages 126–127)

      A. Jaccard, L. Philippe, L. Couronné, J.-F. Benoist and O. Hermine

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_116

    3. You have free access to this content
      LONG-TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION-BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (pages 127–128)

      K.E. Smedby, S. Ekberg, P. Andersson, G. Enblad, B.E. Wahlin, S. Hasselblom, M. Jerkeman and S. Eloranta

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_117

    4. You have free access to this content
      R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS (pages 128–129)

      T. Lamy, G. Damaj, P. Soubeyran, E. Gyan, S. Legouill, G. Cartron, K. Boubdallah, R. Gressin, J. Cornillon, A. Banos, K. Ledu, M. Benchalal, M. Moles, J. Fleury, P. Godmer, H. Maisonneuve, E. Deconninck, K. Laribi, J. Marolleau, O. Tournilhac, A. Deviller, T. Fest, P. Colombat, V. Costes, M. Bene and V. Delwail

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_118

  20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL (pages 129–130)

      M. Pfreundschuh, K. Christofyllakis, B. Altmann, M. Ziepert, M. Haenel, A. Viardot, A. Neubauer, G. Held, L. Truemper, M. Dreyling, L. Kanz, M. Hallek, N. Schmitz, T. Heintges, C. Kölbel, A. Buecker, C. Ruebe, D. Hellwig, C. Berdel, V. Poeschel and N. Murawski

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_119

    2. You have free access to this content
      DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL-B (pages 130–131)

      A.J. Davies, S. Barrans, T. Maishman, T.E. Cummin, M. Bentley, C. Mamot, U. Novak, J. Caddy, D. Hamid, S.H. Kazmi-Stokes, A. Mcmillan, P.A. Fields, C. Pocock, A. Kruger, G. Collins, C. Sha, A. Clipson, M. Wang, R.M. Tooze, M.A. Care, G.O. Griffiths, M. Du, D.R. Westhead, C. Burton, A. Jack and P.W. Johnson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_120

  21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY (pages 131–133)

      L.H. Sehn, M.Z. Oestergaard, M. Trněný, A. Bosi, M. Egyed, A. Illes, H. Nakamae, S. Opat, M. Topp, F. Zaja, G. Fingerle-Rowson, G. Lei, T. Nielsen, E.A. Punnoose, M. Rahman, J. Ray, L. Zhang, M. Martelli and U. Vitolo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_121

  22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA-EPOCH-R (pages 133–134)

      K. Dunleavy, M. Roschewski, J.S. Abramson, B. Link, S. Parekh, D. Jagadeesh, P. Bierman, P.R. Watson, D. Peace, W. Hanna, B. Powell, C. Melani, A. Lucas, S.M. Steinberg, B. Kahl, J.W. Friedberg, R.F. Little, N.L. Bartlett, M.A. Fanale, A. Noy and W.H. Wilson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_122

  23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      CD27 STIMULATION ENHANCES CD20 MAB THERAPY THROUGH ACTIVATION OF INNATE IMMUNITY (pages 134–135)

      A.H. Turaj, M. Rose-Zerilli, K. Cox, S. James, A. Al-Shamkhani, T. Keler, P.W. Johnson, S.M. Thirdborough, S.A. Beers, M.J. Glennie, M.S. Cragg and S.H. Lim

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_123

    2. You have free access to this content
      NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL (pages 135–136)

      M. Fanale, A. Engert, A. Younes, P. Armand, S. Ansell, P.L. Zinzani, J.M. Timmerman, G.P. Collins, R. Ramchandren, J.B. Cohen, J.P. De Boer, J. Kuruvilla, K.J. Savage, M. Trneny, S. Rodig, M. Shipp, K. Kato, A. Sumbul, B. Farsaci and A. Santoro

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_124

    3. You have free access to this content
      PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY (pages 136–137)

      P.L. Zinzani, M.A. Fanale, R. Chen, P. Armand, N. Johnson, P. Brice, J. Radford, V. Ribrag, D. Molin, T.P. Vassilakopoulos, A. Tomita, B. von Tresckow, M.A. Shipp, Y. Zhang, A. Balakumaran and C.H. Moskowitz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_125

    4. You have free access to this content
      A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL) (pages 137–138)

      M.L. Palomba, B.G. Till, S.I. Park, F. Morschhauser, G. Cartron, R. Marks, E. Penuel, S. Chitra, M. Kuhn and L. Popplewell

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_126

    5. You have free access to this content
      HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001) (page 138)

      J. Abramson, M.L. Palomba, L. Gordon, M. Lunning, J. Arnason, M. Wang, A. Forero-Torres, T. Albertson, T. Allen, C. Sutherland, B. Xie, J. Garcia and T. Siddiqi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_127

  24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) (pages 138–139)

      C. Sauter, I. Riviere, B. Senechal, A. Ni, Y. Bernal, X. Wang, T. Purdon, M. Hall, C. Moskowitz, S. Giralt, M. Matasar, K. Curran, J. Park, M. Sadelain and R. Brentjens

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_128

  25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND KI-67 IN PROSPECTIVE TRIALS OF THE EUROPEAN-MCL NETWORK (pages 139–140)

      S.M. Aukema, E. Hoster, A. Rosenwald, D. Canoni, G. Rymkiewicz, C. Thorns, S. Hartmann, H.C. Kluin-Nelemans, O. Hermine, M. Dreyling and W. Klapper

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_129

    2. You have free access to this content
      FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R-CHOP/R-CVP: RESULTS OF THE BRIGHT 5-YEAR FOLLOW-UP STUDY (pages 140–141)

      I. Flinn, R. van der Jagt, J. Chang, P. Wood, T. Hawkins, D. MacDonald, J. Trotman, D. Simpson, K. Kolibaba, S. Issa, D. Hallman, L. Chen and J.M. Burke

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_130

    3. You have free access to this content
      FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL (pages 141–142)

      R. Gressin, N. Daguindau, A. Tempescul, A. Moreau, S. Carras, G. Cartron, A. Schmitt, R. Houot, C. Dartigeas, J. Pignon, S. Corm, A. Bannos, C. Mounier, J. Dupuis, M. Macro, J. Fleury, F. Jardin, L. Karlin, G. Damaj, P. Feugier, L. Fornecker, C. Chabrot, I. Ysebaert, M. Callanan and S. Le Gouill

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_131

    4. You have free access to this content
      IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO (pages 142–143)

      M.L. Wang, H. Lee, S. Thirumurthi, H. Chuang, F. Hagemeister, J. Westin, L. Fayad, F. Samaniego, F. Turturro, W. Chen, O. Oriabure, L. Feng, S. Zhou, S. Huang, S. Li, L. Zhang, M. Badillo, L. Wu, M. Ahmed, F. Yan, K. Nomie, L. Lam, A. Addison and J. Romaguera

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_132

    5. You have free access to this content
      IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY (pages 143–144)

      S. Rule, W. Jurczak, M. Jerkeman, R. Santucci Silva, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, S. Cho, C. Thieblemont, W. Zhou, T. Henninger, J.D. Goldberg, J. Vermeulen and M. Dreyling

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_133

    6. You have free access to this content
      COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY (pages 144–145)

      C.S. Tam, A.W. Roberts, M. Anderson, S. Dawson, R. Hicks, K. Burbury, G. Turner, J. Di Iulio, M. Bressel, D. Westerman, R. Agarwal, C. Pott, M. Dreyling, M. Dawson and J.F. Seymour

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_134

    7. You have free access to this content
      INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION (pages 145–146)

      M. Frigeni, C. Visco, C. Besson, S. Rattotti, H. Fontaine, M. Goldaniga, M. Visentini, H.A. Torres, J. Peveling-Oberhag, R. Rossotti, F. Zaja, L. Rigacci, M. Merli, C. Dorival, L. Alric, F. Piazza, M. Gentile, A. Ferrari, M. Pirisi, A. Tedeschi, I. Defrancesco, V.V. Ferretti, R. Bruno, O. Hermine and L. Arcaini

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_135

    8. You have free access to this content
      IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL) (pages 146–147)

      M. Herold, E. Hoster, A. Janssens, H. McCarthy, A. Tedeschi, C. Pocock, A. Rosta, P. Schmidt, M. Trněný, A. Burciu, G. Fingerle-Rowson, K. Rufibach, H. Zeuner, W. Hiddemann and R. Marcus

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_136

  26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01). (pages 147–148)

      A. Salar, E. Domingo-Domenech, C. Panizo, C. Nicolás, J. Bargay, A. Muntañola, M. Canales, J. Bello, J. Sancho, J. Tomás, M. Rodriguez, F.J. Peñalver, L. Palomera, C. Grande, J.J. Sánchez-Blanco, R. Arranz, E. Conde, M. Garcia, J.F. García, D. Caballero and C. Montalbán

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_137

  27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. ORAL PRESENTATIONS

      You have free access to this content
      PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA (page 148)

      M. Coleman, D.J. Andorsky, A. Yacoub, J.M. Melear, K.S. Kolibaba, H.D. Brooks, J.D. Bitran, S.R. Fanning, F. Lansigan, J.L. Ricker, K.A. Foon, M. Llorente, J. Li and J.P. Sharman

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2437_138

    2. POSTER PRESENTATIONS

      You have free access to this content
      WHOLE-EXOME-SEQUENCING OF NODAL MARGINAL ZONE LYMPHOMAS IDENTIFIES RECURRENT MOLECULAR LESIONS IN GENES INVOLVED IN CHROMATIN REMODELLING AND NOTCH SIGNALLING (page 149)

      V. Pillonel, D. Juskevicius, C.K. Ng, D. Jucker, S. Dirnhofer and A. Tzankov

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438

    3. You have free access to this content
      INTEGRATIVE MUTATIONAL ANALYSIS OF PEDIATRIC-TYPE FOLLICULAR LYMPHOMA REVEALS TNFRSF14 AND MAP2K1 AS THE MOST FREQUENTLY MUTATED GENES (pages 149–150)

      J. Schmidt, J. Ramis-Záldivar, F. Nadeu, B. Gonzalez-Farre, A. Navarro, S. Dojcinov, A. Rosenwald, G. Ott, E. Campo, F. Fend, C. Egan, E. Jaffe, I. Salaverria and L. Quintanilla-Martinez

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_1

    4. You have free access to this content
      DOWN-REGULATION OF MIR-150 AND UP-REGULATION OF ITS TARGET FOXP1 IS ASSOCIATED WITH TRANSFORMATION OF FOLLICULAR LYMPHOMA (pages 150–151)

      K. Musilova, G. Pavlasova, V. Seda, K. Cerna, E. Vojackova, J. Didi, R. Pytlik, V. Prochazka, Z. Prouzova, L. Zlamalikova, H. Mocikova, M. Jarosova, A. Evans, C. Zent, L. Kren, M. Trneny, J. Mayer, A. Janikova and M. Mraz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_2

  28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. POSTER PRESENTATIONS

      You have free access to this content
      NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY (page 151)

      S. Ferrero, E. Genuardi, P. Klous, D. Drandi, B. Mantoan, L. Monitillo, D. Barbero, M. Yilmaz, F. Cattellino, M. Vasta, F. Cavallo, S. Cortelazzo, U. Vitolo, S. Luminari, M. Federico, M. Boccadoro, E. Splinter and M. Ladetto

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_3

    2. You have free access to this content
      HOST GENETIC VARIATION IN THE TNF AND NF-ĸB PATHWAYS AND PROGNOSIS IN MANTLE CELL LYMPHOMA: AN ANALYSIS OF 2 STUDIES (pages 151–152)

      Y. Wang, T.M. Habermann, S.S. Wang, M.J. Maurer, B.K. Link, A.L. Feldman, D.J. Inwards, T.E. Witzig, W. Cozen, L.M. Morton, N. Rothman, S.J. Chanock, S.L. Slager and J.R. Cerhan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_4

    3. You have free access to this content
      HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS—A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL (pages 152–153)

      D.W. Scott, B. Pitcher, Y. Liu, M. Boyle, A. Mottok, J. Said, A. Chadburn, R. Lai, S. Jung, N.L. Bartlett, J.P. Leonard, L.D. Kaplan and E.D. Hsi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_5

    4. You have free access to this content
      ETS1 PHOSPHORYLATION AT THR38 (PETS1) IS ASSOCIATED WITH CELL OF ORIGIN (COO), CELL CYCLE ACTIVATION, AND INFERIOR OUTCOME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (pages 153–154)

      E.Y. Chung, M. Ponzoni, Z.Y. Xu-Monette, L. Cascione, V. Priebe, E. Gaudio, J. Wang, J. Zhang, C. Visco, G. Bhagat, E. Zucca, D. Rossi, K.H. Young and F. Bertoni

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_6

    5. You have free access to this content
      DNMT3A-2 EXPRESSION LEVELS CHARACTERISE DIFFUSE LARGE B-CELL LYMPHOMA WITH DISTINCT METHYLATION PATTERNS AND OUTCOME (page 154)

      A. Kuhnl, R. Shaikh, D. Cunningham, N. Counsell, S. Barrans, C. Burton, M. Bentley, M. Gleeson, L. Edwards, L. Ulrich, P. Smith, L. Clifton-Hadley, O. Schofield, A. Lawrie, D. Linch, M. Hubank and M. Kaiser

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_7

    6. You have free access to this content
      KRAS AND AGO2 INTERACTION PROMOTE INITIATION OF PLASMABLASTIC LYMPHOMA USING AN IN VIVO MOUSE TRANSPLANT MODEL (page 155)

      K. Thai, A. Louissaint Jr, P. Sharp and T. Jacks

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_8

    7. You have free access to this content
      COMPREHENSIVE EPIGENETIC AND TRANSCRIPTIONAL SURVEY OF THE “IMPRINTOME” IN NORMAL B-CELLS AND GERMINAL CENTER DERIVED B-CELL LYMPHOMAS OF THE MMML AND ICGC MMML-SEQ NETWORKS (pages 155–156)

      S. Bens, J. Kolarova, M. Kreuz, S. Bernhart, H. Kretzmer, R. Wagener, R. Küppers, O. Ammerpohl, B. Burkhardt, S. Hoffmann, M. Hummel, W. Klapper, P. Lichter, M. Löffler, P. Möller, B. Radlwimmer, P. Rosenstiel, H. Stein, L. Trümper and R. Siebert

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_9

    8. You have free access to this content
      GENE EXPRESSION PROFILING AND MUTATION ANALYSIS CAN AID TREATMENT DECISION MAKING IN AGGRESSIVE B CELL LYMPHOMA PATIENTS (page 156)

      C.H. Burton, S. Barrans, S. Van Hoppe, C. Sha, J. Taylor, P. Evans, D. Painter, A. Smith, S. Crouch, J.R. Goodlad, E. Roman, D. Westhead, A. Davies and P.W. Johnson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_10

    9. You have free access to this content
      APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS (pages 156–157)

      M. Baptista, G. Tapia, A. Muñoz-Marmol, J. Muncunill, S. Montoto, J. Gribben, M. Calaminici, A. Martinez, B. Gonzalez-Farre, A. López-Guillermo, E. González-Barca, M. Terol, P. Miralles, M. Alcoceba, F. Vall-Llovera, J. Briones, P. Abrisqueta, E. Abella, M. Provencio, C. García-Ballesteros, J. Moraleda, J. Sancho, J. Ribera, J. Mate and J. Navarro

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_11

    10. You have free access to this content
      BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2, AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA (pages 157–158)

      A. Chiappella, C. Agostinelli, M. Martelli, A. Evangelista, M. Fabbri, F. Melle, G. Motta, S. Righi, D. Novero, M. Balzarotti, M.G. Cabras, A.M. Carella, M. Gotti, V. Pavone, A. Tucci, M. Ladetto, G. Gaidano, U. Vitolo and S.A. Pileri

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_12

    11. You have free access to this content
      PROGNOSTIC SIGNIFICANCE AND CORRELATION TO GENE EXPRESSION PROFILE OF EZH2 MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBL) IN 2 LARGE PROSPECTIVE STUDIES (pages 158–159)

      T.E. Cummin, S. Araf, M. Du, S. Barrans, M.A. Bentley, A. Clipson, M. Wang, S. Ahmed, T. Rahim, C. Shah, D. Hamid, J. Dhondt, T. Maishman, N. Vaughan-Spickers, C. Pocock, A. Forbes, A. O'Callaghan, D. Westhead, G.O. Griffiths, J. Fitzgibbon, R.M. Tooze, M.A. Care, C.H. Burton, A.J. Davies and P.W. Johnson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_13

    12. You have free access to this content
      PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA (pages 159–160)

      S.J. Blakemore, S.R. Daigle, A.A. McDonald, F. Morschhauser, V. Ribrag, G. Salles, P. McKay, H. Tilly, A. Schmitt, S. Le Gouill, C. Fruchart, J. Radford, P.L. Zinzani, S. Assouline, G. Cartron, M. Dickinson, R. Morin, H. Wu, M. Sausen, A. Clawson, P.T. Ho and H. Miao

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_14

    13. You have free access to this content
      ARRAY-BASED DNA METHYLOME ANALYSES OF PRIMARY LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM (page 160)

      J. Vogt, R. Wagener, M. Montesinos-Rongen, O. Ammerpohl, W. Paulus, M. Deckert and R. Siebert

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_15

    14. You have free access to this content
      TUMOR GENOMIC COPY NUMBER ABNORMALITIES ANALYZED BY HIGH RESOLUTION SNP ARRAY IMPACT OUTCOME OF PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS ON 68 PATIENTS (pages 160–161)

      H. Ghesquieres, B. Tesson, S. Courtois-Cox, S. Boyault, E. Nicolas-Virelizier, M. Carrere, A. Traverse-Glehen, C. Perrin, C. Chassagne-Clement, E. Jouanneau, G. Salles, J. Honnorat, J. Blay and D. Meyronet

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_16

    15. You have free access to this content
      CHARACTERIZATION OF MEDIASTINAL LYMPHOMAS IN FEMALE SIBLINGS AND IDENTIFICATION OF TIRAP AS A NOVEL LYMPHOMA RISK GENE (pages 161–162)

      R. Burkhard, I. Keller, R. Radpour, D. Juskevicius, A. Tzankov, P. Lundberg, R. Bruggmann, S. Dirnhofer and U. Novak

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_17

    16. You have free access to this content
      PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN STAGE III/IV CLASSICAL HODGKIN LYMPHOMA TREATED FRONTLINE IN THE LYSA EORTC 20012 RANDOMIZED PROTOCOL (pages 162–163)

      D. Canioni, P. Brice, S. Bologna, L. Voillat, J. Gabarre, O. Casasnovas, A. Devidas, B. Coiffier, A. Aoudjhane, B. Audouy, M. Andre, C. Fortpied, P. Carde, N. Mounier and J. Briere

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_18

    17. You have free access to this content
      IDENTIFICATION AND CHARACTERISATION OF THE LYMPHOMA-INITIATING CELL (LIC) POPULATION IN AN ALCL MOUSE MODEL (page 163)

      A.L. Illert, S. Kreutmair, C. Klingeberg, G. Andrieux, C. Miething, M. Follo, D. Pfeifer, M. Boerries and J. Duyster

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_19

    18. You have free access to this content
      ONCOGENIC ACTIVATION OF STAT3 PATHWAY DRIVES PD-L1 EXPRESSION IN NATURAL KILLER/T CELL LYMPHOMA (pages 163–164)

      T. Song, M. Nairismagi, J. Lim, S. Nagarajan, J.W. Pang, Y. Laurensia, G.C. Wijaya, T. Jing and C. Ong

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_20

    19. You have free access to this content
      SAMHD1 IS FREQUENTLY INVOLVED IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) PATHOGENESIS (page 164)

      P. Johansson, L. Klein-Hitpass, A.K. Bergmann, R. Siebert, R. Scholtysik, M. Przekopowitz, M. Seifert, T. Zenz, U. Dührsen, R. Küppers and J. Dürig

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_21

    20. You have free access to this content
      TANSLOCATIONS INVOLVING CD28 ARE RARE IN PERIPHERAL T-CELL LYMPHOMAS (pages 164–165)

      D. Vallois, A. Dupuy, F. Lemonnier, V. Fataccioli, N. Ortonne, G. Allen, O. Tournilhac, R. Delarue, M. Rousselet-Chapeau, B. Fabiani, F. Llamas-Gutierrez, Y.H. Ko, K. Kataoka, P. Gaulard and L. de Leval

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_22

    21. You have free access to this content
      INTEGRATIVE ANALYSIS OF FEATURES ASSOCIATED WITH TET2, IDH2, DNMT3A, AND RHOA MUTATIONS IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: A LYSA STUDY (pages 165–167)

      F. Lemonnier, V. Safar, A. Cottereau, V. Fataccioli, I. Chaillol, R. Pelletier, A. Letourneau, A. Dupuy, C. Bossard, A. Martin, C. Robe, L. Pelletier, A. Pujals, E. Bachy, A. Delmer, M. Moles Moreau, H. Tilly, M. Parrens, M. Delfau-Larue, E. Missiaglia, M. Meignan, L. de Leval, C. Haioun and P. Gaulard

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_23

    22. You have free access to this content
      FOCAL SKELETAL 18F-FDG UPTAKE CHARACTERIZES A SUBSET OF CLASSICAL HODGKIN LYMPHOMA PATIENTS WITH POOR OUTCOME—A DANISH-SWEDISH STUDY OF 209 NEWLY DIAGNOSED PATIENTS (page 167)

      M.A. Pedersen, L.C. Gormsen, P. Kamper, D. Molin, G. Enblad, C. Wassberg, A.L. d'Amore, S.H. Dutoit, R.M. Amini and F. d'Amore

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_24

    23. You have free access to this content
      HISTOLOGICAL VERIFICATION OF POSITIVE POSITRON EMISSION TOMOGRAPHY FINDINGS DURING THE FOLLOW-UP OF PATIENTS WITH MEDIASTINAL LYMPHOMA: LARGE EXPERIENCE ON 96 PATIENTS (pages 167–168)

      F. Quirini, S. Forti Parri, L. Tonialini, V. Stefoni, A. Broccoli, C. Pellegrini, M. Marangon, B. Bonfanti, L. Argnani and P. Zinzani

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_25

    24. You have free access to this content
      SAFETY AND EFFICACY ANALYSIS OF ELDERLY PATIENTS TREATED WITHIN THE GATLA HL-05 CLINICAL TRIAL: PET ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA (pages 168–169)

      E. Ciliberti, I. Fernandez, N. Kurgansky, V. Prates, L. Zoppegno, P. Negri, G. Milone, I. Cerutti, S. Zabaljauregui, R. Mariano, H. Fernandez Grecco, S. Saba, F. Sackmann, V. Castano, G. Remaggi, M. Cabrejo, S. Rudoy, E. Roveri, V. Cabane, C. Gumpel, R. Taus, M. Casale, R. Taus, F. Sakamoto and A. Pavlovsky

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_26

    25. You have free access to this content
      ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMA AFTER A FAILED AUTOGRAFT: LONG TERM OUTCOMES AND GRAFT-VERSUS-HOST DISEASE FREE/RELAPSE-FREE SURVIVAL (GRFS) (pages 169–190)

      F. Spina, T. Radice, S. Dalto, C. De Philippis, V. Montefusco, A. Dodero, L. Farina, A. Mussetti, M. Soldarini, M. Di Chio, S. Viviani and P. Corradini

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_27

    26. You have free access to this content
      BRENTUXIMAB-VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST-LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). (page 170)

      A. Gallamini, F. Bijou, J. Viotti, A. Rossi, A. Perrot, C. Patti, L. Gastaud, R. Sorasio, C. Debaigt, E. Chamorey, S. Viviani and A. Thyss

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_28

    27. You have free access to this content
      REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA (pages 170–171)

      C. Pellegrini, A. Pulsoni, L. Rigacci, C. Patti, G. Gini, M. Tani, C. Rusconi, A. Romano, A. Vanazzi, S. Hohaus, P. Mazza, S. Molica, P. Corradini, F. Gaudio, F. Ronconi, A. Pinto, V. Pavone, S. Volpetti, A. Visentin, M. Bonfichi, C. Schiavotto, M. Spina, A. Carella, L. Argnani and P. Zinzani

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_29

    28. You have free access to this content
      A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED-SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA (pages 171–172)

      A. Kumar, C. Casulo, R. Advani, E. Budde, P.M. Barr, C.L. Batlevi, R. Chen, L.S. Constine, A.I. Courtien, S.V. Dandapani, P. Drullinsky, J.W. Friedberg, P.A. Hamlin, R.T. Hoppe, M.J. Matasar, G.N. McArthur, S.T. Miller, A.J. Moskowitz, A. Noy, H. Schoder, D.J. Straus, J. Yang, A. Younes, A.D. Zelenetz, J. Yahalom and C.H. Moskowitz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_30

    29. You have free access to this content
      OUTCOMES OF TREATMENT FOR OBESE PATIENTS WITH ADVANCED HODGKIN LYMPHOMA IN THE RATHL TRIAL (CRUK/07/033) (page 172)

      A. Preston, A. Kirkwood, M. Federico, J. Trotman, A. Fossa, L. Stevens, L. Clifton-Hadley, P. Patrick, L. Berkahn, F. d'Amore, G. Enblad, S. Luminari, J. Radford and P.W. Johnson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_31

    30. You have free access to this content
      MORTALITY RATES REMAIN INCREASED IN YOUNG PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA EVEN AFTER YEARS IN REMISSION: RESULTS FROM A NORDIC LYMPHOMA GROUP STUDY (pages 172–173)

      J. Biccler, I. Glimelius, S. Eloranta, P. de Nully Brown, L.H. Jakobsen, H. Frederiksen, M. Jerkeman and M. Bøgsted

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_32

    31. You have free access to this content
      PREDICTED CARDIAC AND SECOND CANCER RISKS IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ADVANCED PROTON BEAM THERAPY COMPARED TO PHOTON RADIOTHERAPY (pages 173–174)

      G. Ntentas, K. Dedeckova, M. Andrilik, M.C. Aznar, B. George, S. Darby and D. Cutter

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_33

    32. You have free access to this content
      CARDIAC DISEASE PREDICTION FOLLOWING HODGKIN LYMPHOMA: AN EORTC LYMPHOMA GROUP AND GELA FOLLOW-UP STUDY (page 174)

      M.V. Maraldo, F. Giusti, M.A. van der Kaaij, M. Henry-Amar, B. Aleman, J. Raemaekers, P. Meijnders, E.C. Moser, H.C. Kluin-Nelemans, M. Spina, C. Ferme, C. Fortpied and L. Specht

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_34

    33. You have free access to this content
      USEFULNESS OF N-TERMINAL BRAIN NATRIURETIC PEPTIDE LEVELS AND FRESCO SCALE FOR THE PREDICTION OF ANTHRACYCLINE-INDUCED CARDIOMYOTOXICITY IN PATIENTS WITH HODGKIN LYMPHOMA (pages 174–175)

      M. Ferraro, E. Gimeno, M. Ble, I. Subirana, M. Gómez, J. Díaz, B. Sánchez-González, F. García-Pallarols, L. Martínez, L.C. Belarte, E. Abella, R. Elosua and A. Salar

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_35

    34. You have free access to this content
      DOSE AND/OR VOLUME REDUCTION USING CONSOLIDATION VOLUME RADIATION THERAPY (CVRT) LOWERS DOSE TO HEART AND LUNGS IN EARLY-STAGE HODGKIN LYMPHOMA PATIENTS WITH BULKY DISEASE (pages 175–176)

      J.C. Yang, A. Kumar, K.L. Chapman, S. Burleson, C. Huang, L.S. Constine, R.T. Hoppe, S. Dandapani, D.J. Straus, C.H. Moskowitz and J. Yahalom

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_36

    35. You have free access to this content
      OVERALL AND DISEASE-SPECIFIC SURVIVAL OF PATIENTS WHO SURVIVED HODGKIN LYMPHOMA AND DEVELOPED GASTROINTESTINAL CANCER (pages 176–177)

      F.E. Van Leeuwen, L. Rigter, M. Schaapveld, B. Aleman, C. Janus, A.V. Eggermond, A. Krol, R.V. Maazen, J. Roesink, J. Zijlstra, G.V. Imhoff, P. Poortmans, M. Beijert, P. Lugtenburg, O. Visser, P. Snaebjornsson and M.V. Leerdam

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_37

    36. You have free access to this content
      AUTOIMMUNE DISEASE (AID) IS BOTH A RISK FACTOR AND A PROGNOSTIC FACTOR AFFECTING SURVIVAL IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA (NHL) (pages 177–178)

      O. Paltiel, G. Kleinstern, M. Averbuch, R. Abu Seir, R. Perlman and D. Ben-Yehuda

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_38

    37. You have free access to this content
      MICROENVIRONMENTAL FEATURES REFLECTING IMMUNOCOMPETENCE ARE STRONG OUTCOME DETERMINANTS IN HIV-ASSOCIATED LYMPHOMA (pages 178–179)

      M.Ø. Vase, K. Bendix, S. Hamilton-Dutoit, M.B. Møller, C. Pedersen, G. Pedersen, C.S. Larsen and F. d'Amore

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_39

    38. You have free access to this content
      OUTCOME PREDICTION IN DIFFUSE LARGE B-CELL LYMPHOMA CAN BE GREATLY IMPROVED BY ALTERNATIVE USE OF CLINICAL INFORMATION: A NORDIC LYMPHOMA GROUP STUDY (pages 179–180)

      J.L. Biccler, S. Eloranta, P. de Nully Brown, H. Frederiksen, M. Jerkeman, K.E. Smedby, M. Bøgsted and T.C. El-Galaly

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_40

    39. You have free access to this content
      SIMULTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT THE DIAGNOSIS HAS SIMILAR OUTCOME AS DLBCL (pages 180–181)

      K. Benesova, A. Janikova, D. Belada, V. Prochazka, R. Pytlik, H. Mocikova, A. Sykorova, V. Campr, P. Blahovcova and M. Trneny

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_41

    40. You have free access to this content
      HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA ARE NOT ENROLLED ON CLINICAL TRIALS (pages 181–182)

      P. Reagan, K.P. Loh, A. Baran, J. Hu, C. Casulo, P.M. Barr and J.W. Friedberg

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_42

    41. You have free access to this content
      LONG-TERM FOLLOW-UP AFTER LOCALIZED RADIOTHERAPY IN PATIENTS WITH TRANSFORMED B-CELL LYMPHOMA TREATED WITH RITUXIMAB-CONTAINING CHEMOTHERAPY (pages 182–183)

      K. Nozaki, D. Maruyama, K. Tajima, A.M. Maeshima, J. Itami, T. Shichijo, S. Yuda, T. Suzuki, K. Toyoda, N. Yamauchi, S. Makita, S. Fukuhara, W. Munakata, Y. Kobayashi, H. Taniguchi and K. Tobinai

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_43

    42. You have free access to this content
      OBINUTUZUMAB-MINICHOP FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. A STUDY OF THE FONDAZIONE ITALIANA LINFOMI (pages 183–184)

      F. Merli, S. Luminari, F. Salvi, F. Cavallo, G. Gini, G. Musuraca, G. Gaidano, C. Cellini, M. Merli, A. Ferrari, A. Molinari, A.M. Liberati, A. Conconi, P. Matteucci, S. Pozzi, M. Musso, C. Mammi, F. Monaco, S. Ferrero and A. Tucci

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_44

    43. You have free access to this content
      END OF TREATMENT PET-CT PREDICTS PROGRESSION-FREE SURVIVAL IN DLBCL AFTER FIRST-LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY (pages 184–185)

      L. Kostakoglu, M. Martelli, D. Belada, A.M. Carella, N. Chua, E. Gonzalez-Barca, X. Hong, A. Pinto, L.H. Sehn, Y. Shi, Y. Tatsumi, G. Fingerle-Rowson, F. Mattiello, T. Nielsen, D. Sahin, U. Vitolo and M. Trněný

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_45

    44. You have free access to this content
      RITUXIMAB SC AND IV PLUS CHOP SHOW SIMILAR EFFICACY AND SAFETY IN THE RANDOMISED MABEASE STUDY IN FIRST-LINE DLBCL (pages 185–186)

      P.J. Lugtenburg, I. Avivi, H.W. Berenschot, O. Ilhan, J.P. Marolleau, A. Nagler, A. Rueda, M. Tani, M. Turgut, S.A. Osborne, R.B. Smith and M. Pfreundschuh

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_46

    45. You have free access to this content
      R-COMP VS R-CHOP AS FIRST-LINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP (pages 186–187)

      J. Sancho, F. Gual, R. Fernández-Álvarez, E. González-García, C. Grande, N. Gutiérrez, M. Peñarrubia, A. Batlle-López, E. González-Barca, J. Guinea, E. Gimeno, F. Peñalver, M. Fuertes, J. Gayoso, J. Hernández-Rivas, J. Moraleda, O. García and A. Martín

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_47

    46. You have free access to this content
      ANTHRACYCLINE DOSE INTENSIFICATION IN DIFFUSE LARGE B-CELL LYMPHOMA (pages 187–188)

      W. Zhao, P. Xu, D. Fu, J. Li, X. Wang, J. Hu, J. Zhou, H. Yu, X. Zhao, L. Su, Z. Chen, Q. Zeng, J. Chen, M. Fang, J. Ma, T. Liu, Y. Song, K. Yu, Y. Li, L. Qiu, X. Chen, J. Gu, J. Yan, M. Hou and H. Xiong

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_48

  29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. POSTER PRESENTATIONS

      You have free access to this content
      PHASE 2 RANDOMIZED TRIAL COMPARING STANDARD RCHOP VERSUS BRCAP AS FIRST LINE TREATMENT IN YOUNG PATIENTS WITH HIGH-RISK DLBCL. A STUDY FROM SPANISH GROUP GELTAMO (pages 188–189)

      E. Gonzalez-Barca, E. Carrillo, C. Grande, A. Martín, S. Montes-Moreno, M. Coronado, S. Mercadal, J.M. Roncero, J. Perez De Oteyza, C. Nicolas, M.J. Rodriguez-Salazar, J.M. Sancho, L. Palomera, J. Lopez, C. Albo, F.J. Peñalver, J.A. Hernandez, A. Lopez-Guillermo, M.J. Ramirez, I. Jarque, J. Bargay, M. Canales, E. Conde and D. Caballero

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_49

    2. You have free access to this content
      PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE-013 TRIAL (pages 189–190)

      P. Zinzani, V. Ribrag, C.H. Moskowitz, J. Michot, J. Kuruvilla, N. Bartlett, A. Balakumaran, A. Chatterjee, S. Chlosta, M.A. Shipp and P. Armand

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_50

    3. You have free access to this content
      RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE AND COMBINED WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (pages 190–191)

      J.R. Westin, L. Fayad, Y. Oki, L. Nastoupil, F. Hagemeister, F. Turturro, H.J. Lee, A. Rodriguez, K.H. Young, T. McDonnell, R. Ford, S. Neelapu and R.E. Davis

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_51

    4. You have free access to this content
      SAFETY AND CLINICAL ACTIVITY OF TEMSIROLIMUS IN COMBINATION WITH RITUXIMAB AND DHAP IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA–REPORT OF THE PROSPECTIVE, MULTICENTER PHASE II STORM TRIAL (page 191)

      M. Witzens-Harig, A. Viardot, U. Keller, C. Buske, E. Hönig, J. Atta, P. Larosee, R. Marks, M. Dreyling and G. Hess

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_52

    5. You have free access to this content
      A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (pages 191–192)

      R. Casasnovas, J. Westin, C. Thieblemont, J. Zijlstra, B. Hill, F. De La Cruz Vicente, S. Choquet, P. Caimi, J. Kaplan, M. Canales, J. Kuruvilla, G. Follows, E. van den Neste, J. Meade, B. Wrigley, M. Devlin, J. Saint-Martin, C. Nippgen, H. Gardner, S. Shacham, M. Kauffman and M. Maerevoet

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_53

    6. You have free access to this content
      BENDAMUSTINE AS PART OF CONDITIONING REGIMEN FOR AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE LYMPHOMAS: FINAL ANALYSIS OF A PHASE 2 STUDY FROM GELTAMO (pages 192–193)

      A. Martín, A.M. Redondo, D. Valcárcel, A.P. González, M. Suárez-Lledó, J.L. Bello, M. Canales, J. Gayoso, E. Conde, I. Jarque, R. del Campo, R. Arranz, M.J. Terol, J. Rifón, M.J. Rodríguez, M.J. Ramírez, N. Castro, A. Sánchez, J. López-Jiménez, J. Briones, A. López, L. Palomera and D. Caballero

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_54

    7. You have free access to this content
      REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3-4) FLUDARABINE/BUSULFAN-BASED CONDITIONING REGIMENS FOR NON-HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS (pages 193–194)

      A. Le Bourgeois, M. Labopin, D. Blaise, P. Ceballos, S. Vigouroux, R. Peffault De Latour, F. Suarez, C. Bulabois, J. Bay, S. Chantepie, E. Deconinck, E. Daguindau, N. Contentin, I. Yakoub-Agha, J. Cornillon, S. Francois, P. Turlure, A. Charbonnier, P. Rohrlich, S. N'Guyen, N. Maillard, T. Marchand, M. Mohty and P. Chevalllier

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_55

    8. You have free access to this content
      DOUBLE-EXPRESSOR LYMPHOMAS DO NOT HAVE INFERIOR OUTCOME AFTER AUTOLOGOUS STEM-CELL TRANSPLANT IN THE FIRST LINE TREATMENT (page 194)

      M. Trneny, V. Campr, R. Pytlik, P. Klener, J. Stritesky, R. Jaksa, L. Boudova, K. Benesova, J. Koren, M. Trnkova, P. Blahovcova and M. Klanova

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_56

    9. You have free access to this content
      DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS (pages 194–196)

      M. Merli, L. Alric, L. Mannelli, F. De Angelis, A. Ferrari, M. Capecchi, M. Pirisi, C. Visco, F. Piazza, V. Loustaud-Ratti, M. Goldaniga, M. Zancanella, E. Cencini, D. Marino, F. Benanti, M. Rumi, M. Frigeni, M. Gotti, R. Sciarra, V. Ferretti, P. Grossi, F. Passamonti, R. Bruno and L. Arcaini

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_57

    10. You have free access to this content
      CURRENT THERAPY OF SECONDARY CNS INVOLVEMENT IN MALIGNANT LYMPHOMA: DATA FROM A MULTICENTER PROSPECTIVE INTERNATIONAL REGISTRY (pages 196–197)

      A. Korfel, R. Schroers, U. Schlegel, N. Schmitz, S. Hofer, O. Bairey, M. Schmidt-Hieber, P. Le Coutre, M. Janz, P. Reimer and P. Martus

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_58

  30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. POSTER PRESENTATIONS

      You have free access to this content
      VALIDATION OF THE CNS INTERNATIONAL PROGNOSTIC INDEX IN A LARGE ASIAN COHORT–DATA FROM THE SINGAPORE LYMPHOMA STUDY GROUP (pages 197–198)

      Y. Lee, S.C. Fook-Chong, A.Z. Goh, C. Nagarajan, N.F. Grigoropoulos, S. Gopalakrishnan, Y. Chen, T.P. Tang, M. Tao, R.H. Quek, L. Khoo, M. Farid, S.T. Lim, Y.T. Goh and C. Phipps

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_59

    2. You have free access to this content
      THE 5-YEAR FOLLOW-UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA (pages 198–199)

      H. Ghesquieres, H. Tilly, A. Sonet, J. Dupuis, E. Nicolas-Virelizier, M. Andre, F. Trullemans, J. Eisenmann, R. Delarue, E. Fleck, F. Morschhauser and J. Blay

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_61

    3. You have free access to this content
      Prophylaxis with high-dose methotrexate significantly reduces CNS dissemination in patients with diffuse large B-cell lymphoma (DLBCL) and high-risk CNS-IPI score (page 198)

      A.J. Ferreri, T. Calimeri, C. Cecchetti, A. Vignati, M. Sassone, S. Perrone, S. Girlanda, M. Ponzoni and M. Foppoli

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_60

    4. You have free access to this content
      DOSE-DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS IN PATIENTS WITH HIGH-RISK DLBCL: A COMPARISON OF NORDIC CRY-04 AND CHIC STUDIES (pages 199–200)

      S. Leppä, J. Joergensen, P. de Nully Brown, U. Fagerli, T.S. Larsen, R. Janes, S. Mannisto, L. Munksgaard, M. Maisenhölder, K. Vasala, P. Meyer, M. Jerkeman, M. Björkholm, Ø. Fluge, S. Jyrkkiö, L.M. Pedersen, M. Eriksson and H. Holte

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_62

    5. You have free access to this content
      FREQUENCY OF PERFORATION & IMPACT OF BOWEL REST IN AGGRESSIVE NON-HODGKIN LYMPHOMA WITH GASTROINTESTINAL INVOLVEMENT: AN INTERNATIONAL, MULTI-CENTER RETROSPECTIVE STUDY (pages 201–202)

      C.K. Chin, E. Tsang, H. Mediwake, W. Khair, J.L. Biccler, T.C. El-Galaly, G. Hapgood, P. Mollee, D. Villa, Z. Nizich, D. Joske, D. Radeski, G. Cull and C.Y. Cheah

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_64

    6. You have free access to this content
      LONG-TERM FOLLOW-UP UPDATE FOR PATIENTS ENROLLED IN ECOG 1405 (page 202)

      N. Khan, S. Parekh, D. Perumal, O. Jegede and B.S. Kahl

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_65

    7. You have free access to this content
      MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK (pages 202–203)

      L. Morello, S. Rattotti, M. Jerkeman, T. van Meerten, K. Krawczyk, F. Moita, D. Marino, S. Ferrero, M. Szymczyk, I. Aurer, T.C. El-Galaly, A. Di Rocco, G. Carli, I. Defrancesco, L. Giordano, C. Carlo-Stella, M. Dreyling, A. Santoro and L. Arcaini

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_66

    8. You have free access to this content
      VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL) (pages 203–204)

      M.S. Davids, A.W. Roberts, J.F. Seymour, W.G. Wierda, S.D. Puvvada, L. Gressick, D. Alter, M. Dunbar, L. Zhou, S. Kim, M. Verdugo and J.F. Gerecitano

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_67

    9. You have free access to this content
      R-CHOP/R-HDAC AND RITUXIMAB MAINTENANCE RESULTS IN HIGH COMPLETE REMISSION RATE, MINIMAL RESIDUAL DISEASE NEGATIVITY, AND EXCELLENT SURVIVAL IN ELDERLY MCL PATIENTS (pages 204–205)

      P. Klener, E. Fronkova, D. Belada, K. Forsterova, R. Pytlik, M. Kalinova, M. Simkovic, D. Salek, H. Mocikova, V. Prochazka, P. Blahovcová, A. Janikova, J. Markova, A. Obr, A. Berkova, M. Vaskova, E. Mejstrikova, V. Campr, J. Kubinyi, R. Jaksa, R. Kodet, K. Michalova, J. Trka and M. Trneny

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_68

    10. You have free access to this content
      MAINTENANCE RITUXIMAB IMPROVES SURVIVAL IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP (pages 205–206)

      A. Obr, P. Klener, D. Belada, R. Pytlik, M. Simkovic, D. Salek, H. Mocikova, V. Prochazka, A. Janikova, J. Markova, V. Campr, R. Kodet and M. Trneny

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_69

    11. You have free access to this content
      RITUXIMAB MAINTENANCE AFTER NORDIC PROTOCOL (R-MAXICHOP/HD-ARAC/ASCT) SIGNIFICANTLY PROLONGS SURVIVAL IN YOUNG MANTLE CELL LYMPHOMA PATIENTS (pages 206–207)

      P. Klener, D. Salek, H. Mocikova, P. Blahovcova, R. Pytlik, A. Janikova, V. Prochazka, V. Campr, L. Boudova, R. Jaksa, R. Kodet and M. Trneny

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_70

    12. You have free access to this content
      SAKK 36/13–IBRUTINIB AND BORTEZOMIB FOLLOWED BY IBRUTINIB MAINTENANCE IN PATIENTS WITH RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: PHASE I REPORT OF A PHASE I/II TRIAL (page 207)

      U. Novak, M. Fehr, T. Zander, R. Winterhalder, M. Amram, A. Stathis, S. Rondeau, S. Berardi, K. Eckhardt, C. Driessen and C. Renner

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_71

    13. You have free access to this content
      PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA (pages 207–208)

      M. Frank, M. Khodadoust, M. Chu, H. Kohrt, R. Advani, A. Alizadeh, S. Reddy, L. Maeda, N. Gupta, G. Laport, E. Meyer, D. Miklos, R. Negrin, A. Rezvani, W. Weng, K. Sheehan, D. Czerwinski, M. Faham, A. Okada, H. Moore, D. Phillips, I. Wapnir, J. Brody and R. Levy

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_72

    14. You have free access to this content
      OBINUTUZUMAB PLUS IBRUTINIB IN RELAPSE/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS: FIRST RESULTS OF THE OASIS PHASE I TRIAL (pages 208–209)

      S. Le Gouill, F. Morschhauser, K. Bouabdallah, G. Cartron, O. Casasnovas, A. Davies, D. Chiron and S. Rule

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_73

    15. You have free access to this content
      Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group (page 209)

      S. Le Gouill, C. Thieblemont, L. Oberic, A. Moreau, K. Bouabdallah, C. Dartigeas, G. Damaj, T. Gastinne, V. Ribrag, P. Feugier, O. Casasnovas, H. Zerazhi, C. Haioun, H. Maisonneuve, E. Van Den Neste, O. Tournilhac, K. Le Dû, F. Morschhauser, G. Cartron, L. Fornecker, G. Salles, H. Tilly, T. Lamy, R. Gressin and O. Hermine

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_74

    16. You have free access to this content
      Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study (pages 210–211)

      N. Fowler, A.K. Gopal, S.J. Schuster, J. Trotman, G. Hess, J. Hou, A. Yacoub, M. Lill, P. Martin, U. Vitolo, A. Spencer, J. Radford, W. Jurczak, J. Morton, D. Osmanov, D. Caballero, S. Deshpande, J. Vermeulen, R. Damle, M. Schaffer, S. Balasubramanian, B. Cheson and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_75

    17. You have free access to this content
      Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open-label, phase 2 study (pages 211–212)

      G.P. Collins, A. Noy, S. de Vos, C. Thieblemont, P. Martin, C. Flowers, F. Morschhauser, S. Ma, M. Coleman, S. Peles, S. Smith, J. Barrientos, A. Smith, B. Munneke, I. Dimery, D. Beaupre and R. Chen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_76

    18. You have free access to this content
      PROGRESSION-FREE SURVIVAL FOLLOWING LENALIDOMIDE-BASED TREATMENT IS SIGNIFICANTLY LONGER IN EXTRAGASTRIC THAN IN GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT LYMPHOMA) (pages 212–213)

      B. Kiesewetter, M.E. Mayerhoefer, W. Dolak, J. Lukas, I. Simonitsch-Klupp and M. Raderer

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_77

    19. You have free access to this content
      BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE) (pages 213–215)

      G. Thanarajasingam, A.C. Dueck, P.J. Novotny, T.E. Witzig, T.M. Habermann, G.S. Nowakowski, C.R. Flowers, N.L. Bartlett, K.A. Blum, B.N. Pitcher, S. Jung, P.J. Atherton, A.D. Tan, J.A. Sloan and J.P. Leonard

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_78

    20. You have free access to this content
      TREATMENT WITH COMBINATION OF LENALIDOMIDE AND RITUXIMAB ACHIEVES DURABLE RESPONSES IN A LONG TERM FOLLOW UP OF PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA (pages 215–216)

      M. Chaudhry, L. Nastoupil, F. Samaniego, S.S. Neelapu, F.B. Hagemeister, M.A. Fanale, L. Fayad, J.R. Westin, Y. Oki, L. Feng and N. Fowler

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_79

    21. You have free access to this content
      MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE (pages 216–217)

      C. Pott, D. Belada, N. Danesi, G.R. Fingerle-Rowson, J. Gribben, C.G. Harbron, E. Hoster, B.S. Kahl, B. Kehden, K.E. Mundt, E. Nicolas-Virelizier, L.H. Sehn and B.D. Cheson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_80

    22. You have free access to this content
      R-CP CHEMOIMMUNOTHERAPY IN PATIENTS WITH IGM PARAPROTEINAEMIC NEUROPATHY PRODUCES IMPROVEMENTS IN FUNCTIONAL, ELECTROPHYSIOLOGICAL AND SEROLOGICAL OUTCOMES (pages 217–218)

      A.S. Duncombe, N. Colchester, D. Allen and H. Katifi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_81

    23. You have free access to this content
      BENDAMUSTINE-RITUXIMAB (BR) VERSUS R-CHOP AS UPFRONT THERAPY FOR INDOLENT B-CELL LYMPHOMAS: A COMPARATIVE, POPULATION-BASED ANALYSIS (page 218)

      A.J. Olszewski and J.J. Castillo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_82

    24. You have free access to this content
      A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA (pages 218–220)

      C. Buske, W. Kim, L. Kwak, B. Coiffier, W. Jurczak, J.M. Sancho, E. Zhavrid, J. Kim, J.Á. Hernández Rivas, A. Prokharau, M. Vasilica, R. Nagarkar, D. Osmanov, S. Lee, S. Lee, Y. Bae and M. Ogura

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_83

    25. You have free access to this content
      CHARACTERISTICS AND OUTCOMES OF RELAPSED FOLLICULAR LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA (pages 220–221)

      P. Sesques, C. Golfier, J. Boursier, E. Bachy, A. Traverse-Glehen, S. Le Gouill, O. Casasnovas, H. Ghesquieres and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_84

    26. You have free access to this content
      AUTOLOGOUS STEM CELL TRANSPLANTATION MAY POTENTIALLY ABROGATE THE NEGATIVE PROGNOSTIC EFFECT OF EARLY RELAPSE AFTER CHEMO OR INMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA (pages 221–222)

      A. Jiménez Ubieto, C. Grande, D. Caballero, L. Yañez, S. Novelli, M. Hernández-Garcia, M. Manzanares, R. Arranz, J. Ferreiro, S. Bobillo, S. Mercadal, A. Galego, J. López-Jiménez, J. Moraleda, C. Vallejo, C. Albo, E. Pérez-Ceballos, C. Marrero, L. Magnano, L. Palomera, I. Jarque, A. Martín, E. Coria, A. López-Guillermo, A. Salar and J. Lahuerta

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_85

    27. You have free access to this content
      AUTOLOGOUS TRANSPLANTATION IMPROVES SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA EXPERIENCING EARLY THERAPY FAILURE AFTER FRONTLINE CHEMOIMMUNOTHERAPY: AN NLCS AND CIBMTR ANALYSIS (pages 222–223)

      C. Casulo, J.W. Friedberg, K.W. Ahn, C.R. Flowers and A. DiGilio

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_86

    28. You have free access to this content
      MINIMAL RESIDUAL DISEASE (MRD) IN EARLY STAGE FOLLICULAR LYMPHOMA CAN PREDICT PROGNOSIS AND DRIVE RITUXIMAB TREATMENT AFTER RADIOTHERAPY (pages 223–224)

      A. Pulsoni, I. Della Starza, L.V. Cappelli, M.E. Tosti, G. Annechini, M. Cavalli, L.A. De Novi, G.M. D'Elia, L. Grapulin, A. Guarini, I. Del Giudice and R. Foa'

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_87

    29. You have free access to this content
      LOW GRADE B-CELL NON-HODGKIN LYMPHOMAS INVOLVING THE CENTRAL NERVOUS SYSTEM: AN ANALYSIS FROM THE NATIONAL CANCER DATABASE (pages 224–225)

      P.A. Pophali, G. Thanarajasingam, J. Pulido, P. Johnston and R. Go

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_88

    30. You have free access to this content
      CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR YOUNG PATIENTS WITH FIRST-LINE FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF 4249 PATIENTS FROM THE FLASH DATABASE. (pages 225–226)

      L. Fornecker, F. Ou, J.G. Dixon, C. Casulo, E. Hoster, W. Hiddemann, C. Sebban, F. Morschhauser, R. Marcus, H. Hochster, M. Rummel, A. Hagenbeeck, E. Kimby, M. Herold, B.A. Peterson, E. Gyan, M. Ladetto, E. Zucca, T. Nielsen, K. Foon, U. Vitolo, C.R. Flowers, Q. Shi and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_89

    31. You have free access to this content
      PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX- AND AGE-MATCHED SPANISH GENERAL POPULATION (pages 226–227)

      L. Magnano, S. Alonso-Alvarez, M. Alcoceba, A. Rivas-Delgado, A. Muntañola, M. Andrade-Campos, G. Rodriguez, J. Sancho, S. Mercadal, A. Salar, R. Arranz, M. Terol, A. Jiménez-Ubieto, S. González de Villambrosía, J. Bello, L. López, S. Novelli, E. De Cabo, M. Infante, E. Pardal, M. Canals, M. González, A. Martín, M. Caballero and A. López-Guillermo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_90

    32. You have free access to this content
      POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL. (pages 228–229)

      S. Luminari, L. Marcheselli, M. Manni, A. Anastasia, U. Vitolo, A. Chiarenza, L. Rigacci, E. Angelucci, A. Fama, A. Pulsoni, S. Rattotti, F. Angrilli, G. Gaidano, C. Stelitano, G. Bertoldero, N. Cascavilla, F. Salvi, A.J. Ferreri, V. Tarantino, M. Bellei and M. Federico

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_91

    33. You have free access to this content
      DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA (pages 229–230)

      C. Batlevi, A. Alperovich, A. Ni, J. Soumerai, K. Smith, Z. Ying, P. Caron, P. Drullinsky, J. Gerecitano, A. Hamilton, P. Hamlin, S. Horwitz, A. Kumar, M. Matasar, A. Moskowitz, C. Moskowitz, A. Noy, M. Palomba, C. Portlock, C. Sauter, D. Straus, A. Zelenetz, V. Seshan and A. Younes

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_92

    34. You have free access to this content
      TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA (page 230)

      J.D. Soumerai, A. Ni, C. Batlevi, A. Alperovich, K.S. Bantilan, M. Palomba, J.F. Gerecitano, A. Noy, P. Hamlin, C.H. Moskowitz, A.R. Copeland, M.J. Matasar, P.R. Drullinsky, A. Hamilton, S.M. Horwitz, A.M. Intlekofer, A. Kumar, A. Moskowitz, C. Portlock, C. Sauter, D.J. Straus, P. Caron, Z. Ying, K. Smith, A. Younes and A.D. Zelenetz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_93

    35. You have free access to this content
      STATIN USE AND PROGNOSIS IN 12,865 NON-HODGKIN LYMPHOMA PATIENTS TREATED IN THE RITUXIMAB-ERA (pages 230–232)

      E. Brånvall, S. Eloranta, S. Ekberg, B.M. Birmann and K.E. Smedby

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_94

    36. You have free access to this content
      IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL (pages 232–233)

      P. Cramer, F. Demirkan, G. Fraser, A. Pristupa, N. Bartlett, M. Dilhuydy, J. Loscertales, A. Avigdor, S. Rule, O. Samoilova, A. Goy, S. Ganguly, I. Poggesi, S.M. Lavezzi, G. De Nicolao, J. de Jong, M. Neyens, M. Salman, A. Howes and M. Mahler

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_95

    37. You have free access to this content
      EFFECT OF SINGLE-AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (pages 233–234)

      C.S. Tam, J.C. Byrd, S. O'Brien, S. Coutre, P.M. Barr, R.R. Furman, T.J. Kipps, J.A. Burger, D. Stevens, J. Sharman, P. Ghia, I. Flinn, C. Zhou, J. Ninomoto, D.F. James and W.G. Wierda

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_96

    38. You have free access to this content
      HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY (pages 234–235)

      J.F. Seymour, S. Opat, G. Cull, J. Trotman, D. Gottlieb, D. Simpson, P. Marlton, M. Anderson, M. Ku, D.S. Ritchie, S. Ratnasingam, B. Augustson, W. Kim, L. Wang, L. Xue, J. Hilger, J. Huang, E. Hedrick, A.W. Roberts and C.S. Tam

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_97

    39. You have free access to this content
      LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP (pages 235–236)

      M. Montillo, J.C. Byrd, P. Hillmen, S. O'Brien, J.C. Barrientos, N.M. Reddy, S. Coutre, C.S. Tam, S.P. Mulligan, U. Jaeger, P.M. Barr, R.R. Furman, T.J. Kipps, P. Thornton, C. Moreno, J.M. Pagel, J.A. Burger, J. Jones, S. Dai, R. Vezan, D.F. James and J.R. Brown

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_98

    40. You have free access to this content
      OUTCOMES WITH BRUTON TYROSINE KINASE INHIBITION IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AFTER PROGRESSION ON VENETOCLAX (pages 236–237)

      M. Anderson, T.E. Lew, J.F. Seymour, A.W. Roberts and C. Tam

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_99

    41. You have free access to this content
      OUTCOMES OF PATIENTS POST IBRUTINIB TREATMENT FOR RELAPSED/REFRACTORY CLL: A UK AND IRELAND ANALYSIS (pages 237–238)

      G.A. Follows and U.K. CLL Forum

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_100

    42. You have free access to this content
      IBRUTINIB FOR RELAPSED / REFRACTORY CLL: AN UPDATE OF THE UK AND IRELAND ANALYSIS OF OUTCOMES IN 315 PATIENTS (pages 238–239)

      G.A. Follows and U.K. CLL Forum

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_101

    43. You have free access to this content
      REDEFINING THE ROLE OF ETOPOSIDE IN PERIPHERAL T-CELL LYMPHOMA TREATMENT (pages 239–240)

      Y. Koh, J. Byun, Y. Kim, D. Lee, K. Park, S. Yoon, G. Bea and D. Kim

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_102

    44. You have free access to this content
      PROGNOSTIC FACTORS AND IMPACT OF ETOPOSIDE IN ADULTS WITH SYSTEMIC ALK-POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA: A POOLED ANALYSIS OF SIX STUDIES (page 240)

      D. Sibon, D. Nguyen, N. Schmitz, R. Suzuki, A.L. Feldman, R. Gressin, L. Lamant, D. Weisenburger, S. Nakamura, M. Ziepert, M.J. Maurer, M. Bast, J.O. Armitage, J.M. Vose, H. Tilly, J.P. Jais and K.J. Savage

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_103

    45. You have free access to this content
      OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY PERIPHERAL T CELL LYMPHOMA INTENDED FOR STEM CELL TRANSPLANT (page 241)

      S. Parkin, S. Wong, J.M. Connors, L. Sehn, D. Villa, A. Gerrie, R. Broady, M. Power, C. Toze, K. Song and K.J. Savage

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_104

    46. You have free access to this content
      A MULTI-CENTER STUDY OF GLIDE CHEMOTHERAPY CONSOLIDATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED STAGE IV AND RELAPSED EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA PATIENTS (pages 241–242)

      J. Ji, T. Liu, B. Xiang, Z. Liu, Y. Jia, Y. Lian, Z. Lin, F. Xu, W. Liu, H. Zhu, T. Niu, L. Pan, Y. Gong, H. Chang, J. Huang, Y. Wu, J. Li, C. He, L. Xie, H. Ma, Y. Tang, Y. Guo, P. Kuang and T. Dong

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_105

    47. You have free access to this content
      ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (R/R SALCL). A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING PARTY-EBMT. (pages 242–243)

      E. Domingo Domenech, A. Boumendil, F. Climent, G. Socié, F. Kroschinsky, H. Finel, E. Vandenbergue, D. Nemet, M. Stelljes, J. Bittenbring, S. Montoto, A. Sureda and P. Dreger

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_106

    48. You have free access to this content
      RISK STRATIFICATION BASED ON NCCN-IPI AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA (pages 243–244)

      H. Yhim, Y. Park, Y. Han, J. Choi, J. Moon, H. Shin, D. Kim, W. Lee, J. Lee, Y. Do, M. Kim, Y. Choi, J. Kwak and D. Yang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_107

    49. You have free access to this content
      THE ROLE OF 18F FDG-PET/CT IN PERIPHERAL T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI MULTICENTRE PHASE II RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY (pages 244–245)

      M. Gleeson, C. Peckitt, D. Cunningham, Y.M. To, L. Edwards, I. Chau, P. Johnson, K.M. Ardeshna, A. Wotherspoon, A. Attygalle, R. Begum, I. Zerizer, E.A. Hawkes, M.P. Macheta, G.P. Collins, J.A. Radford, A. Forbes, A. Hart, S. Montoto, P. McKay, K. Benstead, N. Morley, N. Kalakonda, Y. Hasan, D. Turner and S. Chua

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_108

  31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. POSTER PRESENTATIONS

      You have free access to this content
      RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY (pages 245–247)

      S. Horwitz, S. Whittaker, M. Duvic, R. Dummer, Y.H. Kim, J. Scarisbrick, P. Quaglino, P. Zinzani, P. Wolter, H. Eradat, J. Sanches, P. Ortiz-Romero, O. Akilov, J. Trotman, K. Taylor, S. Dalle, M. Weichenthal, J. Walewski, D. Fisher, Y. Wang, M.C. Palanca-Wessels, H. Lin, Y. Liu, M. Little and H.M. Prince

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_109

  32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. POSTER PRESENTATIONS

      You have free access to this content
      PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY (pages 247–248)

      H.M. Prince, R. Dummer, S. Whittaker, S. Horwitz, M. Duvic, J. Scarisbrick, P. Quaglino, P.L. Zinzani, P. Wolter, J. Sanches, P. Ortiz-Romero, O. Akilov, L. Geskin, A. Huen, Y. Wang, M.C. Palanca-Wessels, A. Richhariya, J. Feliciano, Y. Zhu, H. Lin, Y. Liu, M. Little, E. Zagadailov, M. Dalal and Y.H. Kim

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_110

    2. You have free access to this content
      A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL) (pages 248–249)

      F. Locatelli, C. Mauz-Koerholz, K. Neville, A. Llort, A. Beishuizen, S. Daw, M. Pillon, N. Aladjidi, T. Klingebiel, J. Landman-Parker, A. Medina-Sanson, K. August, D. Huebner, J. Sachs, K. Hoffman, J. Kinley, S. Song, G. Song, S. Zhang and L. Gore

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_111

    3. You have free access to this content
      PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T-CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE. (pages 249–250)

      Y. Oki, T. Feldman, D. Chihara, L. Sanchez, M. Fanale, J.M. Connors, S. Wong and K.J. Savage

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_112

    4. You have free access to this content
      CASE MATCH CONTROL ANALYSIS OF PROPEL REVEALS A SURVIVAL ADVANTAGE FOR PATIENTS WITH RELAPSED PTCL RECEIVING PRALATREXATE: A NOVEL APPROACH TO BENCHMARK DRUGS IN RARE DISEASES (page 250)

      O.A. O'Connor, E. Marchi and W.S. Kim

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_113

    5. You have free access to this content
      A POST-MARKETING SURVEILLANCE STUDY OF 703 PATIENTS TREATED WITH CHIDAMIDE FOR PERIPHERAL T-CELL LYMPHOMA (PTCL) IN CHINA. HDAC STUDY GROUP OF UNION FOR CHINA LYMPHOMA INVESTIGATORS (UCLI) (pages 250–251)

      J. Ma, J. Zhu, Y.K. Shi, H.Q. Huang, W.Q. Jiang, W.Y. Li, J.H. Wang, W. Xu, M. Hou, Z.M. Jin, T. Liu, P. Liu, W.L. Zhao, H.L. Zhang, H.Y. Yang, X. Zhang, J. Jin, Z.M. Li, L.G. Qiu, M. Dong, X. Wang, J.F. Zhou, J.Z. Shen, X.Q. Chen and Y.Q. Song

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_114

    6. You have free access to this content
      PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (pages 251–252)

      T. Witzig, L. Sokol, E. Jacobsen, R. Advani, R. Mondejar, M. Piris, F. Burrows, C. Melvin, V. Mishra, C. Scholz and A. Gualberto

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_115

    7. You have free access to this content
      SAFETY AND EFFICACY OF MOGAMULIZUMAB IN PATIENTS WITH ADULT T-CELL LEUKEMIA-LYMPHOMA IN JAPAN: INTERIM RESULTS OF POSTMARKETING ALL-CASE SURVEILLANCE (page 252)

      K. Ishitsuka, S. Yurimoto, K. Kawamura, Y. Tsuji, M. Iwabuchi, T. Takahashi and K. Tobinai

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_116

    8. You have free access to this content
      TARGETING THE T-CELL RECEPTOR Β-CONSTANT DOMAIN FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES (pages 252–253)

      P.M. Maciocia, P. Wawrzyniecka, B. Philip, I. Ricciardelli, A. Akarca, S. Onohua, D. Cole, A. Sewell, K. Peggs, D. Linch, T. Marafioti and M. Pule

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_117

    9. You have free access to this content
      DEVELOPMENT OF NOVEL, NON-TOXIC RIFAMYCINS THAT REVERSE DRUG RESISTANCE IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (pages 253–254)

      S.A. Maxwell, D. Wallis, N. Zhou, D. Baker, S. Mousavi-Fard, K. Loesch, S. Galaviz, Q. Sun, D.M. Threadgill, C.M. Rojas, M. O'Brien, F.J. Clubb, T. Ioerger, M. DeJesus, W. Dong, G. Seemann, T. Fossum and J.C. Sacchettini

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_118

    10. You have free access to this content
      DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) (page 254)

      A.J. Arribas, E. Gaudio, A. Rinaldi, L. Cascione, C. Tarantelli, I. Kwee, A. Stathis, E. Zucca, D. Rossi and F. Bertoni

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_119

    11. You have free access to this content
      DUAL INHIBITION OF EZH2 AND HDAC IS SYNERGISTIC IN EZH2 DYSREGULATED LYMPHOMAS (pages 254–255)

      J.K. Lue, S.A. Prabhu, Y. Liu, A. Verma, O. Elemento and J.E. Amengual

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_120

    12. You have free access to this content
      STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMAS (NHL) (pages 255–256)

      A. Molina, A. Yu, C. Abrahams, M. Embry, X. Li, V. DeAlmeida, J. Lee, S. Matheny, T. Kline, A. Yam, R. Stafford, T. Hallam and M. Lupher

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_121

    13. You have free access to this content
      COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS (pages 256–257)

      E. Gaudio, I. Kwee, F. Spriano, C. Tarantelli, A. Rinaldi, T. Jourdan, M. Berthold, A. Arribas, A. Stathis, D. Rossi, N. Liu, M. Lange, O. Politz, E. Zucca and F. Bertoni

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_122

    14. You have free access to this content
      COPANLISIB IN COMBINATION WITH ANTI-PD-1 INDUCES REGRESSION IN ANIMAL TUMOR MODELS INSENSITIVE OR RESISTANT TO THE MONOTHERAPIES OF PI3K AND CHECKPOINT INHIBITORS (pages 257–258)

      N. Liu, K. Haike, S. Glaeske, J. Paul, D. Mumberg, B. Kreft and K. Ziegelbauer

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_123

    15. You have free access to this content
      PD-1 IMMUNE CHECKPOINT BLOCKADE IMPROVES ANTI-CD20 BASED IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA (pages 257–258)

      C. Rossi, E. Decaup, P. Gravelle, M. Tosolini, D. Franchini, C. Laurent, J. Bordenave, L. Ligat, C. Jean, F. Pont, A. Savina, C. Klein, P. Perez-Galan, M. Poupot, J. Fournié and C. Bezombes

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_124

    16. You have free access to this content
      NOVEL TARGETED STRATEGIES TO OVERCOME MICROENVIRONMENT-DEPENDENT RESISTANCE IN MANTLE CELL LYMPHOMA (page 258)

      D. Chiron, A. Papin, C. Bellanger, M. Amiot, S. Le Gouill and C. Pellat-Deceunynck

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_125

    17. You have free access to this content
      EFFECTIVE THERAPY BY ANTI-CD81 AGAINST B CELL LYMPHOMAS ENGAGES BOTH DIRECT AND INDIRECT IMMUNE MECHANISMS (pages 258–259)

      S. Levy, F. Vences-Catalán, C. Kuo, R. Rajapaksa, C. Duault, R. Levy and S. Levy

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_126

    18. You have free access to this content
      A PHASE I STUDY OF UTOMILUMAB (PF-05082566), A 4-1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON-HODGKIN'S LYMPHOMA (page 260)

      A. Gopal, R. Levy, R. Houot, S. Patel, K. Hatake, L. Popplewell, Y. Chen, C. Davis, B. Huang, R. Cesari, A. Thall, A. Woolfson and N. Bartlett

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_127

    19. You have free access to this content
      EXPRESSION OF LAG-3 DEFINES EXHAUSTION OF INTRATUMORAL PD-1+ T CELLS AND CORRELATES WITH POOR OUTCOME IN FOLLICULAR LYMPHOMA (pages 260–261)

      Z. Yang, H. Kim, J.C. Villasboas, T. Price-Troska, S. Jalali, A.J. Novak and S.M. Ansell

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_128

    20. You have free access to this content
      A DUAL TARGETING CAR-T CELL APPROACH FOR THE TREATMENT OF B CELL MALIGNANCIES (page 261)

      S. Thomas, V. Baldan, E. Kokalaki, M. Righi, J. Sillibourne, S. Cordoba, S. Onuoha, R. Jha, M. Ferrari and M. Pule

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_129

    21. You have free access to this content
      LOW LEVELS OF IMMUNO-SUPPRESSOR CELLS PROMOTE RESPONSES TO A HAPLOIDENTICAL NATURAL KILLER CELL THERAPY AND INDUCE REMISSIONS IN NON-HODGKIN LYMPHOMA (pages 261–62)

      V. Bachanova, D. Sarhan, T. Defor, S. Cooley and A. Panoskaltsis-Mortari

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_130

    22. You have free access to this content
      A PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTORMODIFIED T CELLS DIRECTED AGAINST CD19 IN PATIENTS WITH RELAPSED OR REFRACTORYCD19(+) B CELL LYMPHOMAS: INTERIM ANALYSIS (page 262)

      Z. Ying, X. Xiang, Y. Song, N. Ding, Y. Lin, W. Zheng, X. Wang, N. Lin, M. Tu, Y. Xie, C. Zhang, W. Liu, L. Deng, Y. Liu, Y. Yue, X. Yu, H. Liu, P. Duan, F. Chen, X. Wu, X.F. Huang, L. Jones, X. Kang, S. Chen and J. Zhu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_131

    23. You have free access to this content
      PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) (pages 262–263)

      S.S. Neelapu, J.M. Rossi, F.L. Locke, A. Xue, M. Better, X. Zhang, A. Ghobadi, L.J. Lekakis, D. Miklos, C.A. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Y. Lin, J. Timmerman, P.M. Reagan, L. Navale, W.Y. Go, J. Wiezorek and A. Bot

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_132

    24. You have free access to this content
      SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI-CENTER STUDY (page 263)

      C. Carlo-Stella, P. Barde, R. Delarue, L. Scarfò, S. Viswanadha, S. Locatelli, S. Gandolfi, V. Pittari, L. Morello, M. Magagnoli, K. Pilipow, F. De Paoli, E. Lugli, A. Santoro and A. Ferreri

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_133

    25. You have free access to this content
      A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC-EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (pages 263–265)

      P.F. Caimi, J.P. Eder, E.D. Jacobsen, C.A. Jacobson, A.S. LaCasce, M.A. Shipp, B. Chapuy, E. Labriola-Tomphins, F. Boisserie, S. Passe, E. Chesné, W. Pierceall, J. Zhi, M. DeMario, U. Vaishampayan, A. Dowlati, G.I. Shapiro, D.C. Fisher and P. Armand

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_134

    26. You have free access to this content
      A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (pages 265–266)

      C.S. Sauter, M.J. Matasar, H. Schoder, P. Drullinsky, J. Gerecitano, A. Kumar, A. Noy, M.L. Palomba, C.S. Portlock, D.J. Straus, A.D. Zelenetz, S.S. McCall, S.T. Miller, A.I. Courtien, A. Younes and C.H. Moskowitz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_135

    27. You have free access to this content
      PRELIMINARY RESULTS OF A PHASE 1B STUDY OF TIRABRUTINIB (GS-4059/ONO-4059) IN COMBINATION WITH ENTOSPLETINIB IN PATIENTS WITH B-CELL MALIGNANCIES (page 266)

      F. Morschhauser, A.V. Danilov, D.J. Hodson, G.A. Salles, A. Starodub, S. Mitra, Y. Yang, H. Walter and C. Fegan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_136

    28. You have free access to this content
      COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA. (pages 266–267)

      M.A. Lunning, J.M. Vose, P.J. Bierman, G. Bociek, M.T. Schreeder, T. Siddiqi, S.M. Blumel, K. Cutter, E.K. Pauli, D. Bui, P. Sportelli, H.P. Miskin, M. Purdom, M.S. Weiss and N.H. Fowler

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_137

    29. You have free access to this content
      LENALIDOMIDE AND OBINUTUZUMAB WITH CHOP FOR NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: PHASE I/II RESULTS (pages 267–268)

      J.R. Westin, Y. Oki, L. Nastoupil, L. Fayad, S. Neelapu, F. Turturro, F.B. Hagemeister, A. Rodriguez, H.J. Lee, K.H. Young, T. McDonnell, R. Ford and R.E. Davis

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_138

    30. You have free access to this content
      ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3Kδ INHIBITOR, FOR THE TREATMENT OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES (CITADEL-101) (page 268)

      P. Caimi, R. Ramchandren, T.J. Phillips, M.S. Wertheim, M.E. Gutierrez, W.J. Edenfield, L.P. Akard, J.A. Call, D.O. Persky, D.J. DeMarini, L. Zhou, S. Yeleswaram and A. Forero-Torres

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_139

    31. You have free access to this content
      THE IMMUNOLOGIC DOUBLET OF LENALIDOMIDE PLUS OBINUTUZUMAB IS HIGHLY ACTIVE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, RESULTS OF A PHASE I/II STUDY (pages 268–269)

      N.H. Fowler, F. Samaniego, F. Turturro, S. Neelapu, S. Forbes, J. Westin, L. Fayad, M. Fanale, L. Feng, J. Arafat, E. Neal, F. Hagemeister and L. Nastoupil

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_140

    32. You have free access to this content
      INTEGRATED SAFETY DATA WITH COPANLISIB MONOTHERAPY FROM PHASE I AND II TRIALS IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA (page 269)

      P. Zinzani, M. Dreyling, A. Patnaik, F. Morschhauser, A. Benson, I. Genvresse, A. Miriyala, J. Garcia-Vargas and B.H. Childs

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_141

    33. You have free access to this content
      LYMRIT 37-01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU-LILOTOMAB SATETRAXETAN, A NOVEL CD37-TARGETED ANTIBODY- RADIONUCLIDE-CONJUGATE IN RELAPSED NHL PATIENTS (pages 269–270)

      A. Kolstad, U. Madsbu, M. Beasley, M. Bayne, T. Illidge, N. O'Rourke, I. Lagerlöf, R. Hájek, W. Jurczak, E. Willenbacher, J. Blakkisrud, A. Muftuler Løndalen, L. Rojkjaer, L. Baylor Curtis, M. Bloma, S. Turner, N. Bolstad, S. Spetalen, M. Erlanson, S. Nygaard and H. Holte

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_142

    34. You have free access to this content
      INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT-301, A NOVEL PYRROLOBENZODIAZAPINE-BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON-HODGKIN LYMPHOMA (pages 270–271)

      S.M. Horwitz, M.A. Fanale, A.I. Spira, K. Havenith, S. He, J.M. Feingold and M. Hamadani

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_143

    35. You have free access to this content
      POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY (pages 271–272)

      M. Matasar, A.F. Herrera, M. Kamdar, A. Mehta, S. Assouline, I. Fleury, T.M. Kim, W.S. Kim, F. Bosch, J. Radford, C.R. Flowers, L. Bu, W. Hong and L.H. Sehn

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_144

    36. You have free access to this content
      YourTreatmentChoices: FAST ACCESS TO TRIALS PROGRAMME (pages 272–273)

      J. Radford, J. Gribben, P.W. Johnson, R. Malladi, S. Neeson, B. Asfaw, L. O'Regan, A. Law, C. Ringrose, R. Brownlow, A. Jackson, C. Nolan and C. Nolan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_145

    37. You have free access to this content
      INCREASING CROSS-REFERRAL AND RECRUITMENT TO CLINICAL TRIALS: A NEW APProach (pages 273–274)

      J. Trotman, P. Mahairas, J. Ryan, A. Huseincehajic, X. Badoux, M. Gambrill, C. Lawler, M. Daly, M. Lacey, S. Bryne, P. Patel, C. Rine, K. McCardie, M. Forbes, R. Meti, P. Plenge, S. Clark, R. Suen, A. Bayley and R. Ristuccia

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_146

    38. You have free access to this content
      ORAL AZACYTIDINE (AZA) AND ROMIDEPSIN (R) REVEALS PROMISING ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) (pages 274–275)

      O.A. O'Connor, J.K. Lue, J.E. Amengual, A. Sawas, C. Deng, E. Lichtenstein, K. Khan, H. Kim, L. Atkins, A. Rada, C. Rojas and S. Cremers

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_147

    39. You have free access to this content
      CD70 EXPRESSION IN CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS AND MECHANISMS OF ACTION OF ARGX-110 IN SKIN: HISTOPATHOLOGICAL AND CLINICAL DATA (page 275)

      A. Hultberg, D. Gandini, M. Bagot, M. Maerevoet, K. Zwanenpoel, K. De Winne, F. Morschhauser, M. Moshir, L. van Rompaey, K. Silence, H. de Haard, P. Pauwels, N. Leupin and S. Pileri

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_148

    40. You have free access to this content
      PH 1 TRIAL EVALUATING MRG-106, A MICRORNA-155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T-CELL LYMPHOMA (CTCL) PATIENTS (pages 275–276)

      C. Querfeld, F.M. Foss, P. Porcu, Y.H. Kim, T. Pacheco, B. Haverkos, A.S. Halwani, J. DeSimone, B. William, L. Pinter-Brown, A. Seto, J. Ruckman, M. Landry, A.L. Jackson, B. Dickinson, M. Sanseverino, D. Rodman, P. Rubin and W.S. Marshall

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_149

    41. PUBLICATIONS

      You have free access to this content
      Quantitative analysis of MYD88 L265P mutations by digital PCR is an independent prognostic factor for CNS relapse as well as systemic relapse and poor outcome (page 277)

      N. Nishimura, R. Asaka, K. Takeuchi, N. Tsuyama, N. Inoue, A. Takahashi, H. Yamauchi, Y. Kusano, K. Ueda, Y. Mishima, M. Yokoyama, Y. Terui and K. Hatake

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439

    42. You have free access to this content
      High prevalence and clinical significance of oncogenic CD79B and MYD88 mutations in primary testicular diffuse large B-cell lymphoma: A retrospective study in China (page 278)

      Y. Chen, W. Zhu, J. Lu, C. Xu and G. Chen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_1

    43. You have free access to this content
      Molecular analysis of primary cutaneous diffuse large B-cell lymphoma, leg type (pages 278–279)

      J.R. Goodlad, S. van Hoppe, S. Ahmed, S.L. Barrans, D. Painter, M. Care, J. Taylor, P. Evans, M. Bentley, R.M. Tooze, A. Smith, S. Crouch, E. Roman, D.R. Westhead and C. Burton

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_2

    44. You have free access to this content
      Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma (page 279)

      Q. Pan-Hammarstrom and W. Ren

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_3

    45. You have free access to this content
      Molecular landscape of relapse/refractory diffuse large B-cell lymphoma (pages 279–280)

      J. Michot, V. Camara-Clayette, C. Chahine, J. Lazarovici, J. Bosq, D. Ghez, P. Dartigues, A. Danu, J. Arfi-Rouche, L. Tselikas, B. Ba, S. Cotteret, W. Rahali, V. Vergé and V. Ribrag

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_4

    46. You have free access to this content
      Genetic heterogeneity in B-cell lymphoma detected by next-generation sequencing (NGS) technology in a cohort of 150 Chinese patients (pages 280–281)

      Y. Chen, J. Lu and G. Chen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_5

    47. You have free access to this content
      Identifying somatic mutations in cell-free DNA of aggressive lymphoma patients: First cell-free DNA results from the molecular profiling for lymphoma (MaPLe) study (page 281)

      L.D. Lopez Pascua, S.M. Ahmed, S. Barrans, C. Burton, A.J. Clipson, F. Cucco, A. Cutts, H. Dreau, M. Du, D. Joke, R.T. Mizani, O. Salminen, M. Van Hoppe, N. Vaughan-Spickers, A. Schuh and P.W. Johnson

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_6

    48. You have free access to this content
      Comprehensive characterization of mutations, gene expression, and immune repertoires in malignant lymphoma by anchored multiplex PCR and next-generation sequencing (pages 281–282)

      D. Fugere, H. Wang, K. Trifilo, J. Eberlein, T. Harrison, I. McKittrick, M. Wemmer, L. Griffin, B.P. Culver, L. Johnson and B.A. Kudlow

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_7

    49. You have free access to this content
      Klotho suppresses tumor growth of T-cell lymphoma via inhibiting IGF-1R signaling (page 282)

      X. Zhou, Y. Li, Y. Zhang, Y. Xu and X. Wang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_8

    50. You have free access to this content
      Metadherin promotes the invasiveness of diffuse large B-cell lymphoma (pages 282–283)

      Y. Li, X.X. Zhou, Y. Zhang, Y.X. Meng and X. Wang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_9

    51. You have free access to this content
      Whole-exome analysis of abnormalities leading to Waldenström's macroglobulinemia transformation into aggressive lymphoma (pages 283–284)

      M. Alcoceba, C. Jiménez, S. Alonso-Álvarez, G.R. Ordóñez, M. García-Álvarez, M.I. Prieto-Conde, M.C. Chillón, A. Balanzategui, R. Corral, L.A. Marín, N.C. Gutiérrez, N. Puig, M.E. Sarasquete, M. González and R. García-Sanz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_10

    52. You have free access to this content
      Identification and gene expression analysis of the side population subclone in mantle cell lymphoma (page 284)

      V. Kuci Emruli, R. Rosenquist, C. Sundström, E. Cordero, K. Pietras and S. Ek

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_11

    53. You have free access to this content
      NPM1-ALK overexpression-driven toxicity in ALCL is partner dependent and driven by phosphorylation of novel substrates leading to overstimulation of biosynthetic pathways (pages 284–285)

      J.H. Schatz, S. Sundara Rajan, A. Amin and L. Li

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_12

    54. You have free access to this content
      MIR146-B expression levels correlate with biological and clinical features in T-LGL leukemia (page 285)

      R. Zambello, B. Mariotti, A. Teramo, G. Barilà, M. Rossato, G. Calabretto, C. Vicenzetto, C. Ercolin, F. Bazzoni and G. Semenzato

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_13

    55. You have free access to this content
      Follicular large cleaved cell (centrocytic) lymphoma: A distinctive but unrecognized variant of follicular lymphoma (pages 285–286)

      D.D. Weisenburger, R. El Behery, J.A. Laurini, L.M. Smith, B.J. Dave, J. Yuan, K. Fu, W.C. Chan, B.N. Nathwani, P.J. Bierman, R.G. Bociek, J.M. Vose, J.O. Armitage, T.C. Greiner and P. Aoun

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_14

    56. You have free access to this content
      Unfavorable prognostic impact of MYC increased copy number (ICN) in patients with diffuse large B-cell (DLBCL) and high-grade lymphoma treated with immunochemotherapy (pages 286–287)

      F. Schieppati, P. Balzarini, S. Fisogni, A. Re, A. Peli, A. Passi, A. Roccaro, L. Lorenzi, C. Cattaneo, F. Facchetti, G. Rossi and A. Tucci

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_15

    57. You have free access to this content
      Prognostic impact of “MYC/BCL-2 double expressors” in diffuse large B-cell lymphoma (pages 287–288)

      B. Ferrer Lores, B. Navarro Cubells, A. Teruel Casasús, L. Garcia Sanchís, A. Serrano Alcalá, I. Pastor Galán, D. Morello Gonzalez, C. Martinez Ciarpaglini, P. Amat, M. Melia Prades, M. Rodriguez Ramirez, A. Ferrandez Izquierdo and M. Terol Casterá

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_16

    58. You have free access to this content
      BCL2 mRNA or protein abundance is superior to gene rearrangement status in predicting clinical outcomes in patients with diffuse large B-cell lymphoma (pages 288–289)

      Y. Li, K. Tyryshkin, D. Good, P. Farmer, D.W. Scott, S. Crocker, T. Baetz and D. LeBrun

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_17

    59. You have free access to this content
      The clinical significance of c-MYC expression, rearrangement, and copy number gain in extranodal NK/T-cell lymphoma: A retrospective study in China (page 289)

      Y. Chen, B. Chen, W. Zhu, T. He, J. Lu, C. Xu and G. Chen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_18

    60. You have free access to this content
      CD30 expression in diffuse large B-cell lymphoma correlates with non-GCB subtype but does not have prognostic impact in patients treated with first line R-CHOP/R-CHOP–like (page 290)

      Q. Salas, F. Climent, G. Tapia, M. Riasol, S. Mercadal, E. Domingo Domenech, A. Oliveira, M. Moreno-Velázquez, O. Garcia, C. Aguilera, A. Fernandez de Sevilla, A. Sureda, J. Sancho and E. González Barca

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_19

    61. You have free access to this content
      Analysis of preclinical and clinical samples after treatment with a CD37 targeting antibody drug conjugate (AGS67E) support a high level of CD37 expression in NHL (pages 290–291)

      F. Doñate, P. Yang, K. Morrison, S. Karki, H. Aviña, J.M. Lackey, A. Sawas, K.J. Savage, R.P. Perez, R.H. Advani, J.M. Zain, O.A. O'Connor and L.M. Reyno

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_20

    62. You have free access to this content
      Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: An interim analysis of a multicenter prospective pharmacogenetic study (pages 291–292)

      L. Rigacci, G. Perrone, S. Nobili, S. Kovalchuk, B. Puccini, R. Tassi, M. Brugia, I. Landini, L. Mannelli, G. Benelli, C. Napoli, E. Cencini, A. Fabbri, L. Iovino, M. Petrini, S. Birtolo, A. Melosi, S. Santini, P. Bernardeschi, A. Bosi and E. Mini

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_21

    63. You have free access to this content
      MELK serves as a potent independent biomarker to predict survival of diffuse large B-cell lymphoma patients treated with rituximab-CHOP regimen (pages 292–293)

      Y. Zhang, X. Zhou, Y. Li, Y. Xu and X. Wang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_22

    64. You have free access to this content
      BMI-1 protein expression as a negative independent prognostic factor in DLBCL (pages 293–294)

      M.Ø. Pedersen, M.L. Espersen, A.O. Gang, M.F. Breinholt, H. Knudsen, S.L. Nielsen, E. Høgdall and P. Nørgaard

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_23

    65. You have free access to this content
      Role of the abnormal HIF-1α-glycolysis-aerobic oxidation pathway in non-Hodgkin lymphoma and the intervention study (pages 294–295)

      T. Wang, X. Shao, B. Xu, F. Xiao, J. Cai, Y. Zhang, J. Zhong, H. Huang and F. Chen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_24

    66. You have free access to this content
      Cytoplasmatic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival (page 295)

      P. Neumeister, K. Fechter, A. Deutsch, M. Pichler, K. Prochazka, J. Feichtinger, E. Steinbauer, H. Greinix and C. Beham-Schmid

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_25

    67. You have free access to this content
      Tumor necrosis as a prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP therapy (pages 295–296)

      J. Chung, M. Song, S. Oh, S. Lim, G. Lee and H. Lee

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_26

    68. You have free access to this content
      Microenvironment expression in diffuse large B-cell lymphomas (pages 296–297)

      F. Gaudio, G. Ingravallo, T. Perrone, D. Dabbicco, S. Ruggieri, R. Tamma, F. Laddaga, V. Gagliardi, M. De Candia, D. Ribatti and G. Specchia

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_27

    69. You have free access to this content
      EBV infection promotes tumor infiltrating leucocyte and immune escape in plasmablastic lymphoma according to gene expression profiling (pages 297–298)

      C. Laurent, P. Gravelle, S. Péricart, B. Fabiani, P. Coppo, P. Brousset, M. Tosolini and J. Fournié

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_28

    70. You have free access to this content
      Are differences between pediatric EBV-associated lymphomas and carriers regarding latency profile and microenvironment composition involved in lymphomagenesis? (page 298)

      M. Cohen, A. Vistarop, O. Jimenez, F. Huaman, E. De Matteo, M.V. Preciado and P.A. Chabay

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_29

    71. You have free access to this content
      Histopathological and immunohistochemical study of malignant lymphomas (pages 298–299)

      J.J. Jiménez Galainena, J. Lamadrid García, Z. Gutiérrez Aleaga, M. Nazario Dolz, I. Alarcón Arango, E. Gámez Pérez, W. Marcial Martínez, A. Columbié Molina, M. Amigó de Quesada, R. Guarnaluce Brooks, N. Guillén Gonzalez, A.C. Gárciga Brizuela, T. Bonet Meriño, E. Wilson Batista, J. Peraza Bordao and A. Chong López

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_30

    72. You have free access to this content
      Pan-lymphoma classification (page 299)

      M.A. Bentley, S. Barrans, S.M. Ahmed, J. Taylor, C. Burton, M.A. Care, C. Sha and D. Westhead

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_31

    73. You have free access to this content
      Minimal residual disease by next-generation sequencing in mantle cell lymphoma: The bioinformatics tool HashClone (pages 299–300)

      E. Genuardi, M. Beccuti, G. Romano, L. Monitillo, D. Barbero, R. Calogero, M. Boccadoro, M. Ladetto, F. Cordero and S. Ferrero

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_32

    74. You have free access to this content
      PET-CT–adapted therapy for advanced Hodgkin lymphoma: A systematic review of the literature (pages 300–301)

      I. Amitai, R. Gurion, L. Vidal, E.J. Dann, P. Raanani and A. Gafter-Gvili

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_33

    75. You have free access to this content
      Preliminary results of a phase II study using response-adapted therapy for limited-stage diffuse large B-cell lymphoma based on interim PET/CT (pages 301–302)

      F. Lv, Z. Xia, K. Xue, Q. Zhang, D. Ji, J. Cao, X. Hong and Y. Guo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_34

    76. You have free access to this content
      Prognostic significance of interim 11C-methionine PET for the treatment of primary central nervous system lymphoma (PCNSL) (page 302)

      D. Yang, S. Kwon, H. Yhim, B. Park and Y. Park

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_35

    77. You have free access to this content
      Histological validation by imaging-guided core needle–cutting biopsy of 4- to 5-point scale Deauville criteria (DC): Retrospective analysis in Hodgkin lymphoma at restaging (page 303)

      R. Della Pepa, C. Giordano, I. Zacheo, N. Pugliese, C. Cerchione, F. Pane and M. Picardi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_36

    78. You have free access to this content
      Visual versus metabolic tumour volume assessments as predictors for outcome in patients with diffuse large B-cell lymphoma: A single site retrospective study in 118 patients (pages 303–304)

      L.C. Gormsen, R.F. Brøndum, A. Haraldsen, T.V. Bogsrud, K. Hjorthaug, M.H. Vendelbo, M. Bøgsted, A.L. Nielsen, L.J. Petersen, K. Juul-Jensen and T.C. El-Galaly

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_37

    79. You have free access to this content
      Utility of baseline assessment with FDG-PET-CT compared with CT Scanning in people with diffuse large B-cell lymphoma (DLBCL) (page 304)

      M. Cuadrado, A. Afaq, I. Kayani, K. Cwynarski, J. Lambert, W. Townsend and C. McNamara

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_38

    80. You have free access to this content
      Whole-body diffusion-weighted MR imaging in lymphoma surveillance (pages 304–305)

      J. Rademaker, D. Ryan, M. Matasar and C. Portlock

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_39

    81. You have free access to this content
      Noninvasive prenatal testing and incidental detection of maternal Hodgkin's lymphoma (pages 305–306)

      V.V. Ballova, B. Conrad, L. Schäffer, M. Menk and C. Caspar

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_40

    82. You have free access to this content
      Alcohol-induced pain and pruritus in Hodgkin lymphoma (page 306)

      D. Molin and I. Sandberg

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_41

    83. You have free access to this content
      20-year follow-up of Hodgkin lymphoma: Predictors of survival and secondary malignancies (pages 306–307)

      R.O. Vallansot, C. Talarn, M. Cervera, J. Do Nascimento, J. Gumà, M.J. Miranda, F. Martínez, M.J. Herranz, M. Prats, X. Ortín, R. Aguinaco, M.T. Gimenez, C. Araguás, A. Esteban, A. Martínez, J. Sarra and L. Escoda

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_42

    84. You have free access to this content
      The importance of physical activity in adult lymphoma survivors—Single center's experience with the supervised aerobic and resistance training program (page 307)

      M. Hadrabova, A. Janikova, J. Stastna, P. Stejskal, I. Hrncirikova, L. Dovrtelova, M. Zvonar, Z. Svobodova, A. Mala and J. Mayer

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_43

    85. You have free access to this content
      Prognostic significance of tryptophan catabolism in newly diagnosed Hodgkin lymphoma (pages 307–308)

      A. Masaki, T. Ishida, Y. Maeda, T. Narita, A. Ito, S. Suzuki, M. Ri, S. Kusumoto, H. Komatsu, I. Choi, Y. Suehiro, H. Inagaki, R. Ueda and S. Iida

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_44

    86. You have free access to this content
      Treatment outcomes for Hodgkin's lymphoma patients aged 60 and older: A report from the Brazilian prospective Hodgkin's lymphoma registry (pages 308–309)

      I. Biasoli, M. Delamain, B.P. Simoes, N. Castro, R. Gaiolla, C. Solza, T. Silveira, M. Praxedes, J. Farley, C. Boquimpani, C.B. Sola, N. Clementino, G.F. Perini, F. Franceschi, C.S. Chiattone, O. Baioccchi, K. Pagnano, J. Tabacof, G. Steffenello, A. Soares, C. Milito, C. Souza, S. Luminari, J. Morais and N. Spector

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_45

    87. You have free access to this content
      Attendance to HODGKIN lymphoma survivorship care clinics in the Netherlands (page 309)

      B.M. Aleman, A. Nijdam, M.B. van 't Veer, C.P. Janus, R.J. de Weijer, E.J. Petersen, J. Roesink, J.M. Zijlstra, P.J. Lugtenburg, R.W. van der Maazen, J.M. Raemaekers and F.E. van Leeuwen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_46

    88. You have free access to this content
      Outcome predictors in elderly Hodgkin's lymphoma patients placeholder (pages 309–310)

      I. Avivi, E. Paran, O. Bentur, Z. Neuman, D. Lavie, B. Nachmias, N. Dally, O. Gutwein, Y. Herishanu, S. Peled, N. Sarid, D. Eldad and C. Perry

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_47

    89. You have free access to this content
      25(OH) vitamin D serum levels associate with patient characteristics and outcome in Hodgkin lymphoma (pages 310–311)

      A. Cuccaro, E. Galli, F. Visconti, I. Zangrilli, F. Corrente, S. Bellesi, U. Basile, S. Annunziata, V. Rufini, M. Balducci, F. D'Alò and S. Hohaus

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_48

    90. You have free access to this content
      Impact on survival of early detection of recurrence in the follow-up of high risk Hodgkin lymphoma in first complete remission (page 311)

      N. Pugliese, L. Simeone, R. Della Pepa, C. Giordano, I. Cappuccio, I. Zacheo, G. Campagna, C. Cerchione, M. Picardi and F. Pane

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_49

    91. You have free access to this content
      Long-term quality of life in patients with advanced Hodgkin lymphoma: A systematic review (pages 311–312)

      M.R. Dalal, S.A. Mitchell, C. McCloskey, E.A. Zagadailov and A. Gautam

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_50

    92. You have free access to this content
      Assessment and follow up of bone mineral density using CT attenuation measurements in Hodgkin lymphoma patients (page 312)

      B. Cohen, V. Vainstein and N. Hiller

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_51

    93. You have free access to this content
      Second malignancies and cardiovascular diseases in long-term Hodgkin lymphoma survivors: The Istituto Nazionale Tumori of Milan (INT) experience (page 313)

      S. Viviani, M. Soldarini, N. Cieri, I. Arendar, C. Materazzo, A. Busia, P. Matteucci, A. Di Russo and P. Corradini

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_52

    94. You have free access to this content
      Patients with classical Hodgkin lymphoma (CHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation (pages 313–315)

      J.M. Zaucha, W. Khair, P. Biecek, E. Subocz, J. Tajer, W. Kulikowski, M. Panebianco, J. Grad, J. Rybka, R. Kroll-Balcerzak, A. Romanowicz, E. Chmielowska, P. Kurczab, B. Malkowski, P. Juszczynski, G. Cimino, J. Walewski, T.C. El-Galaly, A. Gallamini and E.J. Dann

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_53

    95. You have free access to this content
      Chemotherapy or combined modality therapy for early-stage Hodgkin lymphoma (page 315)

      C. Kelsey, J. Torok and L. Prosnitz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_54

    96. You have free access to this content
      Chemotherapy and radiation improve survival in early stage classical Hodgkin lymphoma: A statewide cancer registry analysis (pages 315–316)

      R. Shrestha, J. Nee, E.B. Durbin, M. Zia, R. Ramlal, G. Monohan, R.H. Herzig, R. Fleischman, G. Hildebrandt and H. Saeed

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_55

    97. You have free access to this content
      Excellent outcome in Hodgkin lymphoma with ABVD and CMT: A single-centre retrospective analysis (pages 316–317)

      S. Bhatwadekar, S. Deshpande, S. Khadse, B. Shah, D. Desai, U. Kachchhi and R. Vaidya

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_56

    98. You have free access to this content
      Combination of idarubicin, vinblastine, dacarbazine, and gemcitabine (IVDG) as therapy for elderly patients with Hodgkin lymphoma with cardiac and pulmonary comorbidity (page 317)

      K. Kaplanov, T. Klitochenko, A. Shipaeva, M. Shirokova, I. Matveeva and N. Lavrishina

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_57

    99. You have free access to this content
      High-dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma (pages 317–318)

      C. Cerchione, M. Di Perna, R. Della Pepa, N. Pugliese, F. Pane and M. Picardi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_58

    100. You have free access to this content
      Advanced Hodgkin lymphoma in the east of England cancer network: A 10-year comparative analysis of outcomes for ABVD and escalated-BEACOPP treated patients aged 16 to 59 (pages 318–319)

      J. Russell, A. Collins, A. Fowler, M. Karanth, C. Saha, V. Shyamsundar, S. Docherty, A. Kirkwood, K. Maw, L. Cooke, A. Hodson, N. Shah, S. Sadullah, N. Grigoropoulos, B. Uttenthal and G. Follows

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_59

    101. You have free access to this content
      Brentuximab vedotin and bendamustine as salvage therapy for primary refractory or relapsed Hodgkin lymphoma: A multicentre experience of the Polish lymphoma research group (pages 319–320)

      A. Czyz, A. Lojko-Dankowska, J. Rybka, T. Wrobel, J.M. Zaucha, E. Subocz, A. Balcerzak, R. Kroll-Balcerzak, M. Joks and M. Komarnicki

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_60

    102. You have free access to this content
      High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL) (page 320)

      B. Wannesson, G. Remaggi, D. Intile, L. Ferrari, S. Cruset, I. Fernández, M. Miodosky, M.S. Cugliari, J. Bordone and M.A. Pavlovsky

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_61

    103. You have free access to this content
      Brentuximab vedotin: A retrospective multicenter analysis of its indication, safety and efficacy in Argentina (pages 320–321)

      M.F. Negri Aranguren, C. Shanley, S. Cranco, V. Otero, L. Fiad, I. Fernandez, M. Miodosky, G. Kusminsky, A. Corso, A. Bistmans, M. Huber, M. Marull, S. Jarchum, L. Guanchiale, M. Marquez, L. Beligoy, I. Cerutti, A. Navieckas, M. Tamashiro, M. Pujol, R. Taus, V. Canosa, L. Lopez Galletti, M.V. Prates, M. Riddick and A. Pavlovsky

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_62

    104. You have free access to this content
      Nivolumab for relapsed or refractory Hodgkin lymphoma: Experience in Turkey (pages 321–323)

      B. Ferhanoglu, H. Bekoz, N. Karadurmus, S. Paydas, Z. Gulbas, A. Turker, T. Toptas, T. Firatli Tuglular, E. Tekgunduz, A. Kaya, N. Tastemir, M. Arat, F. Pepedil Tanrikulu, V. Ozkocaman, H. Abali, M. Turgut, L. Kaynar, I. Karadogan, M. Ozbalak, M. Dogu, S. Kabukcu Hacioglu, R. Yildirim, I. Barista, M. Kurt Yuksel and M. Sonmez

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_63

    105. You have free access to this content
      Outcomes of allogeneic hematopoietic stem cell transplantation (ALLO-SCT) for Hodgkin's lymphoma: A single institution experience (page 323)

      N.L. Fiad, M.V. Prates, S. Yantorno, J.J. Napal, T. De Luca and J. Milone

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_64

    106. You have free access to this content
      Achievement of complete remission after autologous stem cell transplantation is strongly corelated with improved survival of patients with Hodgkin lymphoma (page 323)

      M. Todorovic Balint, J. Jelicic, B. Balint, J. Bila, D. Antic, D. Vujic, N. Kraguljac Kurtovic, D. Sefer, B. Andjelic, M. Smiljanic, V. Djurasinovic, A. Sretenovic, V. Vukovic and B. Mihaljevic

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_65

    107. You have free access to this content
      Serum biomarkers TARC and IL-6 predict relapse risk in Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (pages 323–324)

      V. Bachanova, B.J. Trottier, Q. Cao, D.J. Weisdorf and L. Burns

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_66

    108. You have free access to this content
      The clinical outcome and prognosis of pediatric mature B cell lymphoma (page 324)

      Z.Y. Hong

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_67

    109. You have free access to this content
      The prognostic implication of the pretreatment nutritional status in diffuse large B-cell lymphoma patients treated with rituximab-based chemotherapy (pages 324–325)

      J. Lee, S. Oh, H. Lee, W. Lee, J. Jo and H. Shin

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_68

    110. You have free access to this content
      Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma (pages 325–326)

      H. Eom, J. Jung, H. Lee, T. Yun, E. Lee, H. Moon, J. Joo, W. Park, M. Choi, J. Lee and J. Lee

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_69

    111. You have free access to this content
      A category-free approach to prognostic modelling in aggressive non-Hodgkin B cell lymphomas based on large patient databases (pages 326–327)

      C. Burton, C. Sha, S. Barrans, A. Jack, D. Painter, A. Smith, E. Roman, S. Crouch, M. Care, R. Tooze and D. Westhead

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_70

    112. You have free access to this content
      Grade 1-2 neutropenia after first treatment for diffuse large B-cell lymphoma is associated with a better outcome compared to grade 3-4—A Danish population-based cohort study (pages 327–328)

      M.R. Clausen, S.P. Ulrichsen, M. Nørgaard and F. d'Amore

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_71

    113. You have free access to this content
      cardiac lymphomas: Incidence and outcome in newly diagnosed non-Hodgkin's lymphomas. Analysis from the Czech lymphoma study group (CLSG) database (pages 328–329)

      A. Janikova, C. Lobello, L. Kren, M. Hermanova, A. Sprlakova-Pukova, J. Krejci, S. Pospisilova, R. Pytlik, J. Dlouha, D. Belada, V. Prochazka, J. Duras, H. Mocikova, J. Mayer and M. Trneny

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_72

    114. You have free access to this content
      Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP–treated patients with diffuse large B-cell lymphoma (pages 329–330)

      Y. Kusano, M. Yokoyama, Y. Terui and K. Hatake

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_73

    115. You have free access to this content
      Epstein-Barr virus load in plasma is an early biomarker of HIV-related lymphomas (page 330)

      M. Baptista, J. Muncunill, A. Hernandez-Rodriguez, J. Dalmau, O. Garcia, G. Tapia, M. Moreno, J. Sancho, J. Martinez-Picado, J. Ribera, E. Feliu, J. Mate and J. Navarro

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_74

    116. You have free access to this content
      The negative prognostic significance of serum immunoglobulin paraprotein in patients with diffuse large B cell lymphoma (pages 331–332)

      W. Xu, Y. Li, L. Wang, H. Zhu, J. Liang, W. Wu and L. Fan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_75

    117. You have free access to this content
      Consolidation radiotherapy does not improve the outcome as compared with chemotherapy alone in patients with limited stage diffuse large B-cell lymphoma of Waldeyer's ring (pages 332–333)

      C. Li, X. Ma, Z. Pan, F. Lv, Z. Xia, K. Xue, Q. Zhang, D. Ji, J. Cao, X. Hong and Y. Guo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_76

    118. You have free access to this content
      Treatment outcomes using involved field and involved site radiotherapy for NHL and HL: Retrospective analysis from a large UK Radiotherapy centre (page 333)

      D.M. Jayalathike, A. Stevens, S. Paneesha, S. Chaganti, Y. Hassan and A.M. Zarkar

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_77

    119. You have free access to this content
      R-CHOP is not effective regimen in CD5(+)DLBCL diagnosed by flow-cytometry/immunohistochemistry, karyotype and BCL2/BCL6 status and expression (pages 333–334)

      G. Rymkiewicz, J. Romejko-Jarosinska, E. Paszkiewicz-Kozik, K. Błachnio, M. Kotarska, Z. Bystydzienski, K. Domanska-Czyz, B. Ostrowska, A. Dabrowska-Iwanicka, R. Woroniecka, B. Grygalewicz, M. Osowiecki, A. Jastrzebska and J. Walewski

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_78

    120. You have free access to this content
      Response of diffuse large B-cell lymphoma treated with R-CHOP and prognostic factors associated: A single institution analysis in Lima, Peru (page 334)

      F. Valencia, J. Muro, R. Solórzano, M. Maldonado, C. Flores and S. Quintana

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_79

    121. You have free access to this content
      Treatment of high risk aggressive B cell lymphomas with DA EPOCH R—A retrospective analysis (pages 334–335)

      M. Panny, K. Prochazka, T. Nösslinger, V. Rathkolb, P. Neumeister, H. Greinix and F. Keil

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_80

    122. You have free access to this content
      R- DAEPOCH as a first line treatment for high grade B cell lymphoma and diffuse large B cell lymphoma with unfavorable features (pages 335–336)

      J. Romejko-Jarosinska, G. Rymkiewicz, E. Paszkiewicz-Kozik, A.P. Dabrowska-Iwanicka, A. Borawska, K. Domanska-Czyz, R. Konecki, M. Kotarska, M. Osowiecki, B. Ostrowska, L. Poplawska, M. Swierkowska-Czeneszew, M. Szymanski, Ł. Targonski, K. Blachnio, Z. Bystydzienski, B. Grygalewicz, R. Woroniecka and J. Walewski

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_81

    123. You have free access to this content
      R-DA-EPOCH improves the outcome over that of the R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high IPI, but not for double expressor lymphoma (pages 336–337)

      W. Xu, X. Zhang, J. Liang, L. Wang, H. Zhu, W. Wu, L. Fan and J. Li

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_82

    124. You have free access to this content
      Newly diagnosed diffuse large B-cell lymphoma benefit from the addition of thymosin alpha 1 to R-CHOP: A propensity matched study from single institution (pages 337–338)

      H. Huang, Y. Xia, Y. Gao, X. Wang, B. Bai, Q. Cai, W. Zhao, Z. Yan, P. Li, T. Lin, Z. Xia, Z. Li and W. Jiang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_83

    125. You have free access to this content
      Outcome of diffuse large B-cell lymphoma in patients over the age of 70 years: Real-world experience in a large U.K. district general hospital (page 338)

      J. Addada, A. Bryan, J. Lala, C. Millar, G. Fellows and A. Smith

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_84

    126. You have free access to this content
      The role of maintenance therapy in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis (pages 338–339)

      A. Rozental, A. Gafter-Gvili, L. Vidal, P. Raanani and R. Gurion

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_85

    127. You have free access to this content
      Double hit lymphoma in the northern region of England—A retrospective analysis of patient and disease characteristics, treatment delivered and survival (pages 339–340)

      T. Creasey, M. Lannon, D. Stocken, J. Swieton, G. Cuthbert and W. Osborne

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_86

    128. You have free access to this content
      Negative impact of zoledronic acid in R-CHOP treated DLBCL with bone metastasis (pages 340–341)

      N. Inoue, N. Nishimura, A. Takahashi, Y. Kusano, H. Yamauchi, K. Ueda, Y. Mishima, M. Yokoyama, Y. Terui, N. Tsuyama, K. Takeuchi and K. Hatake

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_87

    129. You have free access to this content
      Diffuse large B-cell non-Hodgkins lymphoma: R-mini-CHOP or physician's choice dose-adjusted chemotherapy in patients over 80 years old (page 341)

      A. Paschalis, A. White, R. Corser, C. Yeoh and A. O'Callaghan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_88

    130. You have free access to this content
      Treatment and survival of primary effusion lymphoma (PEL): A population-based study among 25 patients diagnosed in the Netherlands between 2002 and 2015 (page 342)

      P.J. Lugtenburg, O. Visser, J.K. Doorduijn and A.G. Dinmohamed

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_89

    131. You have free access to this content
      Burkitt lymphoma–multicenter retrospective data analysis from the Czech Lymphoma Study Group–NiHiL project (pages 342–343)

      A. Sýkorová, R. Pytlík, H. Móciková, A. Janíková, V. Procházka, D. Belada, D. Šálek, K. Benešová, P. Klener, J. Ďuraš, L. Smolej, M. Šimkovič, V. Campr, V. Vosáhlová, P. Blahovcová and M. Trněný

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_90

    132. You have free access to this content
      Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL (pages 343–344)

      J.L. Rubenstein, J. Hwang and G. Mannis

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_91

    133. You have free access to this content
      Effective treatments are required for patients with diffuse large B-cell lymphoma (DLBCL) with primary refractory disease (page 344)

      Q.Q. Salas, E. Domingo Domenech, S. Mercadal, A. Oliveira, C. Aguilera, E. De la Banda, F. Climent, A. Lucas, N. Garcia, C. Baca, A. Fernandez de Sevilla, A. Sureda and E. González Barca

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_92

    134. You have free access to this content
      Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from the Spanish group GELTAMO (page 345)

      A. Martín, M. Baile, G. Rodríguez, I. Dlouhy, J.M. Sancho, I. Jarque, E. González-Barca, A. Salar, M. Espeso, C. Grande, J. Bergua, S. Montes-Moreno, A. López-Guillermo, E. Campo and D. Caballero

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_93

    135. You have free access to this content
      Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B- and T-cell lymphoma (pages 345–346)

      M.C. Tisi, R. Paolini, F. Piazza, E. Ravelli, G. Carli, O. Perbellini, M. Ruggeri and C. Visco

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_94

    136. You have free access to this content
      Patients' decision-making, experiences and preferences regarding Pixantrone treatment in relapsed aggressive B-cell lymphoma: Research protocol for a longitudinal qualitative study (page 346)

      L.E. van Hoogdalem, C. Siemes, P. Lugtenburg, J. van Busschbach and S. Ismail

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_95

    137. You have free access to this content
      Results of a prospective phase II trial with ofatumumab as part of reduced intensity conditioning regimen in high-risk non-Hodgkin B lymphoma patients: A GELTAMO trial (pages 346–347)

      M. Cabrero, L. Lopez-Corral, F. de la Cruz, I. Jarque, D. Valcarcel, E. Perez-Lopez, A. Martin, F. Sanchez-Guijo, C. Grande, M. Martin-Calvo, A. Martin and D. Caballero

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_96

    138. You have free access to this content
      Impact of post-transplant lymphoproliferative disorder subtype on survival (pages 347–348)

      J.L. Koff, J. Li, X.A. Zhang, J.M. Switchenko, C.R. Flowers and E.K. Waller

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_97

    139. You have free access to this content
      PTLD: Survival and analysis of prognostic factors in a cohort of 138 patients from a single institution (pages 348–349)

      R. Bajwa, R. Bishnoi, A. Franke, W. Skeleton, N. Patel, W. Slayton, F. Zou, S. Xiong and N. Dang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_98

    140. You have free access to this content
      Allograft rejection associated with immunosuppression reduction for post-transplant lymphoproliferative disorder: A 20-year single-institutional experience (page 349)

      A.J. Franke, R. Bajwa, R. Bishnoi, W.P. Skelton IV, N. Patel, W.B. Slayton and N.H. Dang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_99

    141. You have free access to this content
      Post-transplant monomorphic Burkitt's lymphoma: Clinical characteristics and outcome of a multicenter series (pages 349–350)

      S. Bobillo, P. Abrisqueta, B. Sánchez-González, E. Giné, S. Romero, M. Alcoceba, E. González-Barca, S. González de Villambrosía, J.M. Sancho, J. Castellví, A. López and F. Bosch

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_100

    142. You have free access to this content
      Presentations, treatment complications and outcomes in HCV-infected B-cell lymphoma patients treated with immunochemotherapy: A single institute retrospective study (pages 350–351)

      S. Pei, M. Wang, M. Ma and C. Kuo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_101

    143. You have free access to this content
      Treatment patterns and outcomes in the DLBCL cohort of a study (MONITOR-GCSF) assessing biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia (page 351)

      P. Gascon, A. Krendyukov, N. Höbel and M. Aapro

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_102

    144. You have free access to this content
      Outcomes in pediatric patients with post-transplant lymphoproliferative disorder (PTLD): Analysis of a 20-year single-institutional experience (page 352)

      A.J. Franke, R. Bishnoi, R. Bajwa, W.P. Skelton IV, N.H. Dang and W.B. Slayton

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_103

    145. You have free access to this content
      Treatment of newly diagnosed central nervous system (CNS) lymphoma patients based on co-morbidities & performance status: A single-centre experience (pages 352–353)

      Y. Lim and J. Smith

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_104

    146. You have free access to this content
      Characteristics and natural history of primary vitreoretinal lymphoma (PVL) compared to the primary lymphoma of the CNS (PCNSL) (page 353)

      R. Pytlík, J. Heissigerová, J. Karolová, A. Klimová, P. Svozílková, M. Brichová, E. Říhová, K. Mrázová, I. Špička, P. Blahovcová and M. Trněný

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_105

    147. You have free access to this content
      CNS relapse in patients with DLBCL according to CNS-IPI score and the initial therapy (pages 353–354)

      E. Verrou, A. Gerofotis, N. Karampatzakis, A. Papadopoulou, C. Keramidioti, V. Palaska, S. Papadaki, E. Katodrytou and P. Konstantinidou

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_106

    148. You have free access to this content
      Initial management of primary central nervous system lymphoma in Spain in the last decade. The experience of the GELTAMO and Spanish neuro-oncology groups (pages 354–355)

      S. Mercadal, N. Vidal, M. López-Parra, M. Ibañez, R. Caldú, S. Bobillo, I. Barceló, E. García, P. Martinez, P. Cacabelos, I. Dlouhy, J. Sancho, A. Muntañola, L. Gómez, E. Erro, J. Gállego, A. Salar, A. Caballero, M. Solé, N. Huertas, J. Estela, M. Baron, N. Barbero, E. González-Barca, F. Graus and R. Velasco

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_107

    149. You have free access to this content
      Craniotomy versus biopsy for primary CNS lymphoma: An institutional series and nationwide NCDB-PUF and SEER database study (page 355)

      F.M. Iwamoto, A. Rae, A. Mehta, M. Cloney and A. Sonabend

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_108

    150. You have free access to this content
      Fertility and social reintegration after modified CODOX-M/IVAC with or without rituximab: A questionnaire survey of non-Hodgkin lymphoma (pages 355–356)

      K. Toyoda, D. Maruyama, S. Kurosawa, T. Suzuki, S. Yuda, N. Yamauchi, S. Makita, S. Fukuhara, W. Munakata, H. Taniguchi, A.M. Maeshima, Y. Kobayashi and K. Tobinai

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_109

    151. You have free access to this content
      Preliminary results for a multimodality imaging approach for early detection and prediction of cardiotoxicity in doxorubicin-treated patients with malignant lymphoma (pages 356–357)

      A.H. Laursen, J. Thune, L. Køber, M.B. Elming, A. Kjær, P. Hasbak, R.S. Ripa and M. Hutchings

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_110

    152. You have free access to this content
      Prognostic value of KI-67, MIPI score and SUV MAX of the PET scan: Result of a single center experience with mantle-cell lymphomas (page 357)

      T. Nguyen, A. de Wind, E. Woff, P. Heimann, M. Vercruyssen, C. Spilleboudt, M. Maerevoet, N. Meuleman, B. Cantinieaux, S. Michiels and D. Bron

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_111

    153. You have free access to this content
      Autologous stem cell transplantation is infrequently utilized but associated with improved overall survival in elderly patients with mantle cell lymphoma (pages 357–359)

      J.B. Cohen, I.B. Greenwell, Y. Liu, M. Behera and C.R. Flowers

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_112

    154. You have free access to this content
      Short course of R-HyperCVAD/MTX/ARA-C followed by ASCT as first-line therapy in mantle cell lymphoma patients prolongs progression-free survival to more than 9 years (pages 359–360)

      M. Andrade Campos, S. Mercadal, E. Domingo Domenech, V. Paredes, C. Aguilera, A. Oliveira, E. de la Banda, F. Climent, R. Parody, A. Fernandez de Sevilla, A. Sureda and E. Gonzalez Barca

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_113

    155. You have free access to this content
      Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease (page 360)

      W. Chen, D. Zeng, A. Desai, M. Badillo, L. Feng, F. Yan, K. Nomie, L. Ping, H. Ye, Y. Liang, H. Lee, Y. Oki, J. Romaguera and M. Wang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_114

    156. You have free access to this content
      Progression-free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era (pages 360–361)

      A. Rivas-Delgado, L. Magnano, M. Moreno-Velazquez, O. Garcia, P. Mozas, I. Dlouhy, T. Baumann, J. Rovira, B. Gonzalez, A. Martinez, O. Balague, J. Delgado, N. Villamor, E. Campo, E. Gine, J.M. Sancho and A. Lopez-Guillermo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_115

    157. You have free access to this content
      Radioimmunotherapy for follicular lymphoma achieves excellent lymphoma control in first line and relapse: 8-year follow-up data of 281 patients from the international RIT-registry (pages 361–362)

      K. Hohloch, C. Scholz, C. Windemuth-Kiesselbach, J. Kolz, P.L. Zinzani, R. Cacchione, W. Woijciech Jurczak, A. Bischof-Delalaoye and L. Truemper

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_116

    158. You have free access to this content
      Beyond rituximab maintenance. relapsing follicular lymphoma during or after end of rituximab maintenance: analysis of Czech Lymphoma Study Group (CLSG) database (pages 362–363)

      A. Janikova, V. Campr, N. Kopalova, K. Benesova, D. Belada, V. Prochazka, J. Duras, J. Dlouha, H. Mocikova, A. Sykorova, M. Brejcha, J. Mayer and M. Trneny

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_117

    159. You have free access to this content
      Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma (pages 363–364)

      E. Cencini, B. Puccini, L. Rigacci, A. Fabbri, S. Kovalchuk, G. Benelli, L. Mannelli, T. Carfagno, G. Simontacchi, M. Bocchia and A. Bosi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_118

    160. You have free access to this content
      Retrospective analysis on R-DHAP/OX and ASCT as salvage treatment for relapsed/refractory high-risk follicular lymphoma (pages 364–365)

      P. Ghione, F. Cavallo, C. Visco, Z. Chen, M. Nicolosi, A. Castellino, M.C. Tisi, I. Dogliotti, M. Boccadoro, J.P. Leonard, U. Vitolo and P. Martin

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_119

    161. You have free access to this content
      PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α (pages 365–366)

      N. Berinstein, L. Smyth, N. Pennell, R. Weerasinghe, M. Cheung, K. Imrie, D. Spaner, L. Chodirker, E. Piliotis, V. Milliken, A. Boudreau, L. Zhang, M. Reis, A. Chesney, D. Good, Z. Ghorab and R. Buckstein

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_120

    162. You have free access to this content
      AN INTERNATIONAL COMPARISON OF THE EFFICACY, COST AND MYELOTOXICITY OF FIRST-LINE THERAPY FOR ADVANCED FOLLICULAR NON-HODGKIN LYMPHOMA (pages 366–367)

      M. Kesavan, A.D. Mcquillan, W.B. Macdonald and J.H. Turner

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_121

    163. You have free access to this content
      CLINICAL CHARACTERISTICS AND PROGNOSIS OF ELDERLY (>70 YEARS) FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE GELTAMO SPANISH GROUP (page 367)

      M. Alcoceba, L. Magnano, S. Alonso-Álvarez, M. Andrade-Campos, N. Espinosa-Lara, G. Rodríguez, J.M. Sancho, M. Moreno, S. Mercadal, F. García-Pallarols, J. Cannata, A.I. Teruel, A. Rodríguez, S. González de Villambrosía, J. Bello, L.I. López, S. Monsalvo, S. Novelli, E. de Cabo, M.S. Infante, E. Pardal, A. Muntañola, M. González, M.D. Caballero, A. Martín and A. López-Guillermo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_122

    164. You have free access to this content
      ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA (pages 367–368)

      T. Shichijo, D. Maruyama, K. Tajima, S. Yuda, A.M. Maeshima, T. Suzuki, K. Toyoda, N. Yamauchi, S. Makita, S. Fukuhara, W. Munakata, Y. Kobayashi, H. Taniguchi and K. Tobinai

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_123

    165. You have free access to this content
      RISK OF SECONDARY HEMATOLOGICAL MALIGNANCY IN PATIENTS WITH FOLLICULAR LYMPHOMA (pages 368–369)

      R. Prusila, M. Sorigue, T. Tanhua, S. Tikkanen, E. Jantunen, O. Kuittinen, P. Karihtala, H. Kuitunen and T. Turpeenniemi-Hujanen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_124

    166. You have free access to this content
      THE PROGNOSTIC VALUE OF FLIPI IN THE ERA OF RITUXIMAB (page 369)

      T. Juznic Setina, S. Borstnar and B. Jezersek Novakovic

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_125

    167. You have free access to this content
      PRETREATMENT SOLUBLE INTERLEUKIN-2 RECEPTOR LEVEL WAS A ROBUST PROGNOSTIC FACTOR IN FOLLICULAR LYMPHOMA IN RITUXIMAB ERA (pages 369–370)

      Y. Kusano, M. Yokoyama, Y. Terui and K. Hatake

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_126

    168. You have free access to this content
      LONG-TERM FOLLOW-UP AND PREDICTORS OF POOR OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA UNDERGOING FRONT-LINE TREATMENT WITH CHEMOIMMUNOTERAPY: A SINGLE CENTER EXPERIENCE. (pages 370–371)

      E. Donato, L. Marriaga, M. Legarda, L. Rubio, M.J. Sayas, M. Fernández, P. Ribas, M.L. Juan, J. Marco, M.J. Fernández, E. Gómez, A. Tolosa, J.A. Hueso, M.J. Cejalvo, D. Ivars and J. De la Rubia

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_127

    169. You have free access to this content
      GENE POLYMORPHISMS AS PREDICTORS OF TREATMENT EFFICACY AND TOXICITY IN PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMAS RECEIVING BENDAMUSTINE AND RITUXIMAB (pages 371–372)

      E. Cencini, A. Sicuranza, A. Fabbri, D. Raspadori and M. Bocchia

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_128

    170. You have free access to this content
      PROGNOSTIC VALUE OF LYMPHOCYTE/MONOCYTE RATIO AND NEUTROPHIL/LYMPHOCYTE RATIO AT DIAGNOSIS OF FOLLICULAR LYMPHOMA. (pages 372–373)

      S. Lee and M. Luque-Fernandez

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_129

    171. You have free access to this content
      THE VALUE OF PROGNOSTIC NUTRITIONAL INDEX AT DIAGNOSIS IN PATIENTS WITH FOLLICULAR LYMPHOMA: A RETROSPECTIVE COHORT STUDY (page 373)

      S. Lee, T. Ng, F. Wong and S. Tung

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_130

    172. You have free access to this content
      A RETROSPECTIVE STUDY OF THE DIAGNOSIS AND THE TREATMENT-ASSOCIATED MORTALITY OF PATIENTS WITH PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE (POA-MALT) LYMPHOMA IN JAPAN. (pages 373–375)

      Y. Masuda, K. Takeuchi, T. Kodama, T. Fujisaki, Y. Imaizumi, E. Ohtsuka, S. Ozaki, S. Hasebe, H. Asai and Y. Yakushijin

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_131

    173. You have free access to this content
      CLINICAL FEATURES AND SURVIVAL OUTCOMES ON LYMPHOPLASMACYTIC LYMPHOMA PATIENTS WITH NON-IGM PARAPROTEINEMIA COMPARED WITH IGM PARAPROTEINEMIA IN KOREA (page 375)

      J. Kang, J. Hong, D. Yoon and C. Suh

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_132

    174. You have free access to this content
      PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA—THE ROLE OF MEDIASTINAL RADIATION (pages 375–376)

      S. Afonso, I. Carvalhais, A. Carneiro, F. Príncipe and J. Guimarães

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_133

    175. You have free access to this content
      PRIMARY EXTRANODAL NON-HODGKIN'S LYMPHOMA OF THE LIVER (PLL) (page 376)

      S. Lepkov, I. Subortceva, G. Tumyan, P. Zejnalova, O. Kolomejtsev, Y. Ryabukhina, A. Semenova, N. Kokosadze, N. Kupryshina, I. Komarov, O. Malikhova, O. Ettinger, S. Borisovskaya, I. Lazarev, V. Ivanova, R. Ivashhenko, Y. Kemizh, A. Alla Kovrigina, I. Nikitin and O. Urvanceva

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_134

    176. You have free access to this content
      OUTCOME OF PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE STOMACH – A SINGLE INSTITUTE EXPERIENCE (page 377)

      T. Mehmood

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_135

    177. You have free access to this content
      LONG-TERM FOLLOW-UP OF PATIENTS WITH NON-HODGKIN PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE STOMACH: BETTER OUTCOME AFTER IMMUNOCHEMOTHERAPY (page 377)

      E. Hatjiharissi, M.D. Diamantidis, A. Papadopoulou, S. Chatzileontiadou, A. Gerofotis, A. Pouptsis, N. Karabatzakis, K. Pentidou, F. Patakiouta, N. Constantinou and M. Papaioannou

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_136

    178. You have free access to this content
      TREATMENT STRATEGIES AND PROGNOSTIC FACTORS OF PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE STUDY OF 303 CASES FROM CHINA LYMPHOMA PATIENT REGISTRY (page 378)

      Y. Song, X. Cen, H. Yang, M. Wu, Y. Shen, T. Lei, X. Leng, L. Ping, Y. Xie and J. Zhu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_137

    179. You have free access to this content
      CLINICAL FEATURES AND PROGNOSES OF PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF 139 CHINESE CASES WITH IMMUNOPHENOTYPING FROM CLAP (pages 378–379)

      Y. Song, X. Cen, M. Wu, Y. Shen, X. Leng, L. Ping, Y. Xie and J. Zhu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_138

    180. You have free access to this content
      CNS TARGETING CHEMOTHERAPY IS ASSOCIATED WITH SUPERIOR SURVIVAL IN PATIENTS WITH TESTICULAR LYMPHOMA – RESULTS FROM FINNISH–DANISH RETROSPECTIVE STUDY (page 379)

      S. Mannisto, P. Vähämurto, M.R. Clausen, P. Marjukka, S. Jyrkkiö, M. Karjalainen-Lindsberg, P. Kellokumpu-Lehtinen, F. d'Amore and S. Leppä

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_139

    181. You have free access to this content
      3D CONFORMAL RADIOTHERAPY (3D-CRT) AT PRIMARY ORBITAL LYMPHOMA (OL) WITH DIFFERENT FRACTIONATION (pages 379–380)

      A. Chumachenko, J. Winogradova and N. Ilyin

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_140

    182. You have free access to this content
      ABSOLUTE PERIPHERAL MONOCYTE COUNT PREDICTS PROGRESSION-FREE SURVIVAL IN EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE (page 380)

      W. Xu, Q. Zhao, L. Wang, H. Zhu, W. Wu, J. Liang, L. Fan and J. Li

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_141

    183. You have free access to this content
      TREATMENT RESULTS ACCORDING TO CELLULAR SUBTYPES OF GASTRIC MALT LYMPHOMA (pages 380–381)

      M. Mallaev and R. Abdusattarov

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_142

    184. You have free access to this content
      INCIDENCE AND OUTCOME OF PRIMARY EXTRANODAL FOLLICULAR LYMPHOMAS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY (pages 381–382)

      A. Janikova, V. Campr, N. Kopalova, K. Benesova, D. Belada, J. Dlouha, J. Duras, V. Prochazka, H. Mocikova, K. Kubackova, A. Sykorova, M. Brejcha, J. Mayer and M. Trneny

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_143

    185. You have free access to this content
      MYD88 MUTATIONS PREDICT UNFAVORABLE PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH MUTATED IGHV GENE (pages 382–383)

      S. Qin, Y. Xia, Y. Miao, C. Qiao, W. Xu and J. Li

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_144

    186. You have free access to this content
      DEFINITION OF DISEASE-PROGRESSION RISK STRATIFICATION IN UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA USING COMBINED CLINICAL, MOLECULAR AND VIROLOGICAL VARIABLES (page 383)

      S. Qin, L. Fan, Y. Xia, J. Liang, W. Xu and J. Li

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_145

    187. You have free access to this content
      PORTUGUESE REAL-LIFE EXPERIENCE WITH IBRUTINIB OUTSIDE CLINICAL TRIALS – A MULTICENTER ANALYSIS (pages 383–384)

      S. Silva, E. Espada, J.A. Melo, M.P. Lima, A. Ionita, J.P. Carda, J. Andrade, M. Neves, R. Cabral, T. Mendes, C. Gaspar, D. Alves, F. Pina, A. Botelho de Sousa, H. Coelho, A. Montalvão, H. Vitória, F. Lima, J. Coutinho, P. Lúcio, J.E. Guimarães, M.L. Ribeiro, M. Gomes da Silva and J. Raposo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_146

    188. You have free access to this content
      EFFECTS ON THE HUMAN IMMUNE SYSTEM AFTER OBINUTUZUMAB MONOTHERAPY TREATMENT (pages 384–385)

      R. Garcia-Munoz, L. Aguinaga, J. Feliu, J. Anton-Remirez, L. Jorge del Val, E. Dominguez-Garrido, P. Rabasa and C. Panizo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_147

    189. You have free access to this content
      COMPARISON OF INNATE IMMUNITY CHANGES FOLLOWING IBRUTINIB AND VENETOCLAX TREATMENT OF RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA (pages 385–386)

      K. Mason, C. Sharpe, J. Davis, R. Koldej, C. Tam and D. Ritchie

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_148

    190. You have free access to this content
      CHRONIC LYMPHOCYTIC LEUKEMIA INVOLVEMENT OF CENTRAL NERVOUS SYSTEM: A SINGLE CENTRE EXPERIENCE (page 386)

      M. Smiljanic, M. Todorovic Balint, D. Antic, N. Kraguljac Kurtovic, J. Bila, B. Andjelic, A. Sretenovic, V. Djurasinovic, V. Vukovic, J. Jelicic and B. Mihaljevic

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_149

    191. You have free access to this content
      MINIMAL RESIDUAL DISEASE ASSESSMENT IN MULTIPLE MYELOMA: UTILITY AND FEASIBILITY IN RESOURCE CONSTRAINT SETTINGS OF INDIA (page 387)

      M.S. Sachdeva, P. Sharma, P. Bose, N. Varma, P. Malhotra and S. Varma

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_150

    192. You have free access to this content
      HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP (pages 387–388)

      I. Hus, J. Manko, D. Jawniak, A. Jurczyszyn, L. Usnarska-Zubkiewicz, M. Sawicki, G. Charlinski, M. Razny, M. Rodzaj, A. Waszczuk-Gajda, J. Drozd-Sokolowska, A. Galazka, A. Swiderska, B. Poglodek, A. Pluta, A. Druzd-Sitek, N. Grzasko, A. Kopinska, A. Pasternak, D. Blonska, M. Hus and A. Dmoszynska

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_151

    193. You have free access to this content
      DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR) (pages 388–389)

      S. Lentzsch, K. Weisel, M.V. Mateos, V. Hungria, M. Munder, A. Nooka, T. Mark, H. Quach, E. Scott, J. Lee, P. Sonneveld, T. Casneuf, C. Chiu, X. Qin, H. Amin, P. Thiyagarajah, J. Schecter, M. Qi and A. Spencer

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_152

    194. You have free access to this content
      DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX) (page 389)

      N.J. Bahlis, P. Moreau, H. Nahi, T. Plesner, H. Goldschmidt, K. Suzuki, R.Z. Orlowski, N. Rabin, M. Leiba, A. Oriol, A. Chari, J. San Miguel, P.G. Richardson, S. Usmani, L. O'Rourke, K. Wu, T. Casneuf, C. Chiu, X. Qin and M.A. Dimopoulos

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_153

    195. You have free access to this content
      EPIDEMIOLOGICAL AND HUMANISTIC BURDEN OF CUTANEOUS T-CELL LYMPHOMAS: RESULTS OF a SYSTEMATIC REVIEW (pages 389–390)

      M.R. Dalal, S.A. Mitchell, C. McCloskey, E.A. Zagadailov and A. Gautam

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_154

    196. You have free access to this content
      ALK EXPRESSION PLAYS DIFFERENT ROLES IN ANAPLASTIC LARGE-CELL LYMPHOMAS AND OUTCOME OF CRIZOTINIB USE IN RELAPSED/REFRACTORY ALK+ PATIENTS IN A CHINESE POPULATION (page 390)

      W. Li, L. Huang, F. Zhang, J. Zeng, H. Guo, S. Liu, X. Wei, Z. Liang, F. Chen, X. Jiang, Y. Chen and Y. Liu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_155

    197. You have free access to this content
      CIRCULATING LOW ABSOLUTE CD4+ T CELL COUNTS MAY PREDICT POOR PROGNOSIS IN PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE (pages 390–391)

      W. Xu, Y. Zhang, J. Liang, L. Wang, H. Zhu, W. Wu, L. Fan and J. Li

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_156

    198. You have free access to this content
      DUSP22 AND TP63 REARRANGEMENTS PREDICT OUTCOME OF ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A DANISH COHORT STUDY (pages 391–392)

      M.B. Pedersen, S.H. Dutoit, K. Bendix, R.P. Ketterling, P.P. Bedroske, I.M. Luoma, C.A. Sattler, N. Bennani-Baiti, P. Noergaard, M.B. Moeller, T. Steiniche, F. d'Amore and A. Feldman

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_157

    199. You have free access to this content
      SERUM 2-HYDROXYGLUTARATE, A PREDICTIVE BIOMARKER OF THE PRESENCE OF IDH2 MUTATIONS IN AITL PATIENTS (page 392)

      S. Broutin, A. Dupuy, S. Koscielny, V. Fataccioli, F. Lemonnier, L. de Leval, C. Robe, A. Pujals, V. Safar, R. Delarue, M.H. Delfau-Larue, V. Ribrag, C. Haioun, P. Gaulard and A. Paci

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_158

    200. You have free access to this content
      THE VALUE OF PET/CT IN DETECTING BONE MARROW INVOLVEMENT IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (pages 392–393)

      R. Gurion, H. Bernstein, L. Vidal, P. Raanani and A. Gafter-Gvili

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_159

    201. You have free access to this content
      EFFICACY AND SAFETY OF PEGASPARGASE, GEMCITABINE, DEXAMETHASONE, AND CISPLATIN COMBINED CHEMOTHERAPY IN NEWLY DIAGNOSED EXTRANODAL NK/T CELL LYMPHOMA (page 393)

      L. Zhang, T. Liu, F. Zhu, Y. Xiao, Q. Li, Q. Liu and G. Wu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_160

    202. You have free access to this content
      A PHASE II TRIAL OF BENDAMUSTINE, CARBOPLATIN AND DEXAMETHASONE (BCD) FOR REFRACTORY OR RELAPSED PERIPHERAL T-CELL LYMPHOMA (BENCART): A CONSORTIUM FOR IMPROVING SURVIVAL OF LYMPHOMA (CISL) TRIAL (pages 393–394)

      B. Park, W. Kim, C. Suh, D. Yang, Y. Do, J. Jo and Y. Park

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_161

  33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. PUBLICATIONS

      You have free access to this content
      PEGYLATED LIPOSOMAL DOXORUBICIN COMBINED WITH CYCLOPHOSPHAMIDE, VINCRISTINE/VINDESINE, AND PREDNISONE IN PATIENTS WITH AGGRESSIVE T-CELL LYMPHOMA: PRELIMINARY RESULTS OF APHASE II STUDY (page 394)

      Z. Xia, F. Lv, K. Xue, Q. Zhang, D. Ji, J. Cao, X. Hong and Y. Guo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_162

  34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. PUBLICATIONS

      You have free access to this content
      THE EFFECT OF LONG-TERM MAINTENANCE CHEMOTHERAPY FOR AGGRESSIVE ADULT T CELL LEUKEMIA/LYMPHOMA (pages 394–395)

      M. Tsukaguchi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_163

    2. You have free access to this content
      RICHTER TRANSFORMATION OF T-CELL LARGE GRANULAR CELL LEUKEMIA (page 395)

      N. Nakmaura, J. Carreras, Y.Y. Kikuti, M. Miyaoka, S. Tomita and F. Ishida

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_164

    3. You have free access to this content
      CLINICO-PATHOLOGICAL PROFILE AND CMYC IMMUNOREACTIVITY OF ALK POSITIVE LARGE B CELL LYMPHOMA: REPORT OF NINE CASES. (pages 395–396)

      S. Mallick, M.R. Lone, P. Ramteke, S. Purokait, A. Gogia, A. Batra, S. Bakhshi, A. Sharma and M.C. Sharma

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_165

    4. You have free access to this content
      GEMCITABINE PLUS LIPOSOMAL DOXORUBICIN FOR RELAPSED REFRACTORY T-CELL LYMPHOMAS (pages 396–397)

      A. Waller, J. Lundberg, K. Porter, S. Hwang, J. Hastings, B. Haverkos, J. Brammer, S. Fabbro, B.M. William, E. Dotson and P. Porcu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_166

    5. You have free access to this content
      THE EFFICACY AND TOLERANCE OF CHIDAMIDE, PREDNISONE, CYCLOPHOSPHAMIDE AND THALIDOMIDE (C-PCT) IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A PILOT STUDY (page 397)

      W. Xu, H. Zhu, L. Wang, J. Liang, Y. Kong, W. Wu, L. Fan and J. Li

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_167

    6. You have free access to this content
      ESTABLISHED CELL LINES AND PATIENT-DERIVED XENOGRAFTS REPRESENT EQUALLY RELEVANT MODELS OF AGGRESSIVE LYMPHOMAS (pages 397–398)

      P. Klener, M. Klánová, J. Molinský, M. Svatoň, A. Berková, Z. Zemanová, R. Jakša, M. Špaček, J. Březinová, I. Tichá, T. Jančušková, D.W. Hardekopf, K. Forsterová, E. Froňková, M. Kotrová, M. Kubričanová-Žaliová, B.C. Maswabi, D. Průková, P. Vočková, D. Tušková, K. Michalová, J. Trka, M. Trněný and P. Klener

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_168

    7. You have free access to this content
      CONSTITUTIVE EXPRESSION OF ΓH2AX PREDICTS BETTER RESPONSE TO HISTONE DEACETYLASE INHIBITOR IN DIFFUSE LARGE B-CELL LYMPHOMA (page 398)

      Y. Liu, P. Zhang and W. Zhou

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_169

    8. You have free access to this content
      EXPRESSION OF PIM KINASES IN REED-STERNBERG CELLS FOSTERS IMMUNE PRIVILEGE AND TUMOR CELL SURVIVAL IN HODGKIN LYMPHOMA (pages 398–399)

      M. Szydlowski, M. Prochorec-Sobieszek, A. Szumera-Ciećkiewicz, E. Derezińska, G. Hoser, D. Wasilewska, O. Szymańska-Giemza, E. Jabłońska, E. Białopiotrowicz, T. Sewastianik, A. Polak, W. Czardybon, M. Gałęzowski, R. Windak, J. Zaucha, K. Warzocha, K. Brzózka and P. Juszczyński

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_170

    9. You have free access to this content
      TARGETING HEAT SHOCK PROTEIN 90 AND ITS DOWNSTREAM SIGNALING HUBS FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (page 399)

      H. Liu, P. Zhang, D. Shang, X. Shi, Z. Lu, L. Liu, M. Shen and Z. Tu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_171

    10. You have free access to this content
      L-TYPE CAV 1.2 CALCIUM CHANNEL PARTICIPATES IN RITUXIMAB-INDUCED APOPTOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA (page 399)

      P. Zhang, Y. Liu and W. Zhou

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_172

    11. You have free access to this content
      MALT1 INHIBITION USING THE SMALL MOLECULE INHIBITOR MI-2 EFFICIENTLY INDUCES APOPTOSIS IN CLL CELLS (page 400)

      Y. Herishanu, N. Dezorella, M. Shapiro, C. Perry and B. Katz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_173

    12. You have free access to this content
      BORTEZOMIB PREVENTS DEVELOPMENT OF CYTARABINE RESISTANCE IN A MANTLE CELL LYMPHOMA IN VITRO MODEL (pages 400–401)

      C. Freiburghaus, V. Kuci Emruli, A. Johansson, R. Olsson, F. Ek, C.H. Geisler, M. Jerkeman and S. Ek

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_174

    13. You have free access to this content
      GSK-3ß INHIBITOR, 9-ING-41 REDUCES CELL VIABILITY AND HALTS PROLIFERATION OF B-CELL LYMPHOMA (pages 400–402)

      R. Karmali, V. Chukkapalli, B. Pro, J.A. Borgia, A. Mazar, A. Ugolkov and F.J. Giles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_175

    14. You have free access to this content
      METABOLIC CHANGES ASSOCIATED WITH METFORMIN POTENTIATES ANTI-BCL-2 INHIBITOR, ABT-199, AND CDK9 INHIBITOR, BAY-1143572 AND REDUCES VIABILITY OF LYMPHOMA CELLS (pages 401–402)

      R. Karmali, V. Chukkapalli, L.I. Gordon and J.A. Borgia

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_176

    15. You have free access to this content
      THE BRUTON'S TYROSINE KINASE INHIBITOR IBRUTINIB EXERTS IMMUNOMODULATORY ACTIVITY TOWARDS TUMOR-INFILTRATING MACROPHAGES (pages 402–403)

      N. Ding, L. Ping, Y. Shi, L. Feng, J. Li, Y. Liu, Y. Lin, C. Shi, X. Wang, Z. Pan, Y. Song and J. Zhu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_177

    16. You have free access to this content
      THE EFFECT OF AN IMMUNOMODULATORY DRUG ON THE VIABILITY AND SURFACE MOLECULE EXPRESSION OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS (page 403)

      G. Barna, C. Tolnai-Kriston, M. Hernádfői, M. Plander, F. Takács and A. Matolcsy

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_178

    17. You have free access to this content
      MOLECULAR MECHANISMS AND COMBINATION STRATEGIES WITH PI3K AND BTK INHIBITORS TO OVERCOME INTRINSIC AND ACQUIRED RESISTANCE IN PRECLINICAL MODELS OF ABC-DLBCL (pages 403–404)

      J. Paul, M. Soujon, A.M. Wengner, S. Zitzmann-Kolbe, A. Sturz, K. Haike, H.M. Koh, S. Tan, M. Lange, D. Mumberg, S. Tan, S. Lim, K. Ziegelbauer and N. Liu

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_179

    18. You have free access to this content
      AZACYTIDINE AND DECITABINE EXHIBIT DIFFERENTIAL EFFECTS ON CYTOTOXICITY AND METHYLATION AND EXHIBIT CLASS SYNERGY WITH HDACI IN MODELS OF PTCL (page 404)

      L. Scotto, C. Kinahan, B. Casadei and O.A. O'Connor

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_180

    19. You have free access to this content
      TARGETING BCL-2 IN ALK+ ALCL: AT THE CROSSROADS BETWEEN AUTOPHAGY AND APOPTOTIC CELL DEATH (pages 404–405)

      P. Brousset, A. Torossian, J. Frentzel and E. Espinos

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_181

    20. You have free access to this content
      A PRELIMINARY EFFICACY STUDY OF CHIDAMIDE IN COMBINATION WITH DICE REGIMEN ON RELAPSED OR REFRACTORY B CELL LYMPHOMAS (page 405)

      Y.Q. Song, L.H. Liu, X. Wang, H.Y. Yang, L.P. Su, H.L. Zhang, A.C. Liu, J. Li and H. Su

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_182

    21. You have free access to this content
      ABSENCE OF PHARMACOKINETIC INTERACTION OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA (INHL) (pages 405–406)

      A. Forero-Torres, J. Claud Chandler, S.P. Iyer, A.S. Kanate, M. Izquierdo, P. Hoever, V. Duval, M. Quinlan and S. Madan

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_183

    22. You have free access to this content
      ME-401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-CELL LYMPHOID MALIGNANCIES (page 407)

      R.G. Ghalie, J.M. Pagel, J. Soumerai, A. Iasonos, K. Patel, O. Moreno, T. Butler and A.D. Zelenetz

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_184

    23. You have free access to this content
      ONO-4059 (GS-4059), A NEXT GENERATION BTK INHIBITOR, MONOTHERAPY IN PATIENTS WITH B-CELL MALIGNANCIES IN THE JAPANESE PHASE 1, DOSE-ESCALATION STUDY (pages 407–408)

      K. Ando, K. Hatake, N. Fukuhara, T. Kinoshita, W. Munakata, Y. Shirasugi, M. Yokoyama, S. Ichikawa, S. Fukuhara, K. Ohmachi and K. Tobinai

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_185

    24. POSTER PRESENTATIONS

      You have free access to this content
      ANTI-INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY-ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL UNDERGOING R-CHOP IMMUNOCHEMOTHERAPY (pages 200–201)

      N. Murawski, J. Amam, B. Altmann, M. Ziepert, M. Haenel, A. Viardot, A. Neubauer, G. Held, L. Truemper, M. Dreyling, L. Kanz, M. Hallek, N. Schmitz, T. Heintges, C. Koelbel, V. Poeschel and M. Pfreundschuh

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2438_63

    25. PUBLICATIONS

      You have free access to this content
      PHARMACOKINETIC ANALYSIS AND CLINICAL RESULTS OF THE PHASE 1 DOSE ESCALATION AND EXPANSION CXD101 TRIAL IN RELAPSED, REFRACTORY LYMPHOMA (page 408)

      T.A. Eyre, L. Folkes, G. Collins, C. Hildyard, M. Stratford, K. Myers, N. La Thangue, D. Kerr and M. Middleton

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_186

    26. You have free access to this content
      SAFETY RUN-IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA (pages 408–410)

      J. Gerecitano, A. Santoro, S. Leppä, T. Kim, W. Kim, A. Janssens, M. Pedersen, D. Reis, C. Granvil, J. Shen, H. Zheng, B.H. Childs and P. Zinzani

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_187

    27. You have free access to this content
      IBRUTINIB IN ASSOCIATION WITH R-DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY (page 410)

      C.M. Bonnet, T. Lamy, C. Fruchart, S. Legouill, K. Gunzer, T. Gastinne, F. Jardin, L. Karlin, R. Houot, J. Dupuis, H. Tilly and G. Salles

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_188

    28. You have free access to this content
      ENGAGING ADMINISTRATIVE DATA TO DETERMINE TIME TO DIAGNOSIS AND TREATMENT OF LYMPHOMA: A POPULATION BASED STUDY (page 411)

      P. Skrabek, M. Seftel, O. Bucher, B. Elias and D. Turner

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_189

    29. You have free access to this content
      PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II-IV PERIPHERAL T-CELL NON-HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T-CELL CONSORTIUM (pages 411–412)

      M. Lunning, S. Horwitz, N. Mehta-Shah, A. Moskowitz, R. Advani, A. Beaven, B. Haverkos, M. Lechowicz, Y. Oki, J. Zain and S. Ansell

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_190

    30. You have free access to this content
      DUAL PI3K δ/γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA: DOSE ESCALATION FINDINGS. (page 412)

      Y. Oki, J. Zain, B. Haverkos, P. Barde, K. Penmetsa and A. Huen

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_191

    31. You have free access to this content
      PICC-RELATED THROMBOSIS IN PATIENTS WITH AGGRESSIVE LYMPHOMA TREATED WITH DA-EPOCH—HOW TO PREVENT IT? (page 413)

      Z. Mitrovic, Z. Prka, M. Lucijanic, O. Jaksic, M. Pirsic, Z. Jonjic, S. Ivos and V. Pejsa

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_192

    32. You have free access to this content
      HIGH RATE OF MORBID CENTRAL LINE ASSOCIATED COMPLICATIONS DURING TREATMENT WITH DOSE-ADJUSTED R-EPOCH THERAPY FOR NON-HODGKIN LYMPHOMA (pages 413–414)

      P. Reagan, R. David, A. Baran, J. Kelly, K. Loh, C. Casulo, P. Barr and J. Friedberg

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_193

    33. You have free access to this content
      SUBCUTANEOUS RITUXIMAB IN B-CELL NON-HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE (page 414)

      B. Sanchez-Gonzalez, E. Torres, M.P. Ferraro, F. Garcia-Pallarols, M. Calafell, C. Gale, L. Martinez, E. Sancho, P. Garcia, E. Gimeno and A. Salar

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_194

    34. You have free access to this content
      PHARMOVIGILANCE OF RITUXIMAB BIOSIMILAR IN THE TREATMENT OF LYMPHOMAS IN ARGENTINA (pages 414–415)

      G. Milone, M.I. Penna, F.A. Fernandez, E. Spitzer, S. Millan, S. Mariani, N. Español and R. Gomez

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_195

    35. You have free access to this content
      REAL-LIFE USE OF BENDAMUSTINE FOR B-CELL NON-HODGKIN LYMPHOMA IN A COMMUNITY HOSPITAL IN JAPAN—RETREATMENT WITH BENDAMUSTINE IS SAFE AND FEASIBLE (page 415)

      E. Matsuki, S. Kohashi, A. Ishida, H. Murakami and M. Kikuchi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_196

    36. You have free access to this content
      THALIDOMIDE IN RELAPSED LYMPHOMA: 5 YEARS OF EXPERIENCE FROM SOUTHEND UNIVERSITY HOSPITAL NHS FOUNDATION TRUST (pages 415–416)

      E. Blacker, F. Laskou, M.A. Islam, K. Ardeshna, P. Kalkur and P. Cervi

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_197

    37. You have free access to this content
      COMPARATIVE ANALYSIS OF PREDICTIVE MODELS FOR THROMBOEMBOLIC EVENTS IN LYMPHOMA PATIENTS (page 416)

      D. Antic, N. Milic, S. Nikolovski, M. Todorovic, J. Bila, P. Djurdjevic, B. Andjelic, V. Djurasinovic, A. Sretenovic, M. Smiljanic, V. Vukovic, J. Jelicic and B. Mihaljevic

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_198

    38. You have free access to this content
      INCIDENCE AND SURVIVAL OF NON-HODGKIN LYMPHOMA AT ONCOSALUD—AUNA: A DYNAMIC COHORT STUDY (pages 416–417)

      C. Flores, C. Samanez, N. Valdivieso, A. Aguilar and C. Vallejos

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_199

    39. You have free access to this content
      LANGERHANS CELL HISTIOCYTOSIS IN ADULTS IS ASSOCIATED WITH INCREASED HEMATOLOGIC AND SOLID MALIGNANCIES (page 417)

      J. Ma, J. Laird, K. Chau, M. Chelius, A.C. Bell, Z. Zhang, B.H. Lok and J. Yahalom

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_200

    40. You have free access to this content
      A PROSPECTIVE STUDY TO EVALUATE THE UTILITY OF GERIATRIC ASSESSMENT AND INTERVENTION IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN A TERTIARY HOSPITAL (pages 417–418)

      M. Bastos-Oreiro, G. Rodriguez-Macias, V. Pradillo, S. Martinez, K. O'Hara, D. Champ, P. Font, M. Vidan, J. Ortiz, J. Menarguez, J. Serra and J. Diéz-Martín

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2439_201

    41. ONGOING TRIALS

      You have free access to this content
      ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP VS PLACEBO/R-CHOP IN UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING (page 419)

      A. Chiappella, T.E. Witzig, U. Vitolo, R. Gascoyne, J. Russo, B. Amoroso, K. Hudak, A. Ogunkanmi, Y. Xu, W. Ruiz, S. Singh and G.S. Nowakowski

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440

    42. You have free access to this content
      PHASE II STUDY OF DURVALUMAB (ANTI–PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (pages 419–420)

      U. Jaeger, N. Kalakonda, H. Everaus, P. Fustier, J. Jaeger, O. Manzke and G.S. Nowakowski

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_1

    43. You have free access to this content
      CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA (pages 420–421)

      L. Nayak, F.M. Iwamoto, A.J. Ferreri, A. Santoro, S. Singer, C. Batlevi, T. Batchelor, J. Rubenstein, P. Johnston, R. Ramchandren, C. Soussain, J. Drappatz, K. Becker, M. Witzens-Harig, G. Illerhaus, A. Herrera, A. Masood and M. Shipp

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_2

    44. You have free access to this content
      MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE (page 421)

      V. Ribrag, P. Feugier, J. Doorduijn, M. Delfau-Larue, O. Hermine, H. Kluin-Nelemans, M. Dasilva, A. Lopez-Hernandez, J. Walewski, M. Szymczyk, C. Pott, C. Homburg, V. Van der Velden, P. Gameiro, R. Garcia-Sanz, M. Ladetto, H. van Krieken, J. Cabeçadas, G. Rymkiewicz, W. Klapper, E. Hoster, S. Le Gouill and M. Dreyling

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_3

    45. You have free access to this content
      PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) (pages 421–422)

      C.S. Tam, S. Rule, S. Le Gouill, U. Vitolo, L.C. Tsao, N. Cavazos, D.M. Beaupre and M.L. Wang

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_4

    46. You have free access to this content
      A HEAD-TO-HEAD PHASE 3 STUDY COMPARING BGB-3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (pages 422–423)

      C. Buske, V. LeBlond, W. Novotny, R. Owen, A. Tedeschi, S. Atwal, A. Cohen, J. Huang and C.S. Tam

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_5

    47. You have free access to this content
      PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN IN REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS TREATED BY CHEMOTHERAPY (ICE) IN SECOND LINE BEFORE AUTOLOGOUS TRANSPLANTATION. (page 423)

      A. Stamatoullas, H. Ghesquières, P. Quittet, F. Morschhauser, V. Ribrag and P. Brice

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_6

    48. You have free access to this content
      A PHASE 1/2 STUDY OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20+ TUMORS, RITUXIMAB IN PATIENTS WITH RELAPSED AGGRESSIVE B- OR T-CELL LYMPHOMAS—THE P[R]EBEN STUDY (pages 423–424)

      F. d'Amore, S. Leppä, T.S. Larsen, P. Brown, T. Relander, S. Mannisto, J.M. Jørgensen, H. Holte, G.F. Lauritzsen, G. Enblad and H. Toldbod

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_7

    49. You have free access to this content
      DEVEC: A PHASE II STUDY OF METRONOMIC CHEMOTHERAPY IN ELDERLY NON-FIT PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS (PROMOTED BY FIL) (pages 424–425)

      M.C. Cox, G. Musuraca, A. Arcari, A. Fabbri, G. Gini, M. Tani, A. Tucci, L. Marcheselli, S. Storti, F. Di Landro, R. Battistini, P. Anticoli Borza, I. Casaroli, V. Zoli, F. Fabbri, A. Aroldi, V. Naso, M. Bianchi, E. Borgo, A. Ferranti, A. Dondi, A. Levis, A. Tafuri and F. Merli

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_8

    50. You have free access to this content
      PET/CT-GUIDED BIOPSY FOR THE DIAGNOSIS OF LYMPHOMA (page 425)

      A. Broccoli, C. Nanni, A. Cappelli, F. Bacci, A. Gasbarrini, L. Zanoni, S. Brocchi, S. Spagnolo, C. Piovani, L. Argnani, S. Boriani, E. Sabattini, R. Golfieri, S. Fanti and P.L. Zinzani

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_9

    51. You have free access to this content
      FIL-PTCL13: PHASE IB/II STUDY OF ROMIDEPSIN/CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS. (page 426)

      A. Chiappella, C. Carniti, M. Ceccarelli, M.G. Cabras, A. Re, F. Salvi, A. Santoro, V. Stefoni, S. Pileri, G. Ciccone and P. Corradini

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_10

    52. You have free access to this content
      A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY) (pages 426–427)

      P. Ghia, L. Scarfò, M. Coscia, R. Sancetta, A. Ferrario, A. Tedeschi, L. Farina, L. Laurenti, E. Orlandi, G. Reda, M. Motta, C. Carlo Stella, M. Massaia, G. Quaresmini, F. Rossini, M. Ladetto, G. Gaidano, V. Rossi and M. Montillo

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_11

    53. You have free access to this content
      PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH TREATMENT-NAÏVE FOLLICULAR LYMPHOMA (PERSPECTIVE) (pages 427–428)

      S. Rule, I.W. Flinn, N. Fowler, R. Chen, L. Kwei, D.M. Beaupre, A.D. Chu and L.I. Gordon

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_12

    54. You have free access to this content
      AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT-NAÏVE CLL/SLL (page 428)

      P. Ghia, C.S. Tam, T. Siddiqi, D. Stevens, I.W. Flinn, K. Russell, K. Eckert, C. Zhou, J. Ninomoto, D.F. James and W.G. Wierda

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2440_13

  35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. Top of page
    2. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 - 17 June, 2017
    3. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017
    4. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    5. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    6. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    7. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    8. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    9. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    10. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    11. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    12. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    13. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    14. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    15. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    16. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    17. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    18. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    19. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    20. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    21. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    22. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    23. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    24. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    25. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    26. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    27. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    28. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    29. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    30. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    31. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    32. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    33. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    34. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14–17 June, 2017
    35. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano Switzerland, 14—17 June, 2017
    36. 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017

    1. AGENDA AND ABSTRACTS OF SATELLITE SYMPOSIA

      You have free access to this content
      14-ICML Satellite symposia programs and abstracts (updated on May 21 2017) (pages 429–437)

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2441

    2. AUTHOR INDEX

      You have free access to this content
      Author Index (By Abstract No.) (pages 438–463)

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2442

    3. KEYWORD INDEX

      You have free access to this content
      Keyword Index (pages 464–466)

      Version of Record online: 7 JUN 2017 | DOI: 10.1002/hon.2443

SEARCH

SEARCH BY CITATION